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The rapid emergence of antibiotic resistance in bacterial pathogens represents a substantial clinical 
and financial burden to our society. The development of antibiotics is generally unprofitable and 
challenged by the need for innovative and evolution-robust drugs. It is thus insufficient to rely on the 
discovery of new therapeutic agents, but important to understand the selection, spread and 
maintenance of bacterial antibiotic resistance in order to counteract its emergence. The work 
presented in this thesis focused on mechanisms and evolutionary dynamics underlying these factors. 
Collateral sensitivity, when bacterial resistance to one antibiotic potentiates the effect of other 
antibiotics, may be exploited in infection treatment to limit resistance evolution. We assessed 
collateral susceptibility changes in ten diverse isolates of single-drug resistant uropathogenic 
Escherichia coli towards 16 antibiotics and found conserved changes especially in ciprofloxacin 
resistant mutants. Collateral responses changed also another parameter important for resistance 
selection, the mutant prevention concentration, accordingly. We reveal that knowledge of the 
mechanism as well as the fitness cost of resistance supports the predictability of bacterial collateral 
responses in antibiotic resistant mutants (paper I). 
Horizontal gene transfer between bacterial pathogens contributes to the rapid spread of antibiotic 
resistance, and natural transformation is one of the major routes for bacterial horizontal gene 
acquisition. We demonstrate, that natural transformation of Acinetobacter baylyi by the resistance-
encoding, replicative transposon Tn1 occurred through its transposition from incoming donor DNA 
into the chromosome. In this process, host and transposon proteins were essential. We present a model 
of transposition-mediated natural transformation from a circular, double-stranded intermediate 
molecule of cytoplasmic donor DNA (paper II).  
Antibiotic resistance plasmids play a major role in the dissemination of multidrug resistance 
between bacteria and are increasingly recognized to establish stable associations with clinical 
bacterial hosts. We show that the biological burden of carrying a clinical resistance plasmid in an E. 
coli uropathogen is reduced after adaptation of this host to the laboratory environment through 
mutations in its CCR and ArcAB regulatory systems. We identify that transcriptional downregulation 
of plasmid genes explains the reduced plasmid cost mechanistically. Thus, we reveal that simple 
niche-adaptation presents a novel solution to the ‘plasmid paradox’ by improving the permissiveness 




Evolution of antibiotic resistance  
Bacteria have been and will always be with us1 and our dependence on effective treatment options 
for human infections with disease causing bacteria is immense. Paul Ehrlich introduced the term 
chemiotherapy to describe the use of chemically synthesized drugs in the treatment of microbial 
infections. The identification of compounds with antisyphilitic and antistreptococcal activity, 
Salvarsan (1909) and the sulfonamide Prontosil (1932), respectively, lead to their worldwide 
distribution and further development2. A major scientific breakthrough of the 20th century was the 
discovery of penicillin, a natural product of the Penicillium mold with activity against Staphylococcus 
aureus, by Sir Alexander Fleming in 19283. Soon after however, a penicillin-destroying enzyme was 
identified in Escherichia coli4, and Fleming highlighted in his Nobel prize lecture that bacterial 
resistance evolution could eventually render these ‘magic’ drugs inefficient5.  
Today, infections with multidrug-resistant (MDR) bacteria endanger basic and modern medicine 
globally since adequate therapeutic options are limited6. Estimates based on European surveillance 
data from the year 2015 indicate that resistant bacteria caused more than 670 000 infections, and 
around 5% of patients died consequently7. This creates a health burden which is, measured in 
disability-adjusted life years, comparable to the combined effect of influenza, tuberculosis and 
HIV/AIDS in Europe7. Members of the Gram-negative (G-) Acinetobacter spp. and 
Enterobacterales8 represent priority MDR pathogens9,10 and are the focus of the presented thesis. For 
the latter, the problem of antibiotic resistance is worsened by the successful association of epidemic 
MDR plasmids11 with high-risk clones, exemplified by E. coli sequence type (ST)131 and Klebsiella 
pneumoniae ST25812. Worldwide in 2014, these two bacterial species were the estimated cause of 50 
million infections that required hospital treatment with last resort antibiotics (carbapenems), while 
3.1 million infections were even resistant to these drugs13. 
In this thesis, the term ‘antibiotics’ comprises substances of microbial origin as well as synthetic 
drugs that are used in the treatment of bacterial infections. Their overuse and misuse in animal and 
human health significantly drives the selection for inherent or acquired bacterial antibiotic 
resistance14. To date, the enormous number of bacterial genetic resistance determinants15 and 
mechanisms16  compromise the effect of all routinely used antibiotics. It is even suggested that 
resistance evolves faster to newly introduced antibiotics17. In order to avoid this development for 
future antibiotics, we require improved understanding of the multiple factors that contribute to 




Figure 1: Factors that influence antibiotic resistance evolution in bacteria. The figure is based on references14,18-20. 
HGT = horizontal gene transfer; MGE = mobile genetic element.  
 
 
Discovery and classification of antibiotics 
Traditionally, antibiotics are small, organic molecules and categorized according to their chemical 
class. The sulfonamides were the first chemically synthesized drugs with antibacterial activity and 
have been used since 193521. The discovery that microbes, mainly Streptomyces spp. in the order 
actinomycetes, produce antibiotics22 led to the identification of the major chemical classes of 
antibiotics that are currently in clinical use. Throughout the 1940’s and 1950’s, the β-lactams, 
aminoglycosides, tetracyclines, macrolides, glycopeptides, ansamycins and polymyxins were isolated 
from bacteria15,23. Nitrofurantoin, quinolones, nitroimidazoles and trimethoprim are examples of 
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chemically synthesized antibiotics that were developed in the 1950’s and 60’s15. Essentially all major 
chemical drug classes were discovered by the 1960’s, and only five additional ones, all active against 
Gram-positive (G+) bacteria, have reached approval for human use since then. These include the 
oxazolidinones (2000, linezolid), lipopetides (2003, daptomycin), pleuromutilins (2007, 
retapamulin), the macrolacton Fidaxomicin (2011) and the diarylquinolone Bedaquiline (2012)24. 
More recently, Teixobactin (2015, depsipeptide) and Malacidin A (2018, malacidins) were 
discovered using in situ cultivation or culture-independent approaches, respectively25,26. Both 
represent novel antibiotic classes with activity against G+ bacteria, while new chemical classes for 
G- infections are alarmingly scarce6. The recently launched agents avibactam and vaborbactam 
represent first-in-class chemical scaffolds that are used in combination with β-lactam antibiotics. 
They inhibit some but not all resistance determinants (β-lactamases; see β-lactam resistance) present 
in G- bacteria and are thus adding only limited clinical benefit over existing treatment options6. It is 
estimated that 11 new antibiotics will be approved between 2019 and 2024, of which the majority 
will only be chemical modifications of already existing drug classes6.  
Antibiotics can further be classified as bacteriostatic (e.g. trimethoprim) or bactericidal (e.g. 
quinolones, β-lactams, nitrofurantoin), which specifies if their effect inhibits bacterial growth or kills 
bacteria, respectively. Their activity against a broad (e.g. tetracyclines, β-lactams, fluoroquinolones) 
or narrow spectrum (e.g. polymyxins) of bacterial species further classifies antibiotics. Finally, 
antibiotics are categorized according to their dose-dependent (e.g. quinolones, aminoglycosides) or 
time-dependent (e.g. β-lactams, macrolides) antibacterial effect. 
 
Molecular target sites of antibiotics 
Antibiotics inhibit growth or induce death in bacterial cells by selectively acting on biochemical 
pathways that are essential for bacterial physiology and metabolism. Examples for the major 
molecular target sites of antibiotics in bacteria are presented below, with a special focus on the 
clinically relevant drugs used in paper I (Figure 2).  
β-lactams represent the oldest but still most important class of antibiotics. They target the bacterial 
cell wall by blockage of enzymes that are bound to the cytoplasmic membrane and involved in 
peptidoglycan synthesis of G- and G+ bacteria27. These so-called penicillin-binding proteins (PBPs) 
exhibit transpeptidase and transglucosylase function and perform polymerization, reconstruction and 
degradation of the bacterial cell wall during active cell growth. Penicillins (e.g. amoxicillin, 
mecillinam, temocillin), cephalosporins (e.g. ceftazidime) and carbapenems (e.g. ertapenem) 
covalently bind to and inhibit these bacterial enzymes. The antibiotic fosfomycin inhibits the 
synthesis of bacterial cell wall precursor molecules by binding to the cytoplasmic enzyme MurA28. 
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Protein synthesis (translation) in G+ and G- bacteria is affected by a variety of antibiotic classes, 
such as macrolides (e.g. azithromycin), aminoglycosides (e.g. gentamicin), tetracyclines (e.g. 
tetracycline, tigecycline) or amphenicols (e.g. chloramphenicol). These drugs bind either to the 
ribosomal RNA or to ribosomal polypeptide-structures of the large (50S) or small (30S) sub-unit of 
bacterial ribosomes. Their binding interferes with the initiation, elongation or termination of protein 
synthesis and results in truncated and misfolded proteins29. DNA transcription to messenger RNA 
is blocked by binding of rifamycin drugs (e.g. rifampicin) to the β-subunit of bacterial RNA 
polymerase, which is encoded by rpoB29. Ciprofloxacin is an example of a fluoroquinolone antibiotic. 
In G- bacteria, quinolone antibiotics bind primarily to the GyrA subunit of the topoisomerase II 
tetramer GyrA2GyrB2 (bacterial gyrase), while the ParC subunit of the topoisomerase IV tetramer 
ParC2ParE2 is a preferred target for antibiotic binding in G+ bacteria30. Both enzymes are involved 
in the cleavage and re-ligation of DNA, which facilitates the molecule’s relaxed and negatively super-
coiled topology, and chromosome separation, during and after DNA replication30. The DNA-
enzyme-fluoroquinolone complex stalls bacterial DNA synthesis by blocking replication fork 
movement. High drug concentrations introduce double-strand breaks and cause chromosome 
fragmentation30. Sulfonamides and trimethoprim are antifolate antibiotics that inhibit the pathway for 
de novo synthesis of folate, which is for example required in bacterial nucleic acid synthesis. 
Sulfonamides such as sulfamethoxazole bind to the enzyme dihydropteroate synthase (DHPS) in 
competition with the enzyme’s bacterial substrate para-aminobenzoic acid. Trimethoprim targets 
folic acid synthesis in a later step than sulfonamides and binds to bacterial dihydrofolate reductase 
(DHFR) in competition with dihydrofolic acid31. The outer membrane of G- bacteria is the target 
site of polymyxins such as colistin. These peptide antibiotics interact with the lipopolysaccharide 
structure on the bacterial outer membrane and subsequently disrupt both, the outer and inner 
membranes23. Nitrofurantoin is a prodrug that requires intracellular bioactivation by type I 
nitroreductase enzymes32,33. The reactive intermediates of the drug are thought to have multiple 






Figure 2: Illustration of the major molecular target sites of antibiotics in bacteria.  
 
 
Development of antibiotic resistance  
Antibiotic resistance develops either from de novo mutational changes in the bacterial genome or 
through horizontal gene transfer (HGT; see Horizontal gene transfer). The relative importance of 
these two modes of resistance acquisition depends on the bacterial species as well as the antibiotic 
class. In M. tuberculosis for example, MDR towards the key therapeutic agents evolves through the 
acquisition of chromosomal resistance mutations, while HGT is assumed to play a limited role in this 
pathogen35. However, in the majority of healthcare-associated pathogens, resistance develops through 
both mutations and HGT. Ciprofloxacin resistance in E. coli, for example, evolves primarily through 
chromosomal mutations but plasmid-associated qnr, aac(6’)-Ib-cr and qep quinolone resistance 
genes also reduce susceptibility to this drug15,36. Resistance to colistin was until 2015 believed to be 
only chromosome-encoded, however, transferable mcr genes were identified to confer resistance to 
this important last-line antibiotic, especially in E. coli and K. pneumoniae isolates23. In 
Enterobacterales, resistance to β-lactams is driven by the horizontal spread of drug-destroying 
enzymes (see β-lactam resistance), and in Acinetobacter spp., resistance development is facilitated 
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resistance mutations are transmitted vertically through bacterial binary fission, HGT facilitates the 
spread of resistance determinants both between related and unrelated bacterial pathogens38,39.  
Resistance evolved also as a natural bacterial trait and independent from the human use of 
antibiotics40,41. This so-called intrinsic or inherent resistance allows bacteria to withstand antibiotics 
that are present in their environmental niche or from their own production but renders them also 
resistant towards therapeutically used antibiotics16,41. Species-specific functional or structural 
characteristics contribute to intrinsically decreased bacterial antibiotic susceptibility42. The 
combination of intrinsic resistance at clinically relevant levels and resistance acquisition by mutations 
or HGT in important nosocomial pathogens such as P. aeruginosa, Acinetobacter spp. and 
enterococci minimizes treatment options tremendously10,43.  
In clinical settings, an infection is considered resistant when appropriate dosing and administration 
of antibiotics are not effective in the eradication of bacteria and/or the patient’s curation. To evaluate 
the likelihood of treatment failure or success, clinical breakpoints were implemented (see below). 
Microbiologically, resistance is defined as the presence of molecular mechanisms that let bacteria 
survive the exposure to antibiotics15,16 (see Bacterial resistance mechanisms towards antibiotics).  
 
Determining antibiotic susceptibility and clinical breakpoints  
Bacterial susceptibility towards an antibiotic is measured as the in vitro growth-preventing effect of 
the drug on the organism. The lowest concentration of an antibiotic that inhibits the visible growth of 
bacteria is defined as the minimal inhibitory concentration (MIC) (Figure 3), and the MIC of resistant 
bacteria is increased compared to the MIC of wildtype bacteria. To determine MIC values, 
antimicrobial susceptibility testing (AST) is performed and involves phenotypic methods such as 
broth microdilution (BMD) or diffusion gradient strip tests. These methods yield the MIC for a 
specific bacteria-antibiotic combination. BMD is the ‘gold standard’ technique for the vast majority 
of species-antibiotic combinations, and other methods of AST should be calibrated against BMD 
(ISO 20776-1:2019)44,45. The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) provides guidance in the interpretation of AST to facilitate the standardized surveillance 
of antibiotic resistance46. 
To assist clinicians in the interpretation of susceptibility testing, the concept of clinical breakpoints 
is internationally applied and regularly revised for clinically relevant species-drug combinations45,47. 
These represent MIC ‘cutoff’ values and are used to categorize bacterial isolates and predict treatment 
outcome. Isolates with MIC values below the clinical breakpoint fall into either of the two susceptible 
categories, where the likelihood of therapeutic success is high under a standard drug dosing regimen 
(S) or when drug exposure is increased (I). However, an MIC value at or above the clinical breakpoint 
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represents the resistant category (R), where the likelihood of therapeutic failure is high46. Clinical 
breakpoints are based on pharmacokinetic/pharmacodynamic data of the tested species-drug 
combination as well as information about the resistance mechanism44. Additionally, knowledge of 
the epidemiological cut-off value, which is the highest MIC value measured for a wildtype population 
of a bacterial species, is addressed44. MICs above the EUCAST clinical breakpoint was the inclusion 
criteria for resistant E. coli mutants generated in paper I. 
 
Mutant selection window 
From a pharmacokinetic perspective it was traditionally assumed, that antibiotic resistance is selected 
for between the MICs of the susceptible and the resistant members of the population. The latter 
antibiotic concentration is termed the mutation prevention concentration (MPC) and the antibiotic 
concentration range between MIC and MPC represents the so-called mutant selection window 




Figure 3: Schematic of the traditional mutant selection window. The growth of wildtype bacteria (until MIC) and 
resistant mutants (until MPC) is illustrated (black line) in increasing antibiotic concentrations. At the MIC, growth has 
declined by 99%. At the MPC, even bacteria with an acquired resistance mutation do not survive antibiotic exposure. The 
minimal selective concentration (= MSC) is indicated as shaded lines. Reprinted and adapted under the Creative 





However, it was later demonstrated that resistant bacteria, pre-existing or de novo generated, are 
selected for even at antibiotic selection pressures far below the MIC. In vitro, Gullberg and colleagues 
showed that antibiotic concentrations at more than 100-fold reduced wildtype MICs still provided a 
growth advantage to E. coli with chromosomal resistance50 or with an MDR plasmid51. Their findings 
suggested that the MSW expands to an even lower concentration than the MIC, which they designated 
the minimal selective concentration (MSC)50. Thus, research on the selection dynamics at MSC and 
MPC elucidates the impact of antibiotic concentration gradients in the treated human body, and also 
in the environment, on the evolution of resistance52. 
 
Bacterial resistance mechanisms towards antibiotics 
Different biochemical mechanisms lead to resistance in bacteria. They may affect the antibiotic agent 
itself, which can be enzymatically inactivated, degraded or modified. Furthermore, the antibiotic 
molecular target can be structurally altered, overproduced or circumvented by alternative cellular 
pathways. Finally, reduced drug uptake or increased drug efflux impacts the effective antibiotic 
concentration in the cell16,53 (Figure 4, from left to right). As a consequence, the pharmacodynamic 
interaction between the drug and the bacterial target is decreased or becomes irrelevant and the 























Figure 4: Illustration of the major antibiotic resistance mechanisms in bacteria. Bacterial enzymes that act on 
the drug are indicated in yellow, molecular target sites of the antibiotic are indicated in green, and bacterial cell 
wall/cell membrane proteins are indicated in purple. 
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The examples for resistance mechanisms given below are based on specific drugs and mechanisms 
focused on in this thesis. They evolved through de novo mutations in E. coli (paper I), or by 
horizontal transfer of plasmids into E. coli (paper III).  
 
Ciprofloxacin resistance 
E. coli acquires ciprofloxacin resistance most frequently by de novo mutations in the drug target 
genes gyrA (bacterial DNA gyrase) and parC (topoisomerase IV) affecting codons that are located in 
the so-called quinolone resistance determining region (abbreviated as QRDR)54. In clinical isolates, 
increasing resistance develops by several mutational paths in a multistep process55-57 and is generally 
initiated by a gyrA-located mutation (S83L)58. Clinical resistance (MIC >0.5 μg/mL) is not achieved 
by acquisition of a single mutation56,57,59 and triple drug target mutants in gyrA (S83L, D87N) and 
parC (S80I) are the predominant genotypes in clinical E. coli. This is likely due to the isolates’ 
selectively beneficial resistance level (up to 16 μg/mL) and growth rate (relatively unchanged)56,58. 
Although gyrB and parE drug target mutations are observed in E. coli clinical isolates57,58,60, their 
role in ciprofloxacin resistance evolution is less characterized. Higher-level resistance (>32 μg/mL) 
results from the acquisition of four to six putative resistance mutations, most often combining drug 
target alterations and increased ciprofloxacin efflux58,61. Mutations in the transcriptional repressor 
genes marR, acrR and soxR lead to upregulation of the major efflux pump in E. coli, AcrAB-TolC61-
63, while mutations in the RNA polymerase β-subunit gene rpoB increase the expression of the MdtK 
efflux pump59 (paper I). Growth reduction of E. coli efflux-mutants inhibits their early selection 
during clinical ciprofloxacin resistance evolution56. Finally, mutations in transcriptional regulator 
genes marA and envZ and the consequent decrease in expression of the outer membrane porin OmpF 
cause resistance by reduced ciprofloxacin uptake64,65 (paper I).  
 
Mecillinam resistance 
In E. coli, the described mutational target for mecillinam resistance is very large. In vitro, E. coli 
resistance levels above the clinical breakpoint (MIC >8 μg/mL) were achieved through single 
mutations in altogether 38 target genes, which affected different cellular functions and occurred at 
high frequencies66,67. In the patient however, resistance arises only at low and stable frequencies68 
and the diversity of mutational targets observed in vitro is not reflected in resistant clinical isolates66. 
This is possibly due to the slow growth that reduces their survival in the rapidly flushing urinary tract, 
as observed in experimentally obtained resistant mutants66. In clinical E. coli isolates, high-level 
resistance (MIC = 32 μg/mL) was due to loss-of-function mutations in cysB, which encodes a 
transcription regulator for the biosynthesis of the amino acid cysteine66. A decline in cellular cysteine 
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caused an oxidative stress response and subsequent increase in the expression of PBP1B, LpoB 
(activator of PBP1B) and FtsZ (cell division protein), which represents a bypass mechanism leading 
to mecillinam resistance67. A recent Tn-seq approach identified that the induction of the stringent 
response or the Rcs envelope stress response through elevated ppGpp levels could be linked to more 
than 100 genes in mecillinam resistant E. coli69 (relA, aspS, tusB or aceE, aceF, respectively), some 
of which were also target for resistance mutations in clinical isolates (paper I). Finally, mutations in 
the cellular drug target PBP2 (mrdA) or its functional partner RodA (mrdB) inhibit peptidoglycan 
synthesis and lead to mecillinam resistance70. 
 
Nitrofurantoin resistance  
E. coli evolves mutational resistance to nitrofurantoin through highly reproducible trajectories in 
vitro71. Since the biologically active toxic intermediates are formed by enzymatic reduction32,33, the 
primary targets for nitrofurantoin resistance mutations, both in resistant clinical isolates and in 
experimentally generated mutants, are the genes nfsA and nfsB of the type I nitroreductase72 (paper 
I). Clinical resistance levels (MIC >64 μg/mL) are reached by the acquisition of multiple mutations, 
although in vitro, this resistance-level was occasionally observed for single-mutants in nfsA as well72 
(paper I). The stepwise acquisition of two putatively inactivating nitroreductase-mutations, first in 
nfsA and then in nfsB, increased resistance in E. coli mutants to high levels (MIC >128 μg/ml)72. In 
vitro, nitroreductase mutations are frequently selected in combination with loss-of-function mutations 
in the gene mprA (encoding EmrR) of an EmrAB-TolC efflux pump repressor71 (paper I), which 
promotes E. coli nitrofurantoin resistance by increased drug efflux73.  
 
Trimethoprim resistance  
The great majority of trimethoprim resistance mutations in E. coli are related to one single locus, the 
folA gene encoding the drug target enzyme DHFR. DHFR is the primary cellular drug target, and in 
experimentally evolved E. coli, DHFR-associated mutations are either found in the substrate-binding 
region of the enzyme or in the promoter region of folA74,75 (paper I). Mutational alterations in active 
site residues of DHFR decreases the binding affinity of trimethoprim, while binding of the natural 
substrate dihydrofolic acid is unaffected76. Mutations in the folA promoter region caused a more than 
100-fold enzyme overproduction in a clinical E. coli isolate, which decreased the impact of drug-
bound DHFR77. It can be assumed that folA-amplification during in vitro drug adaptation resulted in 
DHFR overproduction and resistance above clinical breakpoint74 (paper I). A single drug-target 
mutation leads to resistance just above clinical breakpoint (MIC >4 μg/mL) (paper I), however, high-
level resistance requires the stepwise acquisition of mutations in the DHFR-promoter and drug 
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binding-site, as demonstrated for resistant clinical isolates77 and experimentally generated 
mutants74,75 (paper I). 
 
β-lactam resistance  
Enzymatic inactivation of β-lactam antibiotics was first described in 1940 for penicillin4. Today, it 
represents the predominant resistance mechanism against this drug class in G- bacteria and is 
commonly acquired by HGT mechanisms (see Horizontal gene transfer). The responsible enzymes 
are encoded by bla-genes, universally termed β-lactamases, and close to 3000 variants were identified 
until 201878. β-lactamases are present in the bacterial periplasm and active at the peptidoglycan layer. 
Collectively, they have the ability to inactivate all known β-lactam antibiotics by hydrolytic cleavage 
of the drug’s characteristic β-lactam ring78.  
As shown in Figure 5 (left), β-lactamases are categorized on different levels. Structural and 
biochemical differences separate serine β-lactamases (SBL) from metallo-β-lactamases (MBL). SBLs 
form intermediate acyl-enzymes with β-lactam antibiotics using an active site serine and successively 
perform fast drug-hydrolysis79, whereas MBLs interact with β-lactams via Zn2+-dependent 
recognition before hydrolyzing the drug80. Furthermore, β-lactamases are classified based on amino 
acid sequence relatedness81 (Figure 5, left, class) or characteristics regarding their substrate 





Figure 5: Simplified categorization scheme for β-lactamase enzymes. Biochemical characteristics divide β-lactamases 
according to their active site serine (= SBL) or metal-dependence (= MBL). Further categorization follows Ambler 
molecular classes (A, B, C and D). Clinically important carbapenemases in Enterobacterales are highlighted (grey circle). 
The global spread of major carbapenemases in Enterobacterales is indicated by the number of countries per enzyme. 
Reprinted and adapted with permission from83.  
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In the context of this thesis, the MBLs Verona-Integron-encoded (VIM-type) and New-Delhi MBL 
(NDM-type) are highlighted here. The plasmids employed in paper III harbor variants thereof, 
namely VIM-1 in pG06-VIM-1 and NDM-1 in pK71-77-1-NDM (see Multidrug resistance plasmids). 
They represent so-called carbapenemases which have the capacity to inactivate all β-lactam 
antibiotics except monobactams83. Among the targeted drugs, carbapenems are valuable, synthetic, 
last-line antibiotics for the treatment of MDR infections, especially by extended-spectrum-β-
lactamases (ESBL)-producing Enterobacterales. Compared to other β-lactamases, carbapenemases 
emerged rather late78, for example VIM-1 in 199784 and NDM-1 in 200985. Nevertheless, they are the 
primary cause of carbapenem-resistant G- bacteria today and among Enterobacterales. 
Carbapenemase-producing K. pneumoniae as well as E. coli from the family Enterobacteriaceae are 
clinically predominant and frequently associated with horizontally transferrable carbapenem 
resistance86-88. Besides VIM and NDM-type, widely distributed carbapenemases in Enterobacterales 
are the SBLs K. pneumoniae carbapenemase (KPC-type) and oxacillinases of the OXA-48 subgroup 
(OXA-type), as well as the IMP-type MBL (imipenemase)83 (Figure 5, left). Although VIM-1 is not 
the most common VIM-type variant worldwide, it is endemic both in K. pneumoniae and E. coli in 
Greece83. NDM-type carbapenemases are the geographically most widespread MBL in 
Enterobacterales and its endemicity is currently reported for Bangladesh, India, Pakistan and China83 
(Figure 5, right).   
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Horizontal gene transfer 
Sequence analyses of biological samples from different environmental or clinical sources such as 
plants, soil, wastewater, gut microbiome of human and animals, hospital surfaces or plumbing 
systems frequently confirm that resistance genes are abundant89,90. Pathogenic bacteria can acquire 
these resistance determinants by HGT39,89, of which transduction, conjugation and natural 
transformation represent the three canonical mechanisms91.  
Transduction is mediated by bacteriophages, which accidentally exchange genetic material between 
donor and recipient bacteria during their own propagation between hosts92. During transduction, the 
randomly packed genomic donor DNA in the phages’ head is protected from degradation over a long 
time and over long distances. Phage-host recognition may be limited to closely related bacteria; 
however, some phages have evolved a broader host-range93. Sequence analysis frequently reveals 
that antibiotic resistance genes can be associated with phages in hospital environments39 and in vitro 
transduction transferred resistance plasmids up to 30 kb between clinical isolates of S. aureus94. 
Conjugation is the directed transfer of genetic material from a donor to a recipient cell that are in 
close proximity92 and is mediated either by integrative conjugative elements (ICEs) or by extra-
chromosomal DNA elements called plasmids (see Plasmids). Plasmids either encode the conjugative 
machinery for DNA transport between donor and recipient cell on tra-genes or encode mobility (mob) 
genes that make them mobilizable through simultaneous transport with a conjugative plasmid95. HGT 
by conjugation is the primary mechanism by which antibiotic resistance genes are disseminated 
between bacterial pathogens39, especially Enterobacterales86, and facilitates plasmid-associated 
outbreaks of MDR96,97. Plasmid instability and the metabolic costs related to the conjugation process 
and to plasmid maintenance represent limitations to conjugative gene transfer (see Fitness cost of 
plasmid carriage). Natural transformation was central in the experiments for paper II. The 
requirements for successful gene acquisition in the naturally competent G- bacterium A. baylyi are 
thus described in more detail below. 
Recent studies reveal additional routes for the horizontal transmission of genetic material, for 
example by DNA-containing membrane vesicles released from bacterial cells98, through cell-to-cell 
connecting nanotubes99 or by phage-like gene transfer agents89. The relevance of these newer 
mechanisms in the spread of antibiotic resistance between bacterial pathogens, however, requires 
further confirmation and examination. Intra- and interspecies transfer of resistance-encoding 
plasmids by A. baylyi outer membrane vesicles occurred at low frequencies (10-6 and 10-8; 
respectively)100, and nanotube-mediated transfer of plasmid-DNA among Bacillus subtilis cells99 may 
be a result of the recipients’ ability for DNA uptake by natural transformation101.  
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Natural transformation  
Natural transformation is the process by which bacterial cells take up, integrate and express free DNA 
from the extracellular environment91. This ‘transformation principle’ was first described in 1928 by 
Frederick Griffith. He observed that avirulent Streptococcus pneumoniae cells became virulent when 
he injected them together with heat-inactivated cells of virulent S. pneumoniae into mice, which could 
later be explained by DNA transfer102. Our current understanding of natural transformation developed 
especially through more than 50 years of research in model organisms such as S. pneumoniae, B. 
subtilis, Neisseria gonorrhoeae and A. baylyi103, however experimental evidence for natural 
transformability of more than 80 species, with similar proportions of G+ and G-, exists104. These 
mainly represent environmental species104,105, but also important hospital-associated, pathogenic 
species9,104, and some experimental evidence for the potential to undergo natural transformation was 
also obtained in clinical isolates39,106,107. 
 
Competence and DNA uptake during natural transformation 
Since natural transformation is not facilitated by infecting agents such as phages or plasmids, the 
recipient’s competence to bind and actively transfer donor DNA into the cytoplasm is required108. 
Competence is a physiological state encoded by the recipient, and the ‘competence regulon’ includes 
a conserved set of genes that is common to almost all naturally transformable species104. In A. baylyi, 
the proteins of the DNA-uptake machinery are encoded by the com and pil genes, and drpA109. These 
proteins make up the DNA-uptake pilus and membrane-associated uptake pores and facilitate binding 
and translocation of double-stranded DNA (dsDNA) through the periplasmic space and 
peptidoglycan layer109. They further mediate transport of single-stranded DNA (ssDNA) into the 
bacterial cytoplasm and finally, initiate recombination of the foreign DNA with the bacterial 
genome109 (Figure 6). Competence genes are constitutively expressed in some species, for example 
A. baylyi, Helicobacter pylori and N. gonorrhoeae, while other species require certain conditions and 
signals (growth phase, cell density, chemicals, stress conditions like nutrient starvation, antibiotic 
treatment, DNA damage) to regulate a transient state of competence103. Moreover, the DNA-uptake 
apparatus of N. gonorrhoeae or Haemophilus influenzae only binds DNA that contains a specific 






Figure 6: Illustration of natural transformation in competent G- bacteria. The DNA-uptake machinery of a 
competent recipient bacterium can bind dsDNA (blue) from the environment and translocate it into the cell. The single-
strand DNA-binding protein SSB and DNA processing protein DprA (both in green) protect incoming, linear ssDNA 
from enzymatic degradation by exonucleases, and DprA loads the recombinase (= RecA)111. RecA initiates homology 
search within the recipient’s chromosome, which eventually leads to integration of the transforming ssDNA by 
recombination. DNA-translocation of bound dsDNA (blue) to the cytoplasmic membrane in G- bacteria is achieved by 
retraction of the DNA-uptake pilus (type IV pilus, dark purple), opening of the secretin pore ComQ (light purple) in the 
outer membrane (OM), and binding of the periplasmic, DNA-pulling competence protein ComEA. Finally, dsDNA is 
degraded to ssDNA, which crosses the inner membrane (IM) through the ComA membrane channel (not shown here) and 
reaches the cytoplasm. Reprinted with permission from103 with protein names according to the model of DNA uptake in 
A. baylyi109.  
 
 
DNA uptake during natural transformation requires free and naked DNA in the environment. 
Prokaryotic DNA is abundant in the environment through the lysis of dead bacterial cells, the 
disruption of live cells or active excretion of DNA by, for example, Acinetobacter, Pseudomonas, 
Bacillus and Streptococcus spp.105. Compared to DNA that is transferred during conjugation and 
transduction, this extracellular DNA is not protected by a membrane (pore) or virus capsule, which 
can cause biochemical, chemical and/or physical modification, and fragmentation of the DNA 
spontaneously or by nucleases. However, DNA of different sources (plant, bacteria) was 
demonstrated to persist in environments such as soil, water, saliva or blood to varying degrees and 
may eventually transform bacteria91,105,112. 
 
DNA recombination during natural transformation 
To ensure further inheritance, the incoming ssDNA has to be integrated within the recipient genome 
during natural transformation91. Depending on the type of donor DNA and its sequence similarity to 
the recipient chromosome, different recombination mechanisms are possible after DNA uptake in A. 
baylyi. Plasmids can establish extra-chromosomally and replicate autonomously110 (see Plasmids). 
Homologous recombination is mediated by the RecA recombinase and occurs between donor and 
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recipient DNA segments with at least 20 nucleotides sequence homology105. The integration of 
acquired DNA by RecA-dependent mechanisms during natural transformation is reduced if proteins 
of the RecBCD/RecFOR DNA repair pathways, which generate RecA-loaded 3’-DNA ends, are 
absent113. Interestingly, a RecA-independent mechanism of DNA integration was described for short, 
homologous fragments of 20 to 80 nucleotides114. The recombination frequency for foreign DNA 
decreases with the degree of sequence dissimilarity between donor and recipient DNA but can be 
facilitated even if only limited or no sequence similarity is present (homology-facilitated illegitimate 
recombination (HFIR)115 and double-illegitimate recombination (DIR or HFDIR)116. In A. baylyi, 
recombination during natural transformation can occur at frequencies from 10-3 for homologous 
chromosomal donor DNA and integration of a selectable resistance marker gene, or 10-12 for short 
fragments of fully heterologous DNA (B. subtilis) (short-patch double-illegitimate recombination, 
SPIDR)117. Finally, an important finding was that integron-associated resistance from unrelated 
species can be chromosomally acquired by A. baylyi through the site-specific recombination functions 
of transposons or insertion sequence (IS) elements during natural transformation118. However, the 
frequency of natural transformation events in nature or hospital settings and their relevance for 
clinical antibiotic resistance evolution is poorly understood39.
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Mobile genetic elements 
Mobile genetic elements (MGEs) move between and within DNA molecules. They are abundant in 
bacterial genomes and encode functions for their own mobility and adaptive traits such as antibiotic 
or heavy metal resistance, virulence or pathogenicity factors, or metabolic functions95. Conjugative 
plasmids, ICEs or bacteriophages represent MGEs that move between bacterial cells by HGT 
mechanisms (see Horizontal gene transfer), while transposons and IS elements encode site-specific 
recombination functions to move intracellularly95 (see Transposable elements). Integrons and gene 
cassettes are resistance-encoding genetic elements that are mobilizable through their association to 
MGEs such as plasmids and transposons. Due to interactions between transposable and conjugative 
genetic elements, HGT can essentially mobilize any chromosomal gene, which has great impact on 
bacterial niche-adaption by acquisition of new ecological functions. The relevant MGEs for this thesis 
are plasmids (paper III) and transposons (paper II) and are described in more detail below.  
 
Plasmids  
Plasmids are extra-chromosomal, double-stranded and generally circular DNA molecules that 
naturally exist in bacteria. They represent the best characterized and most promiscuous vectors of 
horizontal resistance spread. The so-called plasmid backbone comprises functions for plasmid 
replication and inheritance or for their horizontal infectious transfer by conjugation (see Horizontal 
gene transfer). A more variable plasmid region harbors accessory genes that promote host adaptation 
to, for example, antibiotics119.  
Plasmids replicate semi-autonomously within the host cell by theta, rolling-circle or strand-
displacement mode of replication120. Theta-type replication is described for small and large plasmids 
and most often used by plasmids in Enterobacterales. Here, leading and lagging strands are replicated 
simultaneously from the plasmid’s origin of replication (ori). In rolling circle replication, first 
identified for small plasmids in G+ bacteria, leading and lagging DNA strands are synthesized in two 
separated cycles, from the double-stranded origin (dso) and the single-stranded origin (sso), 
respectively120. Importantly, plasmid replication usually sequesters host enzymes like helicases, 
primases and polymerases, which reflects the parasitic character of plasmids within a bacterial host120. 
A plasmid therefore contains sites that both plasmid and host-encoded proteins may interact with. For 
example, replication at the ori can be initiated by plasmid-encoded Rep proteins, or independent of 
that, by host polymerases after the binding of a plasmid-encoded RNA II primer120, which is for 
example the case for ColE1-like MDR plasmids in Enterobacterales86.  
The dependence on host-functions for plasmid replication affects the host-range and horizontal spread 
of plasmids, because elements that have similar requirements for their replication and partitioning are 
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unstable if they coexist in the same cell. Such plasmids are members of the same ‘incompatibility 
group’. Current methods identify plasmid-incompatibility (Inc)-types for example by in vitro PCR-
based replicon-typing, which targets conserved regions specific to plasmid replication121, or in silico 
from sequencing data122. In Enterobacterales, contemporary resistance plasmids represent Inc-types 
that were common already before antibiotic introduction123. Enterobacterales species comprise close 
to 30 plasmid Inc-types of varying host ranges, and IncF, IncI, IncA/C and IncH are frequently found 
resistance encoding plasmid types86. IncQ plasmids, for which RSF1010 is a widely used reference, 
replicate by a strand-displacement type and encode their own initiation, helicase and primase proteins, 
which makes them less dependent on host-factors and broadens their host-range beyond 
Enterobacterales120.  
In addition to replication, several plasmid-encoded factors determine the stable vertical inheritance 
of these genetic elements. For example, multimer resolution systems (mrs) facilitate plasmid 
separation into monomers by site-specific recombination after plasmid-replication119. The subsequent 
segregation of plasmid molecules into each daughter cells is enabled by a high plasmid copy-number 
and random diffusion, or by partitioning systems (par) that facilitate the active assembly of plasmid 
molecules at either cell pole119. Plasmid-encoded addiction systems function as post-segregational 
killing systems (psk) and as such ensure survival of plasmid-containing cells while plasmid-free cells 
are eradicated. This can take place by endonuclease attack through restriction-modification systems, 
or by a stable toxin factor in toxin-antitoxin systems119. The majority of resistance plasmids in 
Enterobacterales are present in only a few copies per cell86 and their stability in bacterial populations 
depends on the above-mentioned mechanisms. However, further plasmid-host dynamics affect 
plasmid persistence and are described below (see Fitness cost of plasmid carriage). 
 
Multidrug resistance plasmids 
Since plasmids accumulate and physically link resistance determinants encoded by other MGEs, for 
example transposons or integrons, they contribute greatly to the horizontal spread of resistance. The 
majority of resistance plasmid types that are described in Enterobacterales is conjugative and/or 
exhibit a broad host range, while some are at least mobilizable86,95. Carriage of MGEs and also 
conjugative functions leads to larger plasmids, and the described resistance plasmids in 
Enterobacterales range in size from 45 kb to above 200 kb86. Plasmid-associated resistance 
determinants are described for all major antibiotic classes15 and more than 75% of plasmids in 
Enterobacterales can be associated to resistance gene carriage124. A phylogenetic analysis estimates 
that genes encoding an OXA-type β-lactamase moved onto plasmids already more than 100 million 
years ago125, however, the introduction of antibiotics in medical use reinforced the selection for 
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resistance genes in existing plasmids of human pathogens123. A recent study found up to seven 
plasmids in human intestinal Enterobacteriaceae samples, and plasmid-associated resistance genes, 
including ESBLs, lead to a MDR phenotype126. Carbapenemase genes are frequently mobilized 
through their association to plasmids and other MGEs11, as exemplified here for the enzymes carried 
by the plasmids of paper III, pG06-VIM-1 and pK71-77-1-NDM (Figure 7). The blaVIM-1-gene 
cassette is commonly incorporated into the variable region of a plasmid-located class I integron88, 
and associated to rarely detected, but broad host-range plasmid-types such as IncR (pG06-VIM-1) or 
IncW86. IncR plasmid sequences are also reported as part of multi-replicon plasmids for example with 
the promiscuous IncA/C or IncF plasmids, which facilitates their horizontal mobility as they are 
otherwise immobile11,127. BlaNDM-1 is linked to plasmid-located IS26 and a complete or truncated 
ISAba12588,128, and commonly associated to IncA/C-type plasmids, although many other replicon 




Figure 7: Examples for carbapenemase-encoding MDR plasmids of clinical origin. The maps illustrate the plasmids 
used in paper III. Plasmid pG06-VIM-1 (GenBank KU665641) originates from a K. pneumoniae wound infection 
isolate129. It belongs to the IncR-group, for which repB encodes the replication initiation protein. A carbapenemase is 
encoded by blaVIM-1 and additionally, the plasmid carries aminoglycoside (aadA1, aadA2, aacA7, aphA1), macrolide 
(mphA, mphR, mrx), sulfonamide (sul1) trimethoprim (dfrA1, dfrA12) and antiseptic (qacEΔ1) resistance genes (all in 
green), a toxin-antitoxin system (vagCD), a recombinase for multimer resolution (resD), and genes parAB involved in 
partitioning of the plasmid (blue)130. Mobile elements are indicated in red. Genes blaVIM-1, aacA7, dfrA1, aadA1 are 
associated to a class 1 integron127, and gene aphA1 is part of transposon Tn4352131. Reprinted and adapted with permission 
from130. Plasmid pK71-77-1-NDM (GenBank CP040884) was isolated from uropathogenic E. coli132. It is a IncC type 1 
plasmid (also designated IncA/C2) and replication initiation is encoded by repA (yellow). The plasmid encodes resistance 
to β-lactams (blaNDM-1 and blaCMY-6), aminoglycosides (aac(6’)-Ib, aac(3)-II, rmtC), sulfonamide (sul1) and bleomycin 
(bleMBL) (purple). Genes for conjugative transfer (tra) are blue and mobile elements are indicated in orange. Reprinted 































Transposable elements are distinct DNA segments that are associated to the bacterial chromosome or 
to plasmids and able to move between genomic locations by transposition133. Transposition involves 
the cleaving and rejoining of DNA strands, as well as the formation of double- or single-stranded 
DNA-intermediates134. This autonomous movement of genetic segments was first suggested in 1950 
by Barbara McClintock135. Her observation was, that DNA-translocation in the chromosomal loci 
encoding maize kernel pigmentation resulted in gene activation or inactivation and correlated with a 
varying color pattern of the kernels. Eventually, she received the Nobel prize for her discovery of 
MGE in 1983136. In bacteria, transposition of resistance determinants was first described in the early 
1970’s, and the designation ‘transposons’ was then introduced for bacterial DNA segments with the 
potential to move by transposition137. Today we know that transposons are ubiquitous in bacteria and 
Tn numbers are assigned to more than 600 unique bacterial transposons138. In their entirety, bacterial 
transposons carry resistance determinants against all major classes of antibiotics138, and their site-
specific recombination functions were shown to promote the spread of antibiotic resistance by 
transposition between different plasmids97, or between a chromosomal and plasmid location126,139 in 
clinical strains.  
The best-characterized examples of autonomously moving transposable elements are IS elements140 
and transposons138. IS elements can be as small as 700-900 bp, as is the case for example for the 
ubiquitous IS6-family including IS26, and they typically only contain the minimal transposition 
module consisting of a transposase gene (tnp) and two terminal inverted repeats (IRs) to which the 
transposase binds for transposition initiation95,140 (Figure 8, top). Unit transposons are distinct from 
IS elements in that they carry so-called passenger genes, which encode for example antibiotic, 
antiseptic or heavy metal resistance, virulence, or catabolic processes, in addition to the transposition 
module95. Their size can be up to 86 kb, but the average is around 12 kb138. Further, any genomic 
segment can be moved by transposition if it is flanked by two related IS-elements and is than called 
a composite transposon95. Autonomous transposable elements such as conjugative transposons (= 
ICE) encode genes for their intercellular transfer in addition to excision and insertion functions, or 
carry genes for DNA processing during conjugation such as in mobilizable transposons133.   
Intracellular transposition can also move otherwise immobile resistance elements onto horizontally 
transferable genetic units. For example, genetic elements called integrons do not encode 
transposition functions. Instead, they efficiently capture antibiotic resistance functions encoded by 
gene cassettes; the integron-integrase (intI) performs DNA insertion by site-specific recombination 
between the integron attI site and the gene cassette attC site, or DNA excision by recombination 
between two attC sites of gene cassettes. Despite their own immobility, integrons expressing 
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resistance gene cassettes are important elements in resistance evolution and their translocation to new 
sites is mediated by the transposable elements they are associated with141. Below I will focus on the 
large and widespread Tn3-family of unit transposons of which two members, Tn1 and Tn4401, were 
employed in the work for paper II. 
 
Tn3-family transposons 
Examples for well-described representatives of Tn3-family transposons are Tn1 (Figure 8, middle), 
Tn2 and Tn3, which are the earliest identified bacterial resistance transposons142. Furthermore 
Tn4401143 (Figure 8, bottom) and the integron-carrying Tn21, which also carries a mercury resistance 
operon144, are well-known. More Tn3-family transposons that harbor integrons with associated gene 
cassettes are for example Tn1696 and Tn133195. Tn3-family transposons in clinical isolates are often 
plasmid-associated, and those described in G- bacteria carry for example β-lactam (Tn2 [blaTEM]), 
carbapenem (Tn4401 [blaKPC]), colistin (Tn6452 [mcr]), aminoglycoside (Tn5393 [strA, strB]) and 
tetracycline (Tn1721 [tetA]) resistance genes. In G+ bacteria, Tn1546 is a Tn3-family representative 
that mobilizes vancomycin resistance (vanA)95.  
 
Tn3-family transposons: structure 
Transposons exhibit different structural compositions, transposase types, transposition mechanisms 
(replicative/non-replicative) and target site preferences. Structural characteristics for Tn3-family 
elements are the tnpA and tnpR genes which encode the transposase and resolvase proteins145, 
respectively, as well as the res site and two 38-bp IRs, which together facilitate a replicative 
transposition mechanism (Figure 8, middle and bottom)146. The TnpA proteins of the Tn3-family are 
called DDE-transposases due to a conserved motif of three amino acids in their catalytic site (aspartic 
acid/aspartic acid/glutamic acid, or short DDE), but are also known as RNase H-like enzymes147. 
TnpR represents an S- or Y-recombinase with an active site serine or tyrosine, respectively, and is 
involved in the resolution step of the transposition pathway (see below)147. For members of subgroups 
to this transposon family tnpA and tnpR may be organized differently with respect to the res site 
(Tn21-subfamily) or show little sequence similarity with the same genes in Tn3-like elements 







Figure 8: The genetic composition of a typical IS element, and two thesis-relevant transposons.  
IS elements are simple, short transposable elements and only contain a minimal transposition module consisting of a 
transposase gene (tnpA), and the left and right IRs (IRL and IRR; vertical black bars). The transposase gene usually covers 
the entire element. Tn1 is a Tn3-family transposon and carries a broad-spectrum β-lactam resistance gene (blaTEM-2) in 
addition to the transposition module. This is comprised of tnpA and tnpR, which are transcribed in opposite directions, 
and the two 38-bp IRs, which contain an external transposase cleavage site, and an internal transposase recognition and 
binding site (domain A and B, respectively; not shown). The resolvase TnpR is a site-specific serine recombinase but acts 
also as repressor for tnpR and tnpA145. The 120-bp res site separates these two genes and contains three sub sites (I, II and 
III), which are binding sites for the resolvase during replicative transposition147, and promoters for tnpA and tnpR. Tn4401 
is a Tn3-like transposon and is bracketed by two 39-bp long IRs. The transposon harbors ISKpn7 and ISKpn6 up- and 
downstream of a blaKPC-2 carbapenemase gene, respectively. It is suggested that the interrupted IR (IRD) has evolved from 
ISKpn7 insertion into the ancestral IRR, and a downstream ‘replacement’ IRR now delimits Tn4401143. Reprinted and 
modified with permission from95. 
 
 
Tn3-family transposons: transposition mechanism 
Tn3-family transposons move by a ‘copy-in’ mechanism, and much of our knowledge about the 
biochemistry of this transposition pathway is based on studies using bacteriophage Mu as a model. 
This replicative transposition mechanism involves the formation of a double-stranded, circular DNA 
co-integrate, for which the Tn3-family transposase does not require sequence similarity between the 
transposon and the target site. After resolution of this structure, one copy of the transposon is inserted 
into the target molecule, while the donor molecule also contains the elements147 (Figure 9). In a first 
step, the transposase recognizes and binds the IRs, and catalyzes the cleavage of DNA single-strands 
at the outermost 3′ ends of the transposon by hydrolysis. The transposase binds the transposon ends 
and transfers them to the target DNA. This nucleoprotein complex is also referred to as the 
‘transpososome’134. In the so-called strand-transfer reaction, Tn3-family transposases typically 
introduce a 5-bp single-strand gap into the target DNA which creates free 5’-ends that are joined with 
the transposon’s 3′-OH groups147. This generates a branched molecule, called a Shapiro-intermediate, 
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DNA cleavage149. Further steps involve the repair of the gaps between target and transposon DNA 
and synthesis of the complementary strands of the transposon by host replication functions147 (Figure 
9, left). If the donor and target molecules were circular, the result is a circular, double-stranded co-
integrate structure in which the target and the donor DNA are connected through directly repeated 
copies of the transposon, of which each has one newly synthesized strand147. In this co-integrate, 5-
bp long target site duplications (TSDs) are present where transposon DNA was joined to target DNA 
(Figure 9, middle). These TSDs are direct repeats and a characteristic result of a transposition event. 
They reflect the preferred target site sequence of the transposase protein, the ‘consensus sequence’, 
which is generally AT-rich and 5-bp long for Tn3-family transposases150,151 (Figure 9, right). 
However, transposon insertion is probably not only determined by the sole presence of the consensus 
sequence but may abide also other characteristics of the target DNA152 (paper II). It is suggested that 
replication processes or DNA repair events at the target site provide a signal for transposition147.  
In most characterized Tn3-family transposons, resolution of the cointegrate is mediated by a TnpR 
serine resolvase, which performs site-specific recombination between the two transposon res-sites. 
Once the res recombination sites (subsite I in each element) are aligned in parallel, TnpR can bind 
and introduce double-strand breaks, perform DNA strand-exchange through rotation of the DNA-
protein complex within subsite I, and rejoin DNA147. The donor and target molecules are now 
separated and contain one copy of the transposon each.  
In vitro, Tn3-transposition between plasmid replicons can occur at frequencies of 10-2/10-3 153, and 
for Tn4401 at frequencies of 10-3/10-4 154. Although cointegrate resolution occurs independent from 
host recombination functions, RecA-mediated homologous recombination between the directly 
repeated transposons can resolve co-integrates in the absence of TnpR, although less efficiently155. 
New Tn3-based transposons evolve by a sequence of homology- and resolvase-mediated 
recombination events between related and unrelated elements as it is suggested for Tn2-like 
transposons142, or by the recruitment of ‘replacement’ IRs as described for Tn4401 evolution143 







Figure 9: Schematic of the transposition mechanism used by Tn3-family transposons.  
Replicative transposition by the copy-in mechanism is a two-step process and requires transposon- and host-encoded 
functions (indicated in orange and blue, respectively). The transposase (TnpA) cleaves DNA single-strands at the 
transposon’s IRs (black) and joins them with DNA ends at the target site (blue triangle with 5-bp target sequence) during 
the so-called “strand-transfer” reaction. Single-strand gaps between target and transposon DNA, and also the 
complementary transposon-strand, are filled up by cellular DNA replication functions. This generates a double-stranded, 
circular co-integrate molecule called Shapiro-intermediate, which contains two copies of the transposon. During 
resolution, the resolvase (TnpR) performs site-specific recombination at the transposon’s res-sites (white box), which 
leads to the separation of donor and target molecule. Characteristic TSDs are present at either end of the newly inserted 

















Bacterial fitness and cost of antibiotic resistance 
The biological fitness of bacteria is, at the broadest level, defined as their ability to survive and divide 
in a particular environment. Traditionally, growth rate and competitiveness are measured in vitro or 
in vivo to estimate the fitness of one bacterial genotype relative to another when both strains are 
growing under the same conditions. For example, the maximum exponential growth rate r of strain 
A and strain B is measured, and the relative fitness w is calculated as the ratio of absolute growth 
rates (w = rA/rB). The assessment of competitiveness is the ‘gold standard’ of fitness estimation156. 
Here, a 1:1 volumetric mixture of strains A and B is inoculated and the population density (N) of each 
competitor is determined at the start (i) and the end (f) of an experimental cycle. The respective net 
population growth is calculated as mA/B = ln (NA/B(f)/NA/B(i)) (m = Malthusian parameter), and the 
relative competitive fitness as w = MA/MB157. The relative fitness w can be increased (>1), equal (1) 
or reduced (<1). As a consequence of fitness differences between two bacterial populations, their 
frequencies will change over time, and the less fit population will decrease due to negative selection. 
 
The selective benefit of resistance acquisition in bacteria is futile once antibiotics are removed and 
the fitness of resistant relative to susceptible strains represents a key criterion for the persistence of 
resistance in bacterial populations20. The effect of newly acquired resistance on fitness has been 
studied in vitro for many antibiotics and types of resistance mutations158 (paper I), for resistance 
plasmids (paper III and below), resistance encoding integrons159 and transposons160,161, and also in 
vivo56,160,162. The general observation is that resistance acquisition reduces bacterial fitness in 
antibiotic-free conditions163. The predictability of this so-called ‘fitness cost’ for a particular 
combination of resistance determinant and host genetic background is however limited since both 
factors impact the cost128,130,164-166 (paper I and III), in addition to the bacterial environmental 
context167. A recent meta-analysis shows, however, that costs associated to resistance mutations are 
generally greater than the costs imposed by horizontally acquired resistance determinants168. This is 
explained by the acquired type of resistance mechanism. De novo resistance mutations in the 
antibiotic target site cause perturbation of essential cellular functions like cell wall synthesis, DNA 
replication or protein synthesis by changing the proteins involved in these processes (PBPs, DNA 
gyrase and topoisomerase, RNA polymerase, ribosomes)169. Different from that, horizontally 
acquired resistance determinants mainly encode proteins for enzymatic drug modification (e.g. 
aminoglycoside-modifying enzymes) or degradation (e.g. β-lactamases), or for proteins involved in 
drug influx or efflux, and these alterations interfere less with cellular processes15. For horizontally 
acquired resistance, fitness costs are however also created by other factors than the resistance 
mechanism (see Fitness cost of plasmid carriage; reviewed in170,171).  
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The cost of resistance usually leads to a decline in resistant versus susceptible bacteria in absence of 
antibiotics. The greater the fitness cost is, the faster resistance should theoretically decrease in 
bacterial populations172. However, several studies revealed that newly acquired resistance by 
mutations173 (paper I) or HGT events128,130,160,161 (paper III) can impose a low or no fitness cost, 
and most worryingly, some examples for resistance determinants that confer a fitness benefit to their 
bacterial host also exist for mutations56,165 and plasmids161. Another important observation is that 
resistance-associated fitness costs can be reduced or ameliorated over evolutionary time, while 
resistance is maintained (see Solutions to the plasmid paradox). The evolution of no or low-cost 
resistant bacteria decreases the likelihood that they are outcompeted by drug-sensitive strains even 
when selective pressures are removed and stabilizes antibiotic resistance in bacterial populations. To 
contextualize the work of paper III, I will hereafter focus on the fitness costs associated to horizontal 
plasmid acquisition in bacteria and the proposed mechanisms that reduce this cost.  
 
Fitness cost of plasmid carriage  
There is not one straight forward mechanism that can be attributed to the cost of recently acquired 
plasmids (reviewed in171). Instead, several genetic and molecular conflicts arise from plasmid-host 
interactions, as indicated in Figure 10 and described below.  
All major HGT mechanisms, conjugation, transformation and transduction, facilitate the acquisition 
of plasmids, which involves the entry of ssDNA into the recipient bacterium. RecA-binding to this 
ssDNA triggers the cell’s SOS response, and as a consequence of DNA repair induction and slower 
bacterial cell division, fitness is temporarily reduced171 (Figure 10-2). Furthermore, specific fitness 
costs are associated with plasmid transfer by conjugation and presumably due to several factors such 
as the expression of plasmid-encoded ATPases and the conjugational transfer machinery (T4SS)174, 
as well as the transient overexpression of plasmid-encoded genes upon plasmid arrival in the recipient 
cell171. Likewise, infection of plasmid-carrying cells by so-called ‘male-specific’ phages via the 
conjugation apparatus reduces fitness inevitably (Figure 10-1). Once a plasmid is established in the 
cell, recombinase expression of plasmid-associated MGEs such as transposons can mobilize these 
elements into the host chromosome and cause detrimental effects on bacterial fitness if the element’s 
insertion interrupts genes that code for relevant host proteins or regulators171 (Figure 10-3). Although 
plasmid acquisition implies replication of some additional DNA, the requirement for extra 
nucleotides does generally not restrain bacterial fitness168. However, the expression of plasmid 
replication proteins was associated with induction of the bacterial SOS response and to plasmid costs, 
possibly through sequestration or inhibition of host replication or repair proteins. This was 
demonstrated for example for the interaction of RepA-expression from plasmid pSC101 and the host 
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primase DnaG in E. coli175, interaction of the replication protein gene rep of pNUK73 and P. 
aeruginosa helicases and proteinases176 and was also suggested for TrfA1, an IncP-1b replication 
protein, and the Shewanella oneidensis helicase DnaB177 (Figure 10-4). It appears however, that the 
greatest metabolic burden of plasmid carriage results from the sequestration or occupation of cellular 
components such as RNA polymerases and ribosomes, tRNAs, amino acids, which causes inefficient 
and inaccurate transcription and translation, respectively. In line with this, costly plasmid acquisition 
was associated to an increased, global transcriptional demand on the host cell, involving genes 
associated with translation or SOS response176,178 (Figure 10-5). The resulting lack or 
alteration/misfolding of essential host proteins disturbs downstream bacterial physiology or is lethal 
to the cell. Moreover, the more horizontally acquired proteins interact with established host protein 
networks, for example the cellular replication network, the more they impact a host’s fitness176 
(Figure 10-6). Finally, interference of plasmids with other horizontally transferred MGEs can 
produce fitness costs, which was demonstrated for plasmid pNUK73 in P. aeruginosa and the 





Figure 10: Illustration of plasmid-host interactions. Different stages of plasmid acquisition and maintenance by a 
bacterial host may cause fitness costs: 1) plasmid transfer by conjugation, 2) entry of ssDNA during HGT, 3) 
recombinational interaction between plasmid and chromosome, 4) plasmid replication, 5) plasmid-gene expression 
(transcription, translation), 6) plasmid- and host-protein interaction, 7) plasmid interactions with other MGEs. Reprinted 











The size of a plasmid does generally not correlate with the fitness burden it creates168,179. Both large 
and small resistance-encoding plasmids can be either rather costly or not so costly (Table 1). 
However, clinical resistance plasmids generally show low or no fitness burden in a clinically isolated 
host (see Table 1-a), while model plasmids or artificial plasmids largely impose a significant cost in 
laboratory strains (see Table 1-b). Larger resistance plasmids also carry more resistance genes180. 
However, it is the presence of particular resistance genes or an increasing number of antibiotics that 
the element confers resistance to that are responsible for higher fitness costs rather than the plasmid 
size, as demonstrated experimentally for blaCTX-M-15 and tetA/R in E. coli180, or in a meta-analysis168, 
respectively. For resistance plasmids in E. coli it was further shown in vitro that the number or the 
type of plasmid replicons that a host carries is not a good indicator for fitness costs, and this may be 
because known resistance plasmid replicons vary in their resistance gene content, which is a better 
predictor of fitness cost181. Furthermore, fitness costs vary between different plasmid-host 
combinations and depend both on the genetic background as well as the acquired plasmid that is 
tested128,130,161.   
 
Solutions to the plasmid paradox  
Undoubtedly, plasmids facilitate rapid bacterial adaptation to selective environments. However, their 
accessory traits are not generally essential for bacteria, and host fitness costs in plasmid-unselective 
conditions or their segregational loss during vertical inheritance should cause a decline in the 
frequency of plasmid-bearing cells relative to plasmid-free cells.  However, studies of different 
plasmid-host combinations show that conjugative as well as non-conjugative plasmids persist in 
bacterial populations over several hundred generations of plasmid-unselective cultivation128,130,161,182 
(paper III). This so-called ‘plasmid paradox’ has been the focus of theoretical models183,184 and 
experimental evolution studies (reviewed in 185,186), which describe at least five non-exclusive 
mechanisms for the maintenance of plasmids over evolutionary time scales. Solutions to the plasmid 
paradox comprise mechanisms of plasmid-host adaptation that impact plasmid stability, mobility and 
cost, which originate from genetic changes in the plasmid, the host, or both. The key mechanisms are 
related to:  
 
- improved segregational plasmid stability: evolution of a model plasmid in E. coli showed that 
stability was increased in the absence of plasmid-selection through a small duplication involving the 
plasmid’s ori region. This reduced the interference between plasmid replication and the transcription 
of a plasmid-associated accessory gene in proximity to the ori and improved plasmid stability187. 
Alternatively, plasmids can acquire addiction systems to improve their stability, which was 
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demonstrated for a conjugation-deficient as well as a conjugative plasmid and a transposon-associated 
toxin-antitoxin system in Pseudomonas moraviensis188 or S. oneidensis189, respectively. Similarly, 
the insertion of transposon-associated resolvases into plasmids positively affected the resolution of 
plasmid multimers and thus plasmid segregation188. Finally, an increase in plasmid copy number can 
facilitate plasmid stability by counteracting ineffective plasmid partitioning177,190.  
 
- selection for plasmid-associated traits: in vitro, sporadic exposure to plasmid-selective agents 
promotes the maintenance of extremely costly plasmids in bacteria191,192. However, mathematical 
models postulate that constant selection for plasmid-associated beneficial traits will not maintain the 
element extra-chromosomally, but select for backgrounds that captured the selective trait 
chromosomally184.  This was also demonstrated in vitro and facilitated through the association of 
beneficial plasmid genes to transposons. Surprisingly, transposition to the chromosome of 
Pseudomonas spp. occurred in plasmid selective as well as unselective conditions and decreased 
plasmid frequency178,193. 
 
-high conjugation rates: theory suggests that the loss of plasmid-bearing cells through segregation 
or fitness costs can be offset by high rates of conjugational plasmid transfer183. In vitro, this was 
shown for some very efficient plasmid donors194, but sufficiently high conjugation rates are not 
commonly observed in vitro186. In addition, conjugational plasmids could be maintained by infection 
of bacteria that are not under negative selection, for example other strains or species that are present 
in the specific ecological niche184. However, the costs associated to horizontal plasmid spread by 
conjugation reduce vertical plasmid inheritance195 and conjugation may thus not represent the major 
evolutionary trajectory for plasmid maintenance174,196. Especially since analysis of GenBank plasmid 
sequences shows that only around 50% of these plasmids are conjugative197. Yet, plasmids seem to 
be maintained by other HGT mechanisms or by plasmid-host dynamics described here, and also 
benefit from the simultaneous spread with conjugative plasmids if they are mobilizable.  
 
- compensation of fitness costs: the evolutionary selection for reduced plasmid costs is very likely 
key to plasmid persistence, however the so far described underlying mechanisms are rather diverse. 
This is different from mutational resistance, for which in vitro and in vivo (mice and humans) studies 
frequently demonstrate that cost compensation primarily occurs through the re-establishment of the 
cellular function that got impaired by the resistance mechanisms198. Compensatory mutations can 
arise in the same gene as the resistance mutation, or externally, and restore for example the translation 
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elongation rate at the ribosomes of aminoglycoside resistant E. coli199, or the RNA polymerase 
transcription efficiency in rifampicin resistant E. coli200, thus reducing fitness costs. 
Plasmid cost compensation was first described in the late 80’s by Bouma and Lenski, who found that, 
after 500 generations of host-plasmid adaption, pACYC184-carriage was even beneficial201. More 
recent reports on the genetic changes and mechanisms behind this so-called compensatory evolution 
find that host adaptation occurs more frequent than changes in the plasmid but appears also in both 
loci simultaneously (Table 1). Importantly, compensatory mutations arise specifically in plasmid-
carrying lineages where they improve fitness, but not in plasmid-free cells, where they might even 
reduce fitness178,201. Plasmid-host adaptation was observed after experimental evolution 
with177,188,190,201 and without161,196,202 (paper III) antibiotic selection pressure.  
At least four studies demonstrated that mutations in plasmid or host replication proteins improved 
bacterial fitness by reducing the detrimental interference between the replication machineries, and by 
prevention of the SOS response176,177,190,203. Mechanistically, this was achieved by mutations in the 
plasmid’s replication initiation protein TrfA1189,190, which decreased the protein’s affinity to the DNA 
helicase DnaB of S. oneidensis and Pseudomonas putida177. Likewise, the loss of chromosomal 
UvrD-like helicase or kinase functions of P. aeruginosa PAO1 reduced the expression of a plasmid’s 
replication protein, and thus fitness costs176. In Pseudomonas sp. H2, mutations affecting 
chromosomal helicase functions (Xpd/Rad3 or UvrD-like) were even shown to provide RP4-carrying 
strains with a fitness benefit compared to isogenic plasmid-free strains203. Further, the deletion of 
plasmid-associated resistance genes204, genes for conjugational transfer196, or both174 alleviated the 
plasmid cost. Such events are facilitated if costly genes are flanked by MGEs174,204. In vitro, the cost 
of conjugative plasmids was also decreased by host-adaptive changes that reduced transfer rates196, 
which could also theoretically be correlated to cost reduction195. Finally, compensatory mutations 
that altered the transcriptional demand of plasmid-carriers ameliorated plasmid costs. This was for 
example achieved by mutational inactivation of the global regulators GacA/S in Pseudomonas 
fluorescens178 or inactivation of chromosomal helicase/kinase functions in P. aeruginosa191, which 




Table 1: Fitness costs of newly acquired plasmids in various hosts and the effect of compensatory 
evolution. 
 
Host Plasmid Fitness effectc Effect of adaptation (which partd) 
E. coli128  
(23 isolates) 
pK71-77-1-NDM (~145 kb) (a) 
(blaNDM-1)     
majority no cost,  
3% to 27% cost 
not studied 
E. coli MG1655187  pCON (~3 kb) (b) no cost not studied 
E. coli130  
(2 isolates) 
pG12-KPC-2 (~111 kb) (a) 
(blaKPC-2)  
2 and 4% cost not studied 
K. pneumoniae205  pKpQIL (~114 kb) (a) 
(blaKPC-3)   
no cost not studied 
K. pneumoniae  
and E. coli96  
pUUH239.2 (~220 kb) (a) 
(blaCTX-M-15/TEM-1/OXA-1)  
no and 4% cost not studied 
E. coli206  seven plasmids (>100 kb) (a) 
(blaCTX-M-14/15/27)  
no cost not studied 
Enterobacteriaceae207  
(29 isolates) 
p3R-IncX3 (~46 kb) (a) 
(blaNDM-5)  
majority no cost not studied 
E. coli MG1655208  R1 (~100 kb) (b) 32% cost cost amelioration or 
fitness benefit (p+c) 
E. coli B201,209  pACYC184 (~4 kb) (b) 5-10% cost fitness benefit (c) 
E. coli K12196  RP4 (~60 kb) (b) 
R1 (~100 kb) (b) 
21% cost,  
6% cost 
cost reduction (p+c) 
K. pneumoniae  
and E. coli174  
pKP33, (~73 kb) 
(blaCTX-M-15/TEM-1/OXA-1) (a)  
6% to 12.5% cost cost amelioration (p) 
P. aeruginosa PAO1191  pNUK73 (~5 kb) (b) 21% cost cost amelioration (c) 
P. fluorescens SBW25178  pQBR103 (~425 kb) (b) 27% cost cost amelioration (c) 
E. coli paper III  
(1 isolate)  
pK71-77-1-NDM (~145 kb) (a) 
pG06-VIM-1 (~53 kb) (a) 
(blaNDM-1 and blaVIM-1)   
5% cost cost amelioration (c) 
Pseudomonas sp. H2203  RP4 (~60 kb) (b) 7% cost fitness benefit (c) 
Enterococcus faecium161  
(6 isolates) 
six vanA-plasmids (a) 
(between 80 and 200 kb)  
25% cost, 
no cost, 
or 10% benefit  
fitness benefit (p+c) 
a: clinical plasmid/host; b: model plasmid/lab host; c: fitness assessed by growth rate measurements or competition 
experiments; d: p = plasmid, c = chromosome. 
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In conclusion, plasmid persistence in bacterial populations is impacted by several factors, and the 
long-term maintenance of plasmids is likely due to a combination of the above-described evolutionary 
dynamics. Interestingly, plasmid-host evolution frequently results in trade-offs, such that 
compensation increases fitness and improves the vertical inheritance of plasmids but at the same time 
reduces their horizontal spread174,196 or constrains the plasmid’s host-range by specialization of 
plasmid-host pairs190. However, in addition to cost compensation, plasmid-host adaptation also 
improved the permissiveness of adapted Pseudomonas hosts to various naive plasmids203. So far, our 
knowledge on plasmid-host adaptation is largely based on studies in controlled laboratory 
environments using laboratory-based model systems. This situation warrants research towards 
understanding the evolutionary trajectories that stabilize plasmid-associated resistance in plasmid-
host pairs of clinical origin as in Porse et al.174 or paper III, where we find that growth adaptation of 
patient-derived E. coli isolates to the experimental conditions pleiotropically alleviates the cost of 
clinical MDR plasmids. The cost compensating adaptation occurred independent of plasmid-carriage 
and thus represents a novel solution to the ‘plasmid paradox’.
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Reversibility of resistance 
Since the use of antibiotics selects resistant and removes susceptible clones in bacterial populations, 
a reduction in drug consumption should also decrease the frequency of resistance. The major driving 
force for the loss of resistance in such unselective conditions is the fitness burden that resistance 
determinants usually impose on bacteria, and resistant bacteria theoretically emerge less the greater 
the fitness cost is172. Most antibiotics are prescribed on the community-level210. However, 
interventions to reduce antibiotic use in the community did not result in an adequate decline in 
resistance211,212, showed persisting resistance even after 12 years20, or worse, significantly increased 
the prevalence of plasmid-associated resistance due to a fitness benefit of resistant strains over 
susceptible ones213. These observations can be explained by several biological and evolutionary 
processes that stabilize resistance determinants in bacterial populations20,214, for which examples are 
listed here: 
  
- if bacteria re-acquire resistance at high enough rates by mutations or HGT events 
- if resistance is co-selected with physically linked beneficial traits, for example antibiotic or heavy 
metal resistance genes or virulence factors (e.g. on MGE; see Mobile genetic elements)  
- if resistance is genetically associated with highly transmissible, clinically widespread clones12 
- if resistance is associated with plasmid-stability functions (see Plasmids) 
- if the selective disadvantage of resistance is weak or absent due to low or no cost of resistance, 
and/or compensatory evolution (see Bacterial fitness and cost of antibiotic resistance) 
- if antibiotic selection pressures are sustained either because the overall volume of drug use is 
unchanged or sporadic exposure to antibiotics, even at very low concentrations, occurs50,51 
 
It becomes apparent that, even if antibiotics are removed, straightforward reversal of resistance is 
difficult or even impossible due to the interplay of the many factors mentioned above. Unfortunately, 
the development of innovative antibiotics, for example from a novel drug class, with a novel drug 
target or binding site or with a novel mode of action, is stagnating6. In the light of this antibiotic void, 
research increasingly focuses on optimizing the use of available drugs and minimizing resistance 
evolution. To provide the background for the work done in paper I, I describe an evolution-informed 
approach for infection treatment using drug combinations below. 
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Evolution-informed treatment strategies  
Typically, drug combinations are used in the treatment of chronic or severe infections with the 
rationale to clear the infection more efficiently through a broadened and stronger antibiotic effect, 
and to delay the emergence of de novo resistance215. Treatment efficacy is ideally enhanced by 
interactions between the combined drugs that change the bacterial physiology and increase the killing 
or growth inhibitory effect beyond what is expected based on the individual drug effects 
(synergism215). More recently, selection inversion strategies were described in the context of 
combination therapy216. Those rely on the spontaneous evolution of resistance before the benefit of 
combining antibiotics is conveyed. For example, resistance acquisition can relax a suppressive drug-
interaction or induce synergistic drug-interactions and thus increase antibiotic potency upon evolution 
of single-drug resistant mutants216. Moreover, resistance evolution can lead to a biological 
phenomenon called collateral sensitivity (CS)217. CS is the opposite of cross resistance (CR = 
resistance to one drug confers also resistance to other antibiotics) and confers resistant mutants with 
increased susceptibility to certain antibiotics. Therefore, the phenomenon is also called negative 
cross-resistance218 or hypersensitivity219. Research into the design of CS-informed treatment 
strategies has gained considerable interest during the last decade with the aim of limiting resistance 
development by selecting against resistant mutants. 
 
Collateral sensitivity: concept 
CS in bacteria was first described in 1952, when Szybalski and Bryson reported that “a strain made 
resistant to one antibiotic [became] considerably more sensitive to another”217. The usefulness of this 
sensitivity-tradeoff in bacterial infection treatment was however only put under scrutiny in 2013, 
when Sommer et al. introduced the idea of ‘collateral sensitivity cycling’220. In this context and 
considering the use of two drugs, resistance evolution during treatment with drug A could be 
counteracted by switching to drug B if the genotype resistant to A collaterally increased its 
susceptibility to B (Figure 11). Such an evolutionary tradeoff inverts the usual selection dynamics 
and resistant mutants are not selected anymore. If CS to A and B evolves reciprocally, the drugs can 
be switched periodically upon de novo resistance emergence. At every switch, the resistant 
subpopulation is preferentially eliminated compared to the sensitive wildtype and hence the 
population susceptibility returns to wildtype levels. Then, the infection can be cleared by the 
combined effect of drug treatment and host immune system. CS could be exploited using one drug at 
a time i.e. sequentially/cycled218,220, or by co-administration of drugs219,221,222. Single-drug therapy, 
however, reduces the overall drug load and thus exhibits less adverse effects as well as it decreases 
the likelihood to select for resistance to both drugs. 
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Figure 11: Example of a cycling protocol using a drug pair (A and B) for which resistance evolution in bacteria (orange 
and blue dots) results in reciprocal CS, meaning that resistance to one drug reinforces increased susceptibility to the other 
drug and vice versa (indicated as graphs). Thus, antibiotics can be used to select against the resistant subpopulation. 
 
 
Collateral sensitivity: findings, limitations and predictors 
To identify collateral responses in bacteria, the first systematic in vitro studies measured susceptibility 
changes in laboratory-evolved, single-drug resistant E. coli mutants towards large panels of 
antibiotics219,220. Those first screens found that in E. coli, CS evolved reciprocally between 
aminoglycoside, polymyxin and tetracycline drugs classes220. By today, a variety of clinically 
relevant G+ and G- pathogens such as S. aureus or Staphylococcus epidermidis49,218,222,223, E. 
faecalis224, Burkholderia multivorans225, Salmonella enterica164, P. aeruginosa226, and other clinical 
relevant organisms227 have been investigated for CS/CR, most of the studies using single laboratory 
model strains. Importantly, the more recent reports employed larger sample sets of clinical isolates 
of E. coli (paper I), P. aeruginosa228 or S. aureus222 to study CS/CR responses.  
CS/CR effects are typically assessed by measuring the antibiotic concentration that is required to 
inhibit growth of a resistant strain as well as its susceptible wildtype strain, and calculation of the 
relative fold changes of susceptibility, which are visualized in heat maps and in networks of collateral 
responses219,220 (paper I). Hitherto it was demonstrated, that both CS and CR are common 


























are often as small as 2 to 4-fold219,220,227 (paper I). Even for such small magnitudes, the selective 
consequences associated to CS could be demonstrated by different approaches: in vitro dose-response 
experiments confirmed that the growth of resistant mutants with CS towards a certain antibiotic is 
inhibited at lower drug concentrations than the wildtype219,220 (paper I). Aminoglycoside-resistant E. 
coli exhibited CS towards a particularly large number of antibiotics, also from different drug classes, 
which lead to the selective growth inhibition of such mutants in dose-response experiments219,220. 
Compared to single antibiotic exposure, the combined221,223 or sequential218 use of drugs to which CS 
evolved, slowed down resistance evolution of E. coli221 and S. aureus218,223, which was 
experimentally demonstrated by the lower resistance levels developed during drug exposure 
compared to a wildtype. Time-kill experiments in E. coli demonstrated that a resistant mutant is 
eliminated faster than the wildtype by the drug towards which CS was observed220. The latter was 
shown for antibiotics from different drug classes to which the respective resistant mutant exhibited 
reciprocal CS, for example gentamicin and cefuroxime220. Furthermore, reciprocal CS effects 
between antibiotics of the same drug class (β-lactams) slowed down E. coli229 or methicillin-resistant 
S. aureus222 resistance evolution in vitro and in a mouse model. Finally, in vitro cycling of two 
bactericidal antibiotics with reciprocal CS repeatedly eradicated the resistant subpopulation from a 
mixed E. coli wildtype/resistant population220. 
So far, few in vitro studies investigated in which way collateral effects on growth inhibition of 
resistant mutants also alter the MPC (see Mutant selection window) to secondary drugs. In resistant 
E. coli, the MPC was shifted towards lower or higher antibiotic concentrations according to the sign 
of the collateral susceptibility change220 (paper I). CS towards erythromycin in different single-drug 
resistant S. epidermidis mutants frequently narrowed the concentration range in which first-step 
mutants emerged (MSW)49. Importantly, the same study found that CS network patterns based on 
growth inhibition and MPC were similar49. 
Our knowledge on the relevance of collateral effects emerging from horizontal resistance acquisition 
is still limited, but was investigated for the plasmid-associated genes blaCTX-M-15229 and blaOXA48230, 
or MDR plasmids231 in E. coli. Evolution of resistance to ceftazidime and mecillinam by mutations 
in blaOXA48 and blaCTX-M-15, respectively, resulted in CS towards other β-lactams, including 
carbapenems230 or cefotaxime229, respectively. Furthermore, reciprocal CS between mecillinam-
resistant and cefotaxime-resistant blaCTX-M-15-variants limited resistance evolution in vitro and in 
mice during combination treatment with these drugs229. Such CS phenotypes exemplify how 
collateral responses upon resistance evolution would allow the use of previously ineffective drugs for 
strains that harbor these widely disseminated MDR determinants. E. coli acquisition of MDR 
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plasmids resulted in small but, in some cases, significant CS for aminoglycosides, macrolides or 
polymyxins231. 
Despite the frequent evolution of CS in single-drug resistant bacteria, several factors affect the 
successful use of CS-informed treatment in medical practice. It was demonstrated that CS responses 
evolve repeatedly in independent populations exposed to a specific drug, however the responses 
varied with the diversity of mutational paths towards resistance in vitro164,226 and in a mathematical 
model232. When investigated across different species, even the same resistance mutation led to 
different CS responses164. Also, genetic interaction with de novo resistance mutations in the resistant 
strain during treatment233 or the acquisition of compensatory mutations over evolutionary time 
(Sørum et al., unpublished data) interfere with the stability of collateral networks and how efficient 
bacteria can be eradicated through CS tradeoffs. Importantly, we identified that the resistance 
mechanism, especially efflux mutations, as well as the relative fitness of resistant mutants provide 
some degree of predictability for collateral responses across diverse uropathogenic E. coli isolates 
(paper I). 
 
Collateral sensitivity: mechanisms  
Albeit the number of studies that investigate the frequency of CS is growing, the mechanisms of this 
phenomenon are still poorly understood. CS is likely achieved by an enhanced antibiotic-target 
interaction and growth inhibition, which represents, on a molecular level, an inversion of resistance 
mechanisms234. Firstly, CS can be caused by an increased net uptake of drug molecules into the cell, 
or by their reduced efflux. For the latter, Lazar et al. were the first to describe a CS mechanism in E. 
coli. Mutations in trkH, cyoB/C, ispA, nuo or hemA resulted in aminoglycoside resistance due to a 
decreased inner membrane potential and reduced active uptake of these drugs219. Simultaneously, 
antibiotics that are substrate for proton motif force-dependent efflux pumps such as AcrAB-TolC 
accumulated intracellularly, leading to CS219. Secondly, increased chemical activation of 
nitrofurantoin was linked to CS. Mutations in spoT, lon, or hemL in mecillinam- and tigecycline-
resistant E. coli upregulated expression of the nitroreductases NfsA and NfsB, and the increased 
formation of the toxic intermediate led to CS towards nitrofurantoin234. Thirdly, CS could be caused 
by an increased toxicity of the drug, for example by activation of the SOS response. This effect was 
described for a tigecycline-resistant lon mutant of E. coli with CS towards nitrofurantoin234. Lastly, 
an enhanced drug binding at the target can promote CS. This can be caused by allosteric changes of 
the target structure222, or as suggested for mecillinam-resistant blaCTX-M-15-variants, by reduced 
affinity of the mutated enzyme to another antibiotic, in this case cefotaxime, which is free to bind to 
the target229.  
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Objectives 
This PhD thesis aimed to increase our understanding of the selection, spread and maintenance of 
bacterial antibiotic resistance. We investigated: 
 
1. a strategy of selection inversion in drug resistant populations (paper I) 
2. a mechanism that facilitates the horizontal spread of antibiotic resistance (paper II) 
3. the maintenance of plasmid-mediated antibiotic resistance (paper III). 
 
 
The specific objectives were:  
 
Paper I 
• to determine collateral sensitivity networks for relevant antibiotics across a diverse set of 
single-drug resistant (ciprofloxacin, mecillinam, nitrofurantoin, trimethoprim), clinical 
isolates of uropathogenic E. coli; 




• to determine the frequency of Tn1-transposition during natural transformation of A. baylyi; 
• to identify host and element functions that are required for transposition.  
 
Paper III 
• to determine the fitness of uropathogenic E. coli isolates that carry carbapenemase-encoding 
resistance plasmids (blaVIM-1 or blaNDM-1) before and after experimental evolution; 
• to identify genomic targets of plasmid-host adaptation; 
• to investigate mechanisms that contribute to plasmid maintenance. 
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Materials and Methods 
 
Bacterial species 
Escherichia coli and the ECOSENS collection 
Escherichia comprises motile, facultative anaerobic, G- rods of the family Enterobacteriaceae. The 
first isolate of the genus was obtained from the gut of an infant in 1885235. The species Escherichia 
coli is a symbiotic inhabitant of the mammalian gut and predominantly found in the small intestine236. 
Increasingly, environmental samples of Escherichia can be genetically distinguished237,238. For more 
than 100 years, descendant strains of E. coli K-12 and B239 have been exploited as malleable model 
organisms for molecular, biotechnological and genetic studies240. For example, fundamental findings 
in E. coli are related to sexual recombination in bacteria, such as the discovery of bacterial gene 
transfer by conjugation241 and transduction242, and the description of today’s plasmids243,244. The 
amount of research done on E. coli is also exemplified by over 22 000 E. coli genomes that are 
deposited online to date245. The first fully assembled genome was available in 1997 (E. coli strain 
MG1655)246, followed by increasingly accurate sequences247, which facilitated the construction of an 
E. coli single-gene knock-out collection for the study of gene essentiality248. Experimental evolution 
studies using E. coli cover different aspects of microbial adaptation processes, for example the 
adaptation to different growth conditions249,250, fitness dynamics of adaptation157,161 (paper III) or 
the evolution of antibiotic resistance50,219,221,251 (paper I). An immense effort and scientific 
commitment are put into the continuation and analysis of the long-term experimental evolution of E. 
coli by Lenski and co-workers, which is already exceeding 76 000 bacterial generations252. 
Apart from being a persistent or transient commensal, pathogenic E. coli frequently cause diarrhea, 
urinary tract infections (UTIs) and even serious bloodstream infections or meningitis253,254. From the 
human gut as a common reservoir, intestinal and extra-intestinal sites can be colonized by pathogenic 
E. coli, which are abbreviated as IPEC or ExPEC, respectively255.  E. coli’s etiological potential is 
further categorized into pathotypes based on disease symptoms, virulence determinants and 
phylogeny, for example uropathogenic E. coli (abbreviated as UPEC) or enterohemorrhagic E. coli 
(abbreviated as EHEC)255. Additional subdivision based on surface antigen -O, -H, and -K (serotype), 
multi-locus sequence typing, and biochemical properties (biotype) is important to understand the 
epidemiology of E. coli pathogens255,256. A combination of core and accessory genome analysis is 
suggested to more accurately distinguish E. coli pathogens from commensals255,257, and also E. coli 
pathotypes from one another258.  
UTIs are most often caused by UPEC254. In two multicenter studies including 16 European countries 
and Canada the prevalence of UPEC ranged between 74%-77% of all tested organisms associated to 
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community-acquired uncomplicated UTI in women (ECOSENS Project I259 and II68). UPEC present 
an enhanced metabolic flexibility to survive in the rather hostile microenvironment of the bladder and 
kidney, which is nutritionally poor and nitrogen-rich260. Via the fecal-periurethral route UPEC infect 
the bladder (cystitis), however, the infection can also involve the kidneys (pyelonephritis) and from 
there enter the bloodstream through tissue invasion253. UPEC belong to diverse STs and mainly to 
phylogroups B2, A and D261,262. The E. coli strains used in this thesis originate from the ECOSENS 
studies I259 (paper I) and II68 (paper I and paper III), respectively, and were isolated in Greece, 
Portugal, Sweden, and the UK. These 11 UPEC isolates were pan-susceptible according to disc 
diffusion tests, belonged to diverse STs as determined by multi-locus sequence typing and were 
plasmid-free according to results from pulse-field-gel electrophoresis and PCR-based replicon 
typing261. Our own bioinformatic analysis revealed a different ST than previously described for two 
isolates, the presence of plasmids for three of the employed isolates and an acquired resistance 
element or mutational resistance determinants in four strains (paper I).  
 
Acinetobacter and strain A. baylyi ADP1 
The first organism that represents the current Acinetobacter classification was isolated in 1911 from 
soil263. This genetically diverse genus comprises more than 60 species that belong to the family 
Moraxellaceae264,265. Its members are G-, non-motile, non-spore forming and strictly aerobically 
growing coccobacilli i.e. they may form rod-shaped cells during exponential growth that become 
coccoid when entering stationary phase266. Acinetobacter spp. can be isolated in high abundance from 
soil and aquatic environments267, or activated sludge268. Also food samples (vegetables, dairy 
products, meat and fish) and the human flora, especially skin, represent a natural habitat269,270. 
However, members of the ‘Acinetobacter baumannii complex’ (A. baumannii, A. pittii, A. 
nosocomialis) are only rarely found in environmental habitats but instead represent the frequent cause 
of MDR hospital infections, for example UTI, wound infections, ventilator-associated pneumonia 
and bloodstream infections271-273.  
In paper II, a spontaneous rifampicin-resistant mutant of A. baylyi strain ADP1 was used268,274. 
Taylor and Juni first isolated the organism from soil in 1960275, and its high competence for the uptake 
of exogenous DNA by bacterial natural transformation was soon after demonstrated276. Genome 
analysis of diverse Acinetobacter spp. suggests that most members of the genus can undergo natural 
transformation under conditions that induce the expression of competence genes37. Interspecies 
transformability was confirmed for clinical isolates of A. baumannii and also other Acinetobacter 
spp.106,107,277-280. A. baylyi is closely related to A. baumannii37 and shares around 80% identity in core 
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genes with clinical isolates of this species281,282. It is gaining more attention as a potential pathogen 
due to its, still sporadic, clinical occurrence in immune-compromised patients283,284. 
A. baylyi ADP1 is a widely used model organism to study the adaptive potential of bacterial natural 
transformation113,285,286. This is due to its competence for DNA uptake at high frequencies110,274,287 
from all kinds of sources110, even eukaryotic114, and easy handling in the lab, which results from its 
minimal nutritional requirements and a short generation time288. The transformation capabilities of 
ADP1 are thoroughly investigated; frequencies as high as 10-3 can be measured for homology-
facilitated transformation with chromosomal donor DNA and 10-4 for plasmid transformation, 
respectively110. In liquid culture, ADP1 develops maximum competence for DNA uptake once the 
availability of nutrients is increased, for example directly after dilution of an overnight culture into 
fresh medium110. Competence only drops when the strain enters stationary phase289. Transformation 
is facilitated by the addition of DNA into a growing culture, and ADP1 binds and takes up 
extracellular, dsDNA indiscriminate of origin (e.g. not species-specific287), topology (linear or 
circular DNA110) or nucleotide sequence (heterologous or homologous DNA110). DNA-uptake 
sequences are not described for Acinetobacter spp., and ssDNA transformation of ADP1 can occur 
but is inefficient110,114. The ADP1 genome does not include plasmids281 and is unusually small but 
represents the average genome size of the Acinetobacter genus37 (3.6 and 3.8 Mbp, respectively). A 
single-gene knock-out collection of ADP1 has been constructed290, and further genetic manipulation 
of ADP1 was used to study various metabolic pathways and molecular mechanisms that contribute 
to genome plasticity in bacteria, thereby exploiting its nutritional versatility and natural 
transformability285,291.  
 
No drugs for bad bugs 
Both of the above-described bacterial genera include species that present a particular threat in the 
global emergence of resistant pathogens292. A. baumanni and E. coli are classified as so-called 
ESCAPE organisms293 (originally ESKAPE294) together with E. faecium, S. aureus, Clostridium 
difficile, P. aeruginosa and other Enterobacterales such as K. pneumoniae, for which current 
treatment options are increasingly insufficient due to MDR infections. More specifically, ESBL-
producing or carbapenem-resistant Enterobacterales including E. coli, and carbapenem-resistant A. 
baumannii, represent pathogens for which research and drug development efforts are of critical 
priority according to the World Health Organization9.  
Although the rate of carbapenem-resistant E. coli blood isolates in most European regions is reported 
to be below 2% in 2019, a rising trend can be observed10. For example, colonisations and infections 
with carbapenem-resistant isolates of Enterobacterales in Norway increased 10 times from 2008 to 
2018 (54 patients)295. During this time, selection for carbapenem resistance rose with the clinical use 
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of these drugs in infections with third generation cephalosporin-resistant E. coli, which increased 
significantly across Europe10,296 (Figure 12, top).  
Many Acinetobacter spp., including the clinically predominant A. baumannii, are intrinsically 
resistant to a wide range of antibiotics43. Incidence of clinical Acinetobacter isolates resistant to 
carbapenems (mainly due to carbapenemases), aminoglycosides (mostly through aminoglycoside-
modifying enzymes) and fluoroquinolones (efflux pump-related) is especially high in some Baltic, 
Southern and South-eastern European countries, and evolves through a combination of mutational, 







































Figure 12: National percentages for blood isolates of third generation cephalosporin-resistant E. coli (2019) and 
Acinetobacter spp. resistant to fluroquinolones, aminoglycosides and carbapenems (2018). Reprinted from10,297  
E. coli Acinetobacter spp.
E. coli Acinetobacter spp.
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Methodological approaches  
Further experimental details can be found in the respective papers I-III.  
 
Collateral sensitivity networks in E. coli UTI isolates (paper I) 
As previous studies tested collateral responses against a larger panel of antibiotics only in laboratory 
strains (E. coli MG1655220,221, E. coli BW25113219), we employed ten E. coli isolates from patients 
diagnosed with uncomplicated UTI (ECOSENS I259 and II68). Importantly, the strains were 
phenotypically pan-susceptible to antibiotics and thus collateral effects could be determined for 
individual antibiotic resistance mutations. To account for the impact of strain diversity on collateral 
networks, we chose to work with different STs, as determined in261. The antibiotics to which primary 
resistance was evolved in these strains (ciprofloxacin, nitrofurantoin, mecillinam, trimethoprim) were 
chosen due to their clinical relevance in the treatment of uncomplicated UTI in women according to 
national (Norway)298 and international (Europe and USA)299 guidelines. Nitrofurantoin, trimethoprim 
(-sulfamethoxazole) and (piv)mecillinam represent drugs which are recommended in the first-line, 
empiric therapy of uncomplicated UTIs caused by common uropathogens due to their good clinical 
and microbiological efficacy. Other β-lactams and also fluoroquinolones, such as ciprofloxacin, 
should only be considered as alternative treatment options for complicated UTI298,299.  
To obtain resistant E. coli mutants at or above the respective clinical breakpoint according to 
EUCAST45 (version 7.1), we used a static, stepwise selection regime on solid media containing 
ciprofloxacin, nitrofurantoin, mecillinam or trimethoprim in two-fold increasing concentrations. This 
method is comparable to the gradient plate technique employed in the pioneering studies investigating 
bacterial CR/CS217,220. In several selection rounds, increasing lethal concentrations of antibiotics are 
used to select for increasingly resistant mutants. At each replating event on higher concentrations, 
strong selection pressure for resistance acquisition, and bottlenecks, are applied. The cultivation steps 
were kept at a minimum throughout this selection procedure to avoid acquisition of adaptive 
mutations to the laboratory environment. To confirm resistance of the 40 mutants phenotypically, we 
performed AST by the gradient strip method to obtain the MIC. Next, we assessed collateral effects 
in our mutants by BMD, monitoring bacterial growth in an antibiotic gradient and measuring optical 
density (OD600), determination of the 90% inhibitory concentration therefrom (IC90; strongly 
correlates to inhibition levels IC50 or IC95 and thus approximates the MIC221), and generation of heat 
maps and CS/CR networks, as previously described220. The BMD method represents the gold 
standard in AST and improved overall sensitivity and precision. Compared to strip tests, where 
changes in susceptibilities are estimated from visual determination of growth inhibition and with a 
sensitivity of 2-fold, BMD allowed high-throughput screening of susceptibility changes by automated 
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endpoint absorbance measurements, and an increase in resolution to 1.5-fold. We assayed CR/CS 
responses towards 16 different antibiotics, including bacteriostatic and bactericidal drugs with diverse 
modes of action to which our wildtype strains were phenotypically susceptible. Furthermore, the 
selected agents represented frequently or conservatively used (for example the last-line drug colistin), 
clinically relevant antibiotics, older antibiotics (for example temocillin and fosfomycin), and drugs 
that are not licensed in all European countries (fosfomycin). Conserved collateral effects (when 
CR/CS to a specific antibiotic was prevalent in ≥50% of mutants) where further characterized by 
generating dose-response growth inhibition curves and MPC measurements for representative 
resistant mutant-wildtype pairs, as was also done previously220. 
Similar to Lazar et al.219, we investigated the genetic mechanism of resistance by whole genome 
sequencing (WGS). Short-read next generation, paired-end sequencing was performed by Illumina 
technology, which	 is	currently the most accurate sequencing technique. A reference genome was 
assembled for each wildtype strain. By using WGS, read alignment, BLAST search, and intensive 
literature study, we identified putative resistance mutations. WGS was especially useful for 
mecillinam mutants, since resistance to this drug reportedly can be achieved by mutations in at least 
38 different genes66. The concentration at which first-step resistant mutants are prevented to arise, 
the MPC, was determined similar to Imamovic et al.220. Two-fold increments in antibiotic 
concentrations were employed since the endpoint determination by distinction of growth/no growth 
turned out problematic using 1.5-fold changes. This was likely due to the required large amount of 
inoculum (approximately 1010 cells48) causing an uneven growth inhibition.  
To determine the relative fitness (w) of resistant mutants, we measured the maximum exponential 
growth rate (r), which is a commonly used fitness parameter and reflects a strain’s ability to 
reproduce. Growth rate measurements were performed on all 40 mutants and their respective 
wildtypes and determined by following changes in the optical density (OD600) of individually growing 
strains in liquid culture. Although this measure captures growth dynamics just during exponential 
phase and only fitness differences >5% are detected, it represents a quick and easy method to 
approximate fitness without the need for a selective marker gene156. Multivariate statistical analysis 
was performed by redundancy analysis to quantify how much strain background, presence of efflux-
related mutations and relative fitness explains the observed variation in collateral responses. 
 
Horizontal spread of resistance-transposons by natural transformation (paper II) 
The horizontal dissemination of resistance by transposition-mediated natural transformation was first 
demonstrated in A. baylyi strain ADP1 by Domingues et al.118. To further investigate this finding, we 
employed the same recipient strain since it is highly competent for natural transformation, which 
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facilitated the detection and quantification of the expected rare recombination events, and easy 
genetic manipulation of recipient strains. Standard in vitro assays for bacterial natural transformation 
can be performed either in liquid culture or by applying the transformation mix on a filter (detailed 
protocols in300). Since the frequency of transposition was reported to be low118, we performed our 
transformation assays in liquid culture, as described previously301, where the detection limit can be 
decreased simply by upscaling of the assay volume. 
Domingues et al.118 reported the transposition of Tn21, a well-described element of the Tn3-family 
of replicative transposons. Relating to this finding, our donor DNA contained Tn1, an element of the 
same transposon-family which also moves by a copy-and-paste transposition mechanism147. Tn1 
encodes a β-lactamase (blaTEM-2)302 and its sequence is highly identical to Tn2 and Tn3142. All three 
elements express resistance to ampicillin and additional β-lactam antibiotics and are of clinical 
relevance especially in G- species95. Tn1 has a small size (4.9 kb), which simplified cloning 
procedures. To increase the amount of intracellular transposon copies per net amount of incoming 
DNA during natural transformation, we constructed a plasmid-vector containing Tn1. This narrow-
host range plasmid carried an origin of replication (p15A) that is only functional within 
Enterobacteriaceae, so stable plasmid replication in ADP1 was not expected. Donor DNA and 
recipient genome did not contain sequence similarities that would promote homology-facilitated 
recombination events. 
The efficiency of natural transformation increases with the amount of donor DNA added, following 
a saturation kinetic110. Due to the low frequency of reported transposition events118, near-saturating 
amounts of extracellular donor DNA were added to the assay to ensure DNA uptake by the majority 
of cultured cells. Both circular plasmid DNA as well as linear donor DNA were employed in 
transformation assays to investigate whether the transient expression of transposon genes in the 
bacterial cytoplasm depended on the possibility for plasmid establishment. Linear donor DNA was 
amplified by PCR from plasmid templates, or by restriction enzyme digestion of the plasmid. 
However, the complete elimination of circular template DNA could only be achieved by enzymatic 
restriction of donor DNA and additional agarose gel purification of previously restricted DNA. 
Transposition results in characteristic TSDs147. We verified transposition events phenotypically by 
selection of ampicillin-resistant candidate clones and transposon-specific PCR. To confirm 
transposition events genetically, genomic DNA was isolated from Tn1-containing isolates and Sanger 
sequencing was performed using outward facing primers with respect to the Tn1 sequence. This 
allowed the identification of transposon insertion-site within the ADP1 chromosome. 
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The requirement for host- and/or transposon-functions for transposition in the course of natural 
transformation was not investigated before, and we used ADP1 mutant recipients or modified donor 
DNA to study the role of specific enzymes on transposition-mediated natural transformation.  
 
Evolution of plasmid-mediated antibiotic resistance (paper III) 
With respect to the clinical problem of plasmid-driven resistance, there is a lack of studies employing 
clinically relevant plasmid-bacteria combinations to investigate compensatory evolution303. Here, two 
plasmid-host combinations were constructed from clinical plasmids that confer carbapenem 
resistance, pG06-VIM-1129,130 and pK71-77-1-NDM128,304, and a clinical UPEC isolate (ST537)259,261. 
The plasmids varied in their size, Inc-type, resistance profile and potential for horizontal mobilization.  
Experimental evolution is a common method to study adaptation in bacteria157,305. In vitro evolution 
studies are most often performed using a serial transfer regime on growing liquid cultures, which 
rapidly increases the number of bacterial generations reached306. Transfer bottlenecks of 1/100 
maintain enough genetic diversity for natural selection to act towards the enrichment of the fittest 
mutants. The use of standard laboratory growth media was the most practical starting point to 
investigate the so far unknown evolutionary dynamics of clinical plasmid-host pairs, whereas 
artificial or even human urine represent a more complex environment that could affect growth 
dynamics in unexpected ways. We froze down mixed populations after 300 generations as bacterial 
growth adaptation is highest immediately after transfer to a new medium157. 
Researchers in the field of plasmid-host dynamics are urged to combine 'omic' technologies, for 
example genomics and transcriptomics (and more) to determine the outcome of plasmid-host 
experimental evolution303. We performed WGS on our evolved populations and on purified ancestral 
and evolved clones using short-read, paired-end Illumina sequencing.	For sequence comparison, a 
closed reference genome of the ancestral host was generated by hybrid-assembly of long- (PacBio) 
and short-read sequencing data. Closed plasmid sequences were available from previous studies128,130. 
A high coverage in the evolved populations (average >1000) allowed the identification and 
comparison of single-nucleotide changes and small indels arising above 1% frequency on the 
chromosome and the plasmids. The breseq pipeline allowed the analysis of short-read DNA re-
sequencing data from the heterogenic population data, and also the clonal data, relative to the 
reference307. Although the use of short-read data limited the analysis of structural variations in our 
study, some conclusions on rearrangement, deletion or insertion of larger genomic regions could be 
inferred from read coverage plots generated using breseq.  
To measure the fitness effect of plasmid carriage in ancestral and evolved backgrounds, we 
determined the relative fitness w of representative clones, either from the growth rate (r) or, to gain 
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resolution, by measuring the ‘head-to-head’ competitiveness of two genotypes. The latter captures a 
more comprehensive picture of fitness since growth dynamics across the lag, log and stationary phase 
are considered. The competitors, plasmid-free and plasmid-containing isogenic strains, are mixed 1:1 
in liquid culture and in certain time intervals, viable bacteria are determined156. This method requires 
a selectable marker gene, for example a resistance gene, which was present on the plasmid. We 
employed serial transfer competition experiments over an extended period of time and calculated a 
selection coefficient from the relative frequencies of the competitors, as previously described161,308. 
Small differences in fitness (1%) can be detected by this method169. Smaller differences (0.1%) could 
be revealed by high throughput competition experiments using flow cytometry and fluorescence 
tagged strains (fluorescence-activated cell sorting)191. This would require genetic modification of the 
strains, and the fact that clinical isolates are commonly difficult to manipulate represented an obstacle 
to this approach.  
Since gene expression is a major determinant for the cost of plasmids, transcriptomic analyses are 
used to identify the cellular processes that cause and compensate plasmid fitness costs through 
changed expression levels176,178. For the analysis of bacterial transcription profiles in ancestral and 
evolved strains, we performed Illumina-based RNA-Seq. SARTools (DESeq2-based) was used for 
genome-wide differential gene expression (DGE) analysis309. As established tools for functional 
pathway analysis and visualization of DGE results rely on lab strain annotations, those were not 
suitable for our clinical isolates. We used the PANTHER classification system to assign protein 
families based on our own sequence data310. 
To investigate the role of the individual proteins that were targeted by mutations in plasmid cost 
compensation, we employed single-gene deletion strains in competition assays using knock-out 
strains of the Keio collection248 to circumvent molecular work in our clinical strains. We employed 
ELISA (enzyme-linked immunosorbent assay) to determine the effect of a cpdA mutation on 
intracellular cAMP levels in an evolved strain biochemically. 
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Summary of Results 
 
Paper I: Conserved collateral antibiotic susceptibility networks in diverse clinical strains 
of Escherichia coli.  
Collateral sensitivity-informed treatment aims at reducing the emergence of resistance in bacterial 
populations during antibiotic therapy.  
Resistance mutations affecting drug target (ciprofloxacin, trimethoprim), drug activation 
(nitrofurantoin), drug efflux (ciprofloxacin, nitrofurantoin, mecillinam) and diverse cellular targets 
(mecillinam) were identified by WGS in clinical E. coli isolates with generated single-drug resistance. 
IC90 measurements revealed the most conserved and also strongest collateral responses in 
ciprofloxacin-resistant mutants, including CS towards gentamicin, fosfomycin, ertapenem and 
colistin, and CR towards temocillin, chloramphenicol, ceftazidime, mecillinam and trimethoprim. 
The collateral susceptibility changes in this resistance group were linked to efflux-related resistance 
mechanisms. Reciprocal CS responses were not identified across the different resistance groups. On 
average, resistance acquisition reduced relative fitness by 1% (nitrofurantoin), 6% (trimethoprim), 
36% (mecillinam) and 47% (ciprofloxacin). Multivariate statistical analysis identified that resistance 
mechanisms, particularly efflux mutations (33%) and fitness costs (17%) were significant predictors 
of the observed collateral effects, while the genetic diversity of the strain backgrounds did not 
influence the observed collateral networks. The MPC changed correspondingly to the identified 
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Paper II: Tn1-transposition in the course of natural transformation enables horizontal 
antibiotic resistance spread in Acinetobacter baylyi. 
 
Transposition is a DNA-recombination mechanism that facilitates the movement of transposon-
associated resistance genes intracellularly, and also horizontally through plasmid conjugation. 
Natural transformation of A. baylyi ADP1 by a non-replicative, pACYC184-based donor DNA 
substrate carrying Tn1 (blaTEM-2) resulted in chromosomal transposon-insertion at a frequency of 
8×10-9. Transposition was observed in the wildtype ADP1 and an exonuclease deficient ADP1 strain 
(DrecBCD DsbcCD). Chromosomal target site duplications were verified for 43 insertion events and 
represented the typical consensus sequence that is reported for the Tn3-family. In 80% of cases, a 
170-kb region around the ADP1 replication terminus was the preferred target for Tn1-insertions. 
Transposition was not observed when the Tn1-transposase (tnpA) or Tn1-resolvase (tnpR) were 
deleted from the donor DNA substrate, or when the transposon was present on a linear donor DNA 
fragment. Natural transformation assays with ADP1 mutant strains (DrecO, DrecA, DdprA or 
DrecBCDDsbcCD) revealed an essential (RecA) or inhibiting (RecBCD) role of host proteins on 
plasmid transformation. The results were summarized in a model. This suggests that donor DNA 
circularized in the cytoplasm from rare dimeric plasmid molecules with redundant ends, which 
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Paper III: Piggybacking on niche-adaptation improves the maintenance of multidrug resistance 
plasmids. 
 
The evolution of stable, low-cost plasmid-host relationships drives the maintenance of resistance in 
nosocomial pathogens.  
The clinical MDR plasmids pG06-VIM-1 (blaVIM-1) from K. pneumoniae and pK71-77-1-NDM 
(blaNDM-1) from E. coli displayed a 5.3% and 5.5% cost in a uropathogenic E. coli isolate in head-to-
head competitions, respectively. WGS of experimentally evolved plasmid-free and plasmid-carrying 
lineages revealed strong parallel adaptation of the E. coli regulatory systems ArcAB and CCR. The 
targeted genes, arcA, arcB, cpdA, crp and cyaA presented known targets for bacterial growth 
adaptation under laboratory conditions. None of the evolved plasmid sequences were altered by point 
mutations. Growth rate measurements of evolved relative to ancestral strains displayed growth 
improvement (7-17%) irrespective of pG06-VIM-1 presence. The cost of pG06-VIM-1-carriage was 
ameliorated to below 1% in head-to-head competitions of adapted backgrounds. CpdA had lost its 
cAMP-degrading function in adapted backgrounds (cpdA.D3.bp488‑490) with and without pG06-
VIM-1, which was indicated by the doubling of intracellular cAMP. The cost of pG06-VIM-1 
carriage was either significantly reduced (DcpdA) or ameliorated to no cost (Dcrp) in E. coli single-
gene deletion mutants. Transcriptome analysis revealed a net downregulation of plasmid gene 

















This thesis approached the problem of antibiotic resistance by investigating aspects of its selection, 
spread and maintenance in bacteria (paper I, II and III, respectively). 
The development of resistance in bacterial pathogens increasingly challenges empiric infection 
therapy9,10. Besides the usual strategies to fight antibiotic resistance such as the reduction in drug 
consumption or misuse, the search for novel drugs or improved diagnostics, it is also important to 
consider concepts from evolutionary biology, for example collateral sensitivity19. This evolutionary 
tradeoff makes bacteria that are resistant to one antibiotic more vulnerable to other antibiotics. Hence, 
CS-informed treatment strategies have the potential to select against rather than for resistance in 
bacteria220. In paper I, we described this biological phenomenon in the context of UTI treatment and 
identified predictors for conserved collateral susceptibility changes across clinical uropathogenic E. 
coli (UPEC) isolates. 
Horizontal gene transfer (HGT) facilitates the rapid dissemination of plasmids and associated 
resistance elements therein, for example transposons95. The horizontal spread of transposons relies 
however not only on their plasmid-location and the possibility to ‘hitch a ride’ during conjugation. In 
addition, they have the potential to activate their transposition properties during natural 
transformation118. In paper II, we determined the frequency and mechanistic requirements of such 
events for a replicative transposon in the natural transformation model organism A. baylyi and 
propose a mechanistic model for this route of horizontal transposon spread. 
From a bacterial perspective, antibiotic resistance acquisition often confers selective pitfalls. The 
bacterial host frequently experiences a fitness burden of maintaining resistance plasmids in the 
absence of antibiotic selection pressures, and the biological cost of resistance is a major determinant 
for the stability or loss of plasmids in bacterial populations. However, this conflict is resolved by 
adaptive mechanisms that compensate plasmid fitness costs171. In paper III, we demonstrate the 
compensatory evolution of two clinical MDR plasmids in a UPEC isolate and provide a new solution 
to the question why plasmids persist, the so-called plasmid paradox185,186.   
 
Collateral susceptibility changes in a clinical context 
UTIs caused by UPEC are very common both in the community and hospitals and linked to 
considerable morbidity and mortality254. Over the years 2000 to 2014, a significant increase in 
ciprofloxacin and trimethoprim resistant UPEC was reported for five European countries (4-16% and 
17-31%, respectively), while resistance to mecillinam and nitrofurantoin remained at low levels (2-
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4%)311. In paper I, we employed UPEC isolates to investigate collateral susceptibility changes in a 
clinical context, rather than in single laboratory strains219,220. 
A finding of clinical relevance in our study was that resistance development towards trimethoprim, 
nitrofurantoin and mecillinam did not limit the choice of secondary drugs in our strains, since only 
few collateral responses (trimethoprim, nitrofurantoin) or more frequent cases of CS than CR 
(mecillinam) were found. Hence, our results encourage continuation of first-line use of these 
antibiotics as recommended by national and international guidelines298,299. Furthermore, our results 
support the reserved use of ciprofloxacin in the treatment of complicated UTI, as our ciprofloxacin 
resistant mutants evolved conserved CR responses towards the two UTI drugs trimethoprim and 
mecillinam, and cases of CR towards chloramphenicol and amoxicillin beyond clinical breakpoints. 
Both would limit treatment choices for ciprofloxacin-resistant strains.  
It should be noted that we did not observe any cases of reciprocal CS-effects, which are a prerequisite 
for clinical drug cycling approaches as suggested by Imamovic et al.220. However, our results 
provided support for the mutant selection window hypothesis48 and implied, that CR increases the 
likelihood to select for MDR strains. In this regard, results from a recent investigation of collateral 
effects on MPCs in S. epidermidis confirm our finding49. Importantly, the results from our statistical 
model suggested that specific resistance mechanisms in a given clinical isolate forecast collateral 
effects. Hence, their rapid identification could inform clinical CS-based treatment. 
 
Predictors for conserved collateral responses 
The main research question asked in paper I was whether conserved collateral susceptibility changes 
occur across different UPEC strains. We found that this was particularly the case in ciprofloxacin-
resistant mutants and this finding agreed with frequent collateral responses in ciprofloxacin-resistant 
mutants of a clinical P. aeruginosa strain228. In that study, CS towards several aminoglycosides was 
common, and similarly, CS towards gentamicin was observed in all our ciprofloxacin-resistant 
mutants. 
Our data demonstrates for the first time, that strain diversity does not contribute to collateral changes 
as much as resistance mechanism and/or relative fitness of the resistant strains, which we identified 
as main predictors for the observed collateral responses. However, the identified costly mutations in 
our ciprofloxacin- and mecillinam-resistant mutants (paper I) are less commonly acquired in vivo56,66 
and thus highly conditional. In contrast to our finding, a recent study modelled susceptibility and 
fitness changes that were experimentally derived from S. pneumoniae resistant mutants, together with 
antibiotic pharmacodynamics, and found that fitness has no predictive value for collateral responses 
in this species312. Furthermore, it is well-established that compensatory evolution can ameliorate the 
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fitness cost associated to resistance mutations198. Especially the costly efflux-related resistance in 
ciprofloxacin-resistant mutants (paper I) imposes selective pressures towards evolutionary 
adaptation, and our research group recently demonstrated that fitness cost compensation returned 
drug-efflux to wildtype levels and weakened collateral responses in E. coli (Sørum et al., unpublished 
data).  
Although the results of paper I cannot be generalized beyond E. coli, they revealed important aspects 
of collateral responses in clinical isolates. It will be important to separate the contribution of distinct 
resistance mechanisms and genetic background on susceptibility changes in future studies and assess 
collateral networks for a variety of resistance mechanisms across large isolate collections using the 
isogenic wildtype for comparison. Confounding factors could for example be epistatic interactions 
between resistance mutations and preexisting mutations in the genome164 or inherent resistance 
mechanisms227. Furthermore, fitness as well as resistance levels of resistant mutations are context-
dependent167,313, and thus collateral responses may vary in different growth media.  
 
Knowledge-gaps in CS-based treatment strategies 
The clinical implementation of CS-informed antibiotic therapy depends strongly on the predictable 
evolution of collateral responses across different bacterial strains and species. However, it was shown 
that for some antibiotics, several (mutational) evolutionary paths towards resistance are possible and 
depending on the order of mutation acquisition, different collateral responses evolved within the same 
species226. More recent CS/CR studies also demonstrated divergent outcomes of de novo resistance 
evolution towards the same drug across different pathogen species in vitro227 and in theoretical 
models of stepwise resistance evolution164. In P. aeruginosa, the order of drug use affected the 
efficient killing of resistant strains or the evolution of CS phenotypes differently233. Thus, even 
though collateral responses in bacteria appear pervasive and our results suggest possible 
predictability, the existing literature confirms various complicating factors which require further 
investigation before this useful trade-off can be exploited in medical practice.  
Furthermore, the major bulk of studies on collateral responses was generated in single-drug resistant 
mutants, although resistance in clinical settings is mainly driven by horizontal plasmid 
acquisition11,86. Three reports have so far demonstrated that clinical MDR plasmids231 or plasmid-
associated resistance genes229,230 contributed to relevant collateral susceptibility changes in E. coli. It 
is however not clear if collateral phenotypes associated with plasmids are due to particular resistance 
genes alone or if other plasmid-specific traits play a role. Different collateral responses may be caused 
by horizontally acquired resistance towards the employed primary drugs in paper I, especially in the 
case of trimethoprim, where resistance is mainly mediated by plasmids15,31, and frequently co-
 54 
selected with mobile ciprofloxacin resistance genes68. However, ciprofloxacin36 and nitrofuratoin314 
resistance above the clinical breakpoint is largely only achieved in the presence of additional 
chromosomal resistance mutations. Similarly, it is likely that mecillinam resistance in UPEC cannot 
be attributed substantially to horizontal gene transfer, since the drug is relatively stable against 
plasmid-mediated β-lactamases including ESBLs and some carbapenemases315. 
 
Evolution of better plasmid hosts in a clinical context 
Plasmid-mediated resistance is the main driver of multidrug resistance (MDR) in isolates of 
Enterobacterales11,86, however, plasmid persistence in absence of antibiotic selection pressures 
represents an enigma183,185. In paper III, we approached the lack of studies that mimic plasmid 
acquisition events as they occur in nosocomial pathogens303 and we expand the so far limited 
molecular data on co-evolution dynamics between clinical plasmids and their G- hosts174. We found 
that the carbapenemase-encoding plasmids pG06-VIM-1 and pK71-77-1-NDM moderately reduced 
fitness of our UPEC strain by around 5%, which was consistent with existing literature in that clinical 
plasmid-host combinations are less costly205,316. The main research question asked in paper III was, 
if and how such low costs could be minimized during plasmid-host co-evolution by compensatory 
adaptation, as opposed to the amelioration of large costs previously observed in laboratory-plasmid 
combinations178,191. We found that general adaptation of our UPEC strain to the laboratory 
environment, and not plasmid-specific compensatory evolution, improved its permissiveness towards 
the here employed, unrelated, non-conjugative and conjugative plasmids. Importantly, niche-
adaptation ameliorated plasmid-associated fitness burdens and may represent a more commonly 
distributed way of plasmid pre-adaptation in bacteria than so far anticipated, with the potential to 
promote long-term maintenance of plasmids in their clinical hosts. Hence, our observations added a 
new rationale to the already described mechanisms of plasmid persistence in bacterial populations.  
 
Pleiotropic effect of niche-adaptation on plasmid maintenance 
In paper III, we examined the genetic basis underlying plasmid-mediated fitness costs and their 
compensation, which were so far mainly investigated in laboratory strains and plasmids171. Our WGS 
analysis revealed that two E. coli regulatory systems (CCR and ArcAB) were target for mutational 
niche-adaptation across all evolved replicate lineages, while the plasmids were largely unchanged. 
The improved growth of adapted strains independent of pG06-VIM-1 presence confirmed that CCR 
and ArcAB mutations were associated with E. coli adaptation to the in vitro conditions, as previously 
reported249,317,318. The results of paper III agreed with existing reports in laboratory plasmid-host 
pairs in that plasmid-associated fitness costs were frequently mitigated by adaptation of the bacterial 
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host to the plasmid178,203,209,319. Likewise, global regulators (e.g. gacA/S178) were previously identified 
as mutational targets for the compensation of costly plasmids. Different to existing reports, we 
demonstrated that the effect on plasmid costs was the consequence of UPEC adaptation to the 
experimental conditions, and not to the plasmid. Previously, population genomic analysis of the high-
risk clone E. coli ST131 showed that alterations in gene regulatory regions can be associated to the 
acquisition and maintenance of MDR plasmids320. Importantly, the results of paper III provided in 
vitro evidence that links bacterial niche-adaptation and plasmid persistence as it happens that hosts 
adapt to their environment by regulatory changes249,317,318. Further research is warranted to understand 
if such pleiotropic effects improve the ability of pathogens to maintain MDR plasmids also across 
other growth media (e.g. urine), plasmid types and kinds of environmental adaptation. 
 
Transcriptional changes that relieve plasmid burden 
Gene expression processes have been advocated to be the major causes of fitness burdens associated 
to plasmid acquisition171. This was supported and exemplified in two studies where plasmid 
acquisition led to 13% (749 genes176) and 17% (1006 genes178) changes in chromosomal gene 
expression. In contrast, our findings revealed that acquisition of a clinical plasmid resulted in less 
dramatic chromosomal gene expression changes (max. 0.4% = 16 genes; paper III) and thus agreed 
with recent reports of low fitness and also transcriptional burdens from MDR plasmid uptake in 
clinical hosts316. In vitro, compensatory mutations in global regulators mitigated the translational 
burden in P. fluorescens plasmid-carriers178, and similarly we found that the majority of chromosomal 
genes with altered expression upon plasmid acquisition in adapted clones were associated to 
translation (Clone 2+VIM; paper III). As expected from the nature of CCR and ArcAB related 
mutations, niche-adapted backgrounds showed frequent transcriptional changes to chromosomal 
genes (21-34% of genes), which did not appear plasmid-specific. 
Two recent transcriptomic studies provided evidence for an association between plasmid gene 
expression and plasmid cost, which was supported by highly expressed plasmid genes compared to 
chromosomal genes166, and particularly high expression of plasmid-associated antibiotic resistance 
genes166,180. We hypothesized that the observed regulatory mutations would impact plasmid gene 
expression in a beneficial way, as compensatory evolution relieved bacterial hosts also from the 
transcriptional demand generated by plasmid genes176,178. We found that 14-28% of plasmid genes 
altered their expression in niche-adapted backgrounds, which resulted in a net decrease of pG06-
VIM-1-associated transcriptional burden. This effect was consistent with a 17% downregulation of 
plasmid gene expression in P. fluorescens due to compensatory mutations in global regulators178. 
Three pG06-VIM-1-located antibiotic resistance genes (strB, aadA2, sul1; paper III) were 
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downregulated in adapted backgrounds, however, the low total number of altered genes per clone 
complicated the systematic analysis of affected biological processes. Since not one single pG06-VIM-
1 gene changed expression beyond the 2-fold threshold and the remaining affected plasmid genes 
varied between the two investigated adapted clones, we were careful to conclude on the specific cause 
of fitness cost more precisely. Taken together, the results of paper III demonstrated that niche-
adaptive mutations ameliorated plasmid costs by reducing the transcription-associated burden of 
pG06-VIM-1 in our UPEC strain. The findings advanced our understanding of plasmid-mediated 
resistance and the emergence of successful relationships between plasmids and their bacterial host. 
More studies should examine the transcriptional perturbations caused by MDR plasmids in their 
clinical hosts to increase our knowledge on the biological pathways that are impacted by plasmid-
host conflicts and thus represent targets for compensatory evolution. Ideally, such investigations also 
examine how transcriptional changes transfer into proteomic and metabolomic alterations. 
 
Multiple evolutionary strategies towards plasmid persistence  
In two cases, mobile elements associated with the large, conjugative pK71-77-1-NDM may have been 
responsible for the removal of costly plasmid traits (paper III), corresponding to the previously 
reported loss of plasmid-encoded conjugation machinery174,196 and/or resistance genes174. The relative 
growth rates for the pK71-77-1-NDM-co-evolved replicate clones were significantly improved by 
14-23%, with exception of the strain in which the ∼8.8 kb deletion in pK71-77-1-NDM occurred 
(unchanged) (unpublished results paper III). Future studies could investigate the consequences of 
pK71-77-1-NDM-deletions as well as CCR/ArcAB mutations on competitive fitness, plasmid 
conjugation and plasmid stability in pK71-77-1-NDM-hosts. While deletion of the observed costly 
regions likely promotes plasmid maintenance over short terms by improving host fitness and thus 
vertical inheritance174,195, it limits the potential for horizontal plasmid spread or host adaptation to a 
selective niche by conjugation. Alternatively, increased conjugational transfer can promote plasmid 
persistence in a population, and we found that native pK71-77-1-NDM transferred at a higher 
frequency from adapted backgrounds. The results of paper III were thus in agreement with existing 
literature in that long-term plasmid persistence is facilitated by a combination of different 
evolutionary processes that impact plasmid cost compensation, plasmid mobility, plasmid 
maintenance functions as well as episodes of positive selection for plasmid traits191. In addition, 
transduction and natural transformation may have a greater potential to contribute in plasmid 
dissemination than anticipated so far, as suggested previously197.  
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Resistance spread by transposition during natural transformation 
The relevance of natural transformation events in clinical settings is poorly understood, although the 
ability to acquire novel genetic information by this HGT mechanisms is prevalent in G+ as well as 
G- species including highly important nosocomial pathogens39. In paper II, we showed that the 
blaTEM-2-encoding transposon Tn1 can spread horizontally by replicative transposition during natural 
transformation. This was hence the second study that evidenced the potential of (replicative) 
transposons to participate in the horizontal, nonclonal spread of their associated resistance traits 
beyond plasmid conjugation, but during natural transformation of competent species, as proposed by 
Domingues et al.118. As the species-specific requirements for competence development are still 
largely unexplored104, we probably underestimate the contribution of natural transformation in 
general, and the specific mechanism described here, in antibiotic resistance evolution. It would be 
interesting to test the capacity for Tn1-mediated natural transformation in clinically relevant species. 
Isolates of A. baumannii could be possible recipients. In vitro studies increasingly demonstrate the 
specie’s ability to undergo natural transformation, and different experimental conditions are identified 
that promote competence induction106,107,277-280.  
 
A mechanistic model of transposon-mediated natural transformation  
Transposition during natural transformation uncouples transposon spread from the host-range 
properties of conjugative elements and recombines genetic material independent from the relatedness 
between donor and recipient bacterium118. In paper II, we were the first to examine the molecular 
requirements for this mechanism of transposon mobilization in more detail. Taken together, we 
showed that transposition in our model system depended on the stabilization of incoming vector-
DNA through intramolecular circularization, followed by transposon gene expression. More 
specifically, our results indicated that the Tn1-encoded proteins TnpA and TnpR rather than A. baylyi 
recombinases (transposases and ISs321) or RecA-mediated homologous recombination155 facilitated 
replicative transposition into the chromosome of A. baylyi via formation of typical, circular co-
integrate structures and their resolution, as described for this transposon-family147. We concluded that 
the absence of TnpR halted Tn1-transposition at the step of co-integrate resolution. This implied that 
stable, circular co-integrates were formed once tnpA was expressed from reconstituted donor DNA 
vector, which appeared more efficient when the tnpA repressor, TnpR322, was deleted. This model 
was consistent with the occurrence of transient plasmid transformants of A. baylyi when naturally 
transformed with donor DNA vector. It is however not clear why lack of TnpA abolished not only 
the formation of transposants or co-integrate transformants, but also that of transient plasmid 
transformants. Finally, the requirement for a transient circular cytoplasmic intermediate, and not a 
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linear as previously suggested118, was further supported by the lack of colony growth with linear Tn1-
vector as donor DNA. DNA that enters the bacterial cytoplasm in the course of natural transformation 
is however linear and single-stranded108, but double-stranded plasmid DNA reassembles efficiently 
when dimeric plasmid strands are present intracellularly323. The genomic integration of transforming 
DNA by recombination with the chromosome113,324,325 or plasmid reconstitution326 is impacted by 
cytoplasmic proteins that act on DNA single-strands (RecA, DprA, RecO) or degrade DNA double-
strands (RecBCD). We inferred the role of these host factors in the circularization of cytoplasmic 
Tn1-vector DNA from plasmid transformation frequencies in A. baylyi deletion mutants. We found 
that RecA-mediated homology search and DprA-mediated loading of RecA on ssDNA are processes 
that facilitated plasmid transformation to a greater degree than RecO-mediated hybridization of 
complementary ssDNA strands did. According to our model, a dimeric ssDNA strand with 
overlapping ends, and a complementary strand-fragment, are minimum requirements for plasmid 
reconstitution with involvement of the above-mentioned enzymes. Lack of RecBCD increased 
plasmid transformation efficiencies, which implied that plasmid circularization in A. baylyi involved 
RecBCD-sensitive linear dsDNA intermediates. Building up on our results, also larger fragments of 
transforming chromosomal DNA could circularize at repeat regions or be protected from RecBCD 
degradation by Chi sequences327, and facilitate transient transposon-gene expression in the course of 
natural transformation. Generally, one should keep in mind that chromosomally inserted resistance 
may confer lower resistance levels than plasmid-associated genes126,328, and selection pressures for 
transposition events may have to be adjusted.  
 
Dynamics of transposition events  
Transposon-insertion can disrupt genes that are essential for viability, and have further metabolic 
effects for example on host fitness170. In paper II, Tn1-transposition did not occur into essential 
genes of A. baylyi but revealed a clear preference for the replication terminus. Interestingly, this 
resembled the pattern of Tn917-transposition into the chromosome of the G+ species E. faecalis329 
and B. subtilis152 from a temperature-sensitive plasmid. It was demonstrated, that the activity of 
proteins that mediate DNA replication fork termination or chromosome separation attracted Tn917-
transposition into the B. subtilis terminus152. Unexpectedly, lack of the XerC-recombinase, which 
resolves chromosome dimers in A. baylyi, abolished transformant growth (paper II). In conclusion, 
we cannot exclude that local DNA repair or replication dynamics represent mechanistic requirements 
of Tn1-transposition that underlie the observed transposon insertion in proximity to the A. baylyi 
terminus, since host replication factors are required during replicative transposition147. This 
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hypothesis is further supported by the lack of correlation between the prevalence of consensus 
sequence in the recipient chromosome and Tn1-insertion around the terminus (paper II).  
The fitness of A. baylyi transposants was not investigated in paper II. In previous reports, transposon 
acquisition had variable outcomes, including beneficial160, neutral or negative118,161 effects of 
different elements. The different transposants obtained in paper II could be used in the future to 
compare fitness-consequences of Tn1-acquisition into the terminus region versus other chromosomal 
loci, and it remains to be tested whether transposition from our Tn1-vector is attracted to the terminus 
of other naturally competent bacterial species. 
 
Potential of transposon spread by transposition during natural transformation  
Although we confirm that transposition-mediated natural transformation contributes to the horizontal 
transfer of resistance at lower frequencies than other HGT mechanisms (10-9 paper II; < 10-8 118), it 
has the potential to facilitate MDR dissemination across species borders. Subsequently, transposon-
associated resistance can spread more efficiently between related species. This can for example occur 
by the intermolecular movement of the chromosome-located transposon to a plasmid and between 
plasmids, which represents a relevant mean of transposon-associated MDR spread in hospital 
settings97,126,330. Furthermore, once chromosomally acquired, transposons can promote the spread of 
their embedded resistance determinants via homologous recombination-mediated natural 
transformation. The latter possibility is exemplified by the 1,000-times increased (now 10-4 to 10-5) 
intraspecies transfer of a Tn21-embedded integron during natural transformation with donor DNA 
from an A. baylyi Tn21-transposant in vitro118.  
A possible effect of altered transposon activity on the frequency of transposition during natural 
transformation could be investigated based on reports of transposition ‘triggers’ such as nutritional 
starvation in E. coli331 or antibiotic-induced SOS-response and its consequences on integrase 
activity332. It would be interesting to use our Tn1-vector and test the potential for transposition-
mediated natural transformation in a plasmid-carrying strain as recipient, since it was previously 
observed that Tn3-transposition between plasmid replicons occurred more frequent than between 




The presented thesis examined the dynamics of bacterial antibiotic resistance evolution by 
chromosomal (paper I) as well as mobile resistance determinants (paper II, III).  
In paper I, the evolution of conserved collateral responses across resistant mutants of diverse E. coli 
isolates was demonstrated for the first time. Collateral changes were primarily driven by efflux-
mutations, and resistance mechanism may hence be a useful predictor of bacterial collateral responses 
during evolution-informed treatment. Furthermore, transposons mobilized antibiotic resistance 
during natural transformation of A. baylyi (paper II). Future research can build up on our model of 
transposition-mediated natural transformation to explore molecular requirements and insertion 
dynamics of other transposons in different bacterial hosts. Finally, E. coli accidentally became a better 
plasmid-host by adapting to a new environmental niche (paper III). This finding advanced plasmid 
paradox research in clinical pathogens and represented a novel explanation for the persistence of 





1. Sender, R., Fuchs, S. & Milo, R. Revised Estimates for the Number of Human and Bacteria 
Cells in the Body. PLoS Biol 14, e1002533 (2016). 
2. Wright, P. M., Seiple, I. B. & Myers, A. G. The evolving role of chemical synthesis in 
antibacterial drug discovery. Angew Chem Int Ed Engl 53, 8840-8869 (2014). 
3. Fleming, A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference 
to their Use in the Isolation of B. influenzæ. Br J Exp Pathol 10, 226-236 (1929). 
4. Abraham, E. P. & Chain, E. An Enzyme from Bacteria able to Destroy Penicillin. Nature 146, 
837-837 (1940). 
5. Sir Alexander Fleming – Nobel Lecture 1945. NobelPrize.org. Nobel Media AB 2021, 
Available from https://www.nobelprize.org/prizes/medicine/1945/fleming/speech/ (Wed. 17 
Mar 2021). 
6. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical 
development pipeline. Geneva: World Health Organization (2019). 
7. Cassini, A. et al. Attributable deaths and disability-adjusted life-years caused by infections 
with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a 
population-level modelling analysis. Lancet Infect Dis 19, 56-66 (2019). 
8. Adeolu, M., Alnajar, S., Naushad, S. & R, S. G. Genome-based phylogeny and taxonomy of 
the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families 
Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. 
nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. 
International journal of systematic and evolutionary microbiology 66, 5575-5599 (2016). 
9. Organization, W. H. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, 
Discovery, and Development of New Antibiotics. WHO Press, p. 1-7 (2017). 
10. Antimicrobial resistance in the EU/EEA (EARS-Net) Annual Epidemiological Report for 
2019 (2019). 
11. Carattoli, A. Plasmids and the spread of resistance. Int J Med Microbiol 303, 298-304 (2013). 
12. Mathers, A. J., Peirano, G. & Pitout, J. D. The role of epidemic resistance plasmids and 
international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. 
Clinical microbiology reviews 28, 565-591 (2015). 
13. Temkin, E. et al. Estimating the number of infections caused by antibiotic-resistant 
Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. Lancet Glob Health 
6, e969-e979 (2018). 
14. Holmes, A. H. et al. Understanding the mechanisms and drivers of antimicrobial resistance. 
Lancet 387, 176-187 (2016). 
15. van Hoek, A. H. et al. Acquired antibiotic resistance genes: an overview. Frontiers in 
microbiology 2, 203 (2011). 
16. Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular 
mechanisms of antibiotic resistance. Nature reviews. Microbiology 13, 42-51 (2015). 
17. Witzany, C., Bonhoeffer, S. & Rolff, J. Is antimicrobial resistance evolution accelerating? 
PLoS pathogens 16, e1008905 (2020). 
18. Hughes, D. & Andersson, D. I. Evolutionary Trajectories to Antibiotic Resistance. Annual 
review of microbiology 71, 579-596 (2017). 
19. Andersson, D. I. et al. Antibiotic resistance: turning evolutionary principles into clinical 
reality. FEMS microbiology reviews 44, 171-188 (2020). 
20. Johnsen, P. J. et al. Factors affecting the reversal of antimicrobial-drug resistance. Lancet 
Infect Dis 9, 357-364 (2009). 
21. Domagk, G. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dtsch. Med. 
Wochenschr. 61 (7), 250-253 (1935). 
 62 
22. Waksman, S. A., Schatz, A. & Reynolds, D. M. Production of antibiotic substances by 
actinomycetes. Ann N Y Acad Sci 1213, 112-124 (2010). 
23. Andrade, F. F., Silva, D., Rodrigues, A. & Pina-Vaz, C. Colistin Update on Its Mechanism of 
Action and Resistance, Present and Future Challenges. Microorganisms 8 (2020). 
24. Butler, M. S. & Paterson, D. L. Antibiotics in the clinical pipeline in October 2019. J Antibiot 
(Tokyo) 73, 329-364 (2020). 
25. Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 
455-459 (2015). 
26. Hover, B. M. et al. Culture-independent discovery of the malacidins as calcium-dependent 
antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat Microbiol 
3, 415-422 (2018). 
27. Egan, A. J., Biboy, J., van't Veer, I., Breukink, E. & Vollmer, W. Activities and regulation of 
peptidoglycan synthases. Philos Trans R Soc Lond B Biol Sci 370 (2015). 
28. Dijkmans, A. C. et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. 
Antibiotics 6 (2017). 
29. Kohanski, M. A., Dwyer, D. J. & Collins, J. J. How antibiotics kill bacteria: from targets to 
networks. Nature reviews. Microbiology 8, 423-435 (2010). 
30. Drlica, K., Malik, M., Kerns, R. J. & Zhao, X. Quinolone-mediated bacterial death. 
Antimicrobial agents and chemotherapy 52, 385-392 (2008). 
31. Huovinen, P. Resistance to trimethoprim-sulfamethoxazole. Clinical Infectious Diseases 32, 
1608-1614 (2001). 
32. Asnis, R. E. The reduction of Furacin by cell-free extracts of Furacin-resistant and parent-
susceptible strains of Escherichia coli. Arch Biochem Biophys 66, 208-216 (1957). 
33. McCalla, D. R., Kaiser, C. & Green, M. H. Genetics of nitrofurazone resistance in Escherichia 
coli. Journal of bacteriology 133, 10-16 (1978). 
34. Jenkins, S. T. & Bennett, P. M. Effect of mutations in deoxyribonucleic acid repair pathways 
on the sensitivity of Escherichia coli K-12 strains to nitrofurantoin. Journal of bacteriology 
125, 1214-1216 (1976). 
35. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 
74, 417-433 (2010). 
36. Redgrave, L. S., Sutton, S. B., Webber, M. A. & Piddock, L. J. Fluoroquinolone resistance: 
mechanisms, impact on bacteria, and role in evolutionary success. Trends in microbiology 22, 
438-445 (2014). 
37. Touchon, M. et al. The genomic diversification of the whole Acinetobacter genus: origins, 
mechanisms, and consequences. Genome Biol Evol 6, 2866-2882 (2014). 
38. Juhas, M. Horizontal gene transfer in human pathogens. Crit Rev Microbiol 41, 101-108 
(2015). 
39. Lerminiaux, N. A. & Cameron, A. D. S. Horizontal transfer of antibiotic resistance genes in 
clinical environments. Can J Microbiol 65, 34-44 (2019). 
40. D'Costa, V. M. et al. Antibiotic resistance is ancient. Nature 477, 457-461 (2011). 
41. D'Costa, V. M., McGrann, K. M., Hughes, D. W. & Wright, G. D. Sampling the antibiotic 
resistome. Science 311, 374-377 (2006). 
42. Cox, G. & Wright, G. D. Intrinsic antibiotic resistance: mechanisms, origins, challenges and 
solutions. Int J Med Microbiol 303, 287-292 (2013). 
43. The European Committee on Antimicrobial Susceptibility Testing - EUCAST. Intrinsic 
resistance and unusual phenotypes version 3.2. Available from 
http://www.eucast.org/expert_rules_and_intrinsic_resistance/ (2019). 
44. Kahlmeter, G. The 2014 Garrod Lecture: EUCAST - are we heading towards international 
agreement? J Antimicrob Chemother 70, 2427-2439 (2015). 
 63 
45. The European Committee on Antimicrobial Susceptibility Testing - EUCAST. Breakpoint 
tables for interpretation of MICs and zone diameters, version 10.0. Available from 
https://www.eucast.org/clinical_breakpoints/ (2020). 
46. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 
https://www.eucast.org. 
47. Clinical and Laboratory Standards Institute (CLSI). https://www.fda.gov/drugs/development-
resources/antibacterial-susceptibility-test-interpretive-criteria. 
48. Drlica, K. & Zhao, X. Mutant selection window hypothesis updated. Clinical Infectious 
Diseases 44, 681-688 (2007). 
49. Lozano-Huntelman, N. A. et al. Evolution of antibiotic cross-resistance and collateral 
sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the 
mutant selection window. Evol Appl 13, 808-823 (2020). 
50. Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS 
pathogens 7, e1002158 (2011). 
51. Gullberg, E., Albrecht, L. M., Karlsson, C., Sandegren, L. & Andersson, D. I. Selection of a 
multidrug resistance plasmid by sublethal levels of antibiotics and heavy metals. mBio 5, 
e01918-01914 (2014). 
52. Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of antibiotics. 
Nature reviews. Microbiology 12, 465-478 (2014). 
53. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-
781 (2000). 
54. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. Quinolone resistance-determining 
region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial agents and 
chemotherapy 34, 1271-1272 (1990). 
55. Heisig, P. & Tschorny, R. Characterization of fluoroquinolone-resistant mutants of 
Escherichia coli selected in vitro. Antimicrobial agents and chemotherapy 38, 1284-1291 
(1994). 
56. Marcusson, L. L., Frimodt-Moller, N. & Hughes, D. Interplay in the selection of 
fluoroquinolone resistance and bacterial fitness. PLoS pathogens 5, e1000541 (2009). 
57. Komp Lindgren, P., Karlsson, A. & Hughes, D. Mutation rate and evolution of 
fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract 
infections. Antimicrobial agents and chemotherapy 47, 3222-3232 (2003). 
58. Huseby, D. L. et al. Mutation Supply and Relative Fitness Shape the Genotypes of 
Ciprofloxacin-Resistant Escherichia coli. Mol Biol Evol 34, 1029-1039 (2017). 
59. Pietsch, F. et al. Ciprofloxacin selects for RNA polymerase mutations with pleiotropic 
antibiotic resistance effects. J Antimicrob Chemother 72, 75-84 (2017). 
60. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. & Nakamura, S. Quinolone 
resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. 
Antimicrobial agents and chemotherapy 35, 1647-1650 (1991). 
61. Wang, H., Dzink-Fox, J. L., Chen, M. & Levy, S. B. Genetic characterization of highly 
fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. 
Antimicrobial agents and chemotherapy 45, 1515-1521 (2001). 
62. Duval, V. & Lister, I. M. MarA, SoxS and Rob of Escherichia coli - Global regulators of 
multidrug resistance, virulence and stress response. Int J Biotechnol Wellness Ind 2, 101-124 
(2013). 
63. Oethinger, M., Podglajen, I., Kern, W. V. & Levy, S. B. Overexpression of the marA or soxS 
regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrobial agents 
and chemotherapy 42, 2089-2094 (1998). 
64. Cohen, S. P., McMurry, L. M. & Levy, S. B. marA locus causes decreased expression of 
OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli. Journal of 
bacteriology 170, 5416-5422 (1988). 
 64 
65. Forst, S., Delgado, J. & Inouye, M. Phosphorylation of OmpR by the osmosensor EnvZ 
modulates expression of the ompF and ompC genes in Escherichia coli. Proc Natl Acad Sci 
U S A 86, 6052-6056 (1989). 
66. Thulin, E., Sundqvist, M. & Andersson, D. I. Amdinocillin (Mecillinam) resistance mutations 
in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrobial agents 
and chemotherapy 59, 1718-1727 (2015). 
67. Thulin, E. & Andersson, D. I. Upregulation of PBP1B and LpoB in cysB Mutants Confers 
Mecillinam (Amdinocillin) Resistance in Escherichia coli. Antimicrobial agents and 
chemotherapy 63, e00612-00619 (2019). 
68. Kahlmeter, G. & Poulsen, H. O. Antimicrobial susceptibility of Escherichia coli from 
community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J 
Antimicrob Agents 39, 45-51 (2012). 
69. Lai, G. C., Cho, H. & Bernhardt, T. G. The mecillinam resistome reveals a role for 
peptidoglycan endopeptidases in stimulating cell wall synthesis in Escherichia coli. PLoS 
Genet 13, e1006934 (2017). 
70. Thulin, E. Mechanisms and Dynamics of Mecillinam Resistance in Escherichia coli ISBN 
978-91-513-0090-0 thesis, Acta Universitatis Upsaliensis, Uppsala (2017). 
71. Chevereau, G. et al. Quantifying the Determinants of Evolutionary Dynamics Leading to 
Drug Resistance. PLoS Biol 13, e1002299 (2015). 
72. Sandegren, L., Lindqvist, A., Kahlmeter, G. & Andersson, D. I. Nitrofurantoin resistance 
mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 62, 495-503 (2008). 
73. Puertolas-Balint, F., Warsi, O., Linkevicius, M., Tang, P. C. & Andersson, D. I. Mutations 
that increase expression of the EmrAB-TolC efflux pump confer increased resistance to 
nitroxoline in Escherichia coli. J Antimicrob Chemother 75, 300-308 (2020). 
74. Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug 
selection. Nat Genet 44, 101-105 (2011). 
75. Baym, M. et al. Spatiotemporal microbial evolution on antibiotic landscapes. Science 353, 
1147-1151 (2016). 
76. Watson, M., Liu, J. W. & Ollis, D. Directed evolution of trimethoprim resistance in 
Escherichia coli. FEBS J 274, 2661-2671 (2007). 
77. Flensburg, J. & Sköld, O. Massive overproduction of dihydrofolate reductase in bacteria as a 
response to the use of trimethoprim. Eur J Biochem 162, 473-476 (1987). 
78. Bush, K. Past and Present Perspectives on beta-Lactamases. Antimicrobial agents and 
chemotherapy 62 (2018). 
79. Knott-Hunziker, V., Waley, S. G., Orlek, B. S. & Sammes, P. G. Penicillinase active sites: 
Labelling of serine-44 in β-lactamase I by 6β-bromopenicillanic acid. FEBS Letters 99, 59-
61 (1979). 
80. King, D. T., Worrall, L. J., Gruninger, R. & Strynadka, N. C. New Delhi metallo-beta-
lactamase: structural insights into beta-lactam recognition and inhibition. J Am Chem Soc 134, 
11362-11365 (2012). 
81. Ambler, R. P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. 289, pp. 321-331 
(1980). 
82. Bush, K. & Jacoby, G. A. Updated functional classification of beta-lactamases. Antimicrobial 
agents and chemotherapy 54, 969-976 (2010). 
83. Logan, L. K. & Weinstein, R. A. The Epidemiology of Carbapenem-Resistant 
Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis 215, S28-
S36 (2017). 
84. Lauretti, L. et al. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-
lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrobial agents and 
chemotherapy 43, 1584-1590 (1999). 
 65 
85. Yong, D. et al. Characterization of a new metallo-beta-lactamase gene, blaNDM-1, and a novel 
erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae 
sequence type 14 from India. Antimicrobial agents and chemotherapy 53, 5046-5054 (2009). 
86. Rozwandowicz, M. et al. Plasmids carrying antimicrobial resistance genes in 
Enterobacteriaceae. J Antimicrob Chemother 73, 1121-1137 (2018). 
87. Wu, W. et al. NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care 
Settings. Clinical microbiology reviews 32, e00115-00118 (2019). 
88. Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T. & Daikos, G. L. 
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis 
of global dimensions. Clinical microbiology reviews 25, 682-707 (2012). 
89. von Wintersdorff, C. J. et al. Dissemination of Antimicrobial Resistance in Microbial 
Ecosystems through Horizontal Gene Transfer. Frontiers in microbiology 7, 173 (2016). 
90. Weingarten, R. A. et al. Genomic Analysis of Hospital Plumbing Reveals Diverse Reservoir 
of Bacterial Plasmids Conferring Carbapenem Resistance. mBio 9, e02011-02017 (2018). 
91. Thomas, C. M. & Nielsen, K. M. Mechanisms of, and barriers to, horizontal gene transfer 
between bacteria. Nature reviews. Microbiology 3, 711-721 (2005). 
92. Frost, L. S., Leplae, R., Summers, A. O. & Toussaint, A. Mobile genetic elements: the agents 
of open source evolution. Nature reviews. Microbiology 3, 722-732 (2005). 
93. Mazaheri Nezhad Fard, R., Barton, M. D. & Heuzenroeder, M. W. Bacteriophage-mediated 
transduction of antibiotic resistance in enterococci. Letters in applied microbiology 52, 559-
564 (2011). 
94. Varga, M. et al. Efficient transfer of antibiotic resistance plasmids by transduction within 
methicillin-resistant Staphylococcus aureus USA300 clone. FEMS Microbiol Lett 332, 146-
152 (2012). 
95. Partridge, S. R., Kwong, S. M., Firth, N. & Jensen, S. O. Mobile Genetic Elements Associated 
with Antimicrobial Resistance. Clinical microbiology reviews 31, e00088-00017 (2018). 
96. Sandegren, L., Linkevicius, M., Lytsy, B., Melhus, A. & Andersson, D. I. Transfer of an 
Escherichia coli ST131 multiresistance cassette has created a Klebsiella pneumoniae-specific 
plasmid associated with a major nosocomial outbreak. J Antimicrob Chemother 67, 74-83 
(2012). 
97. Sheppard, A. E. et al. Nested Russian Doll-Like Genetic Mobility Drives Rapid 
Dissemination of the Carbapenem Resistance Gene blaKPC. Antimicrobial agents and 
chemotherapy 60, 3767-3778 (2016). 
98. Domingues, S. & Nielsen, K. M. Membrane vesicles and horizontal gene transfer in 
prokaryotes. Current opinion in microbiology 38, 16-21 (2017). 
99. Dubey, G. P. et al. Architecture and Characteristics of Bacterial Nanotubes. Dev Cell 36, 453-
461 (2016). 
100. Fulsundar, S. et al. Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi 
and effects of stress on vesiculation. Applied and environmental microbiology 80, 3469-3483 
(2014). 
101. Pospisil, J. et al. Bacterial nanotubes as a manifestation of cell death. Nat Commun 11, 4963 
(2020). 
102. Griffith, F. The Significance of Pneumococcal Types. The Journal of hygiene 27, 113-159 
(1928). 
103. Blokesch, M. Natural competence for transformation. Current Biology 26, R1126-R1130 
(2016). 
104. Johnston, C., Martin, B., Fichant, G., Polard, P. & Claverys, J. P. Bacterial transformation: 
distribution, shared mechanisms and divergent control. Nature reviews. Microbiology 12, 
181-196 (2014). 
105. Lorenz, M. G. & Wackernagel, W. Bacterial gene transfer by natural genetic transformation 
in the environment. Microbiological reviews 58, 563-602 (1994). 
 66 
106. Domingues, S. et al. Competence for Natural Transformation Is Common among Clinical 
Strains of Resistant Acinetobacter spp. Microorganisms 7 (2019). 
107. Hu, Y., He, L., Tao, X., Meng, F. & Zhang, J. High DNA Uptake Capacity of International 
Clone II Acinetobacter baumannii Detected by a Novel Planktonic Natural Transformation 
Assay. Frontiers in microbiology 10, 2165 (2019). 
108. Dubnau, D. & Blokesch, M. Mechanisms of DNA Uptake by Naturally Competent Bacteria. 
Annual review of genetics 53, 217-237 (2019). 
109. Averhoff, B. & Graf, I. in Acinetobacter Molecular Biology (edited by Ulrike Gerischer), Ch. 
The Natural Transformation System of Acinetobacter baylyi ADP1: A Unique DNA 
Transport Machinery, 119 (Caister Academic Press, U.K, 2008). 
110. Palmen, R., Vosman, B., Buijsman, P., Breek, C. K. & Hellingwerf, K. J. Physiological 
characterization of natural transformation in Acinetobacter calcoaceticus. Journal of general 
microbiology 139, 295-305 (1993). 
111. Mortier-Barriere, I. et al. A key presynaptic role in transformation for a widespread bacterial 
protein: DprA conveys incoming ssDNA to RecA. Cell 130, 824-836 (2007). 
112. Nielsen, K. M., Johnsen, P. J., Bensasson, D. & Daffonchio, D. Release and persistence of 
extracellular DNA in the environment. Environmental biosafety research 6, 37-53 (2007). 
113. Hulter, N. et al. Costs and benefits of natural transformation in Acinetobacter baylyi. BMC 
Microbiol 17, 34 (2017). 
114. Overballe-Petersen, S. et al. Bacterial natural transformation by highly fragmented and 
damaged DNA. Proc Natl Acad Sci U S A 110, 19860-19865 (2013). 
115. de Vries, J. & Wackernagel, W. Integration of foreign DNA during natural transformation of 
Acinetobacter sp. by homology-facilitated illegitimate recombination. Proc Natl Acad Sci U 
S A 99, 2094-2099 (2002). 
116. Hulter, N. & Wackernagel, W. Double illegitimate recombination events integrate DNA 
segments through two different mechanisms during natural transformation of Acinetobacter 
baylyi. Molecular microbiology 67, 984-995 (2008). 
117. Harms, K. et al. Substitutions of short heterologous DNA segments of intragenomic or 
extragenomic origins produce clustered genomic polymorphisms. Proc Natl Acad Sci U S A 
113, 15066-15071 (2016). 
118. Domingues, S. et al. Natural transformation facilitates transfer of transposons, integrons and 
gene cassettes between bacterial species. PLoS pathogens 8, e1002837 (2012). 
119. Norman, A., Hansen, L. H. & Sorensen, S. J. Conjugative plasmids: vessels of the communal 
gene pool. Philos Trans R Soc Lond B Biol Sci 364, 2275-2289 (2009). 
120. del Solar, G., Giraldo, R., Ruiz-Echevarria, M. J., Espinosa, M. & Diaz-Orejas, R. Replication 
and control of circular bacterial plasmids. Microbiol Mol Biol Rev 62, 434-464 (1998). 
121. Carattoli, A. et al. Identification of plasmids by PCR-based replicon typing. Journal of 
microbiological methods 63, 219-228 (2005). 
122. Carattoli, A. et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid 
multilocus sequence typing. Antimicrobial agents and chemotherapy 58, 3895-3903 (2014). 
123. Datta, N. & Hughes, V. M. Plasmids of the Same Inc Groups in Enterobacteria before and 
after the Medical Use of Antibiotics. Nature 306, 616-617 (1983). 
124. Shintani, M., Sanchez, Z. K. & Kimbara, K. Genomics of microbial plasmids: classification 
and identification based on replication and transfer systems and host taxonomy. Frontiers in 
microbiology 6, 242 (2015). 
125. Barlow, M. & Hall, B. G. Phylogenetic analysis shows that the OXA beta-lactamase genes 
have been on plasmids for millions of years. J Mol Evol 55, 314-321 (2002). 
126. Brolund, A. et al. Dynamics of Resistance Plasmids in Extended-Spectrum-beta-Lactamase-
Producing Enterobacteriaceae during Postinfection Colonization. Antimicrobial agents and 
chemotherapy 63, e02201-02218 (2019). 
 67 
127. Drieux, L. et al. Complete nucleotide sequence of the large conjugative pTC2 multireplicon 
plasmid encoding the VIM-1 metallo-beta-lactamase. J Antimicrob Chemother 68, 97-100 
(2013). 
128. Gama, J. A., Kloos, J., Johnsen, P. J. & Samuelsen, O. Host dependent maintenance of a 
blaNDM-1-encoding plasmid in clinical Escherichia coli isolates. Sci Rep 10, 9332 (2020). 
129. Samuelsen, O. et al. Molecular characterization of VIM-producing Klebsiella pneumoniae 
from Scandinavia reveals genetic relatedness with international clonal complexes encoding 
transferable multidrug resistance. Clin Microbiol Infect 17, 1811-1816 (2011). 
130. Di Luca, M. C. et al. Low biological cost of carbapenemase-encoding plasmids following 
transfer from Klebsiella pneumoniae to Escherichia coli. J Antimicrob Chemother 72, 85-89 
(2017). 
131. Papagiannitsis, C. C., Miriagou, V., Giakkoupi, P., Tzouvelekis, L. S. & Vatopoulos, A. C. 
Characterization of pKP1780, a novel IncR plasmid from the emerging Klebsiella 
pneumoniae ST147, encoding the VIM-1 metallo-beta-lactamase. J Antimicrob Chemother 
68, 2259-2262 (2013). 
132. Samuelsen, O. et al. Identification of NDM-1-producing Enterobacteriaceae in Norway. J 
Antimicrob Chemother 66, 670-672 (2011). 
133. Roberts, A. P. et al. Revised nomenclature for transposable genetic elements. Plasmid 60, 
167-173 (2008). 
134. Hickman, A. B. & Dyda, F. Mechanisms of DNA Transposition. Microbiol Spectr 3, 
MDNA3-0034-2014 (2015). 
135. McClintock, B. The Origins And Behaviour Of Mutable Loci In Maize. Proc Natl Acad Sci 
36, 344-355 (1950). 
136. Press release. NobelPrize.org. Nobel Media AB 2021, Available from 
https://www.nobelprize.org/prizes/medicine/1983/press-release/ (Thu. 18 Mar 2021). 
137. Jacob, A. & Hedges, R. Transposition of Ampicillin Resistance from RP4 to Other Replicons. 
Molec. gen. Genet. 132, 31-40 (1974). 
138. Tansirichaiya, S., Rahman, M. A. & Roberts, A. P. The Transposon Registry. Mob DNA 10, 
40 (2019). 
139. Martinez, T., Vazquez, G. J., Aquino, E. E., Martinez, I. & Robledo, I. E. ISEcp1-mediated 
transposition of blaKPC into the chromosome of a clinical isolate of Acinetobacter baumannii 
from Puerto Rico. J Med Microbiol 63, 1644-1648 (2014). 
140. Siguier, P., Perochon, J., Lestrade, L., Mahillon, J. & Chandler, M. ISfinder: the reference 
centre for bacterial insertion sequences. Nucleic acids research 34, D32-36 (2006). 
141. Gillings, M. R. Integrons: past, present, and future. Microbiol Mol Biol Rev 78, 257-277 
(2014). 
142. Partridge, S. R. & Hall, R. M. Evolution of transposons containing blaTEM genes. 
Antimicrobial agents and chemotherapy 49, 1267-1268 (2005). 
143. Naas, T. et al. Genetic structures at the origin of acquisition of the beta-lactamase blaKPC gene. 
Antimicrobial agents and chemotherapy 52, 1257-1263 (2008). 
144. Liebert, C. A., Hall, R. M. & Summers, A. O. Transposon Tn21, flagship of the floating 
genome. Microbiol Mol Biol Rev 63, 507-522 (1999). 
145. Gill, R. E., Heffron, F. & Falkow, S. Identification of the protein encoded by the transposable 
element Tn3 which is required for its transposition. Nature 282, 797-801 (1979). 
146. Kostriken, R., Morita, C. & Heffron, F. Transposon Tn3 encodes a site-specific recombination 
system: identification of essential sequences, genes, and actual site of recombination. Proc 
Natl Acad Sci U S A 78, 4041-4045 (1981). 
147. Nicolas, E. et al. The Tn3-family of Replicative Transposons. Microbiol Spectr 3, MDNA3-
0060-2014 (2015). 
148. Partridge, S. R. Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS 
microbiology reviews 35, 820-855 (2011). 
 68 
149. Shapiro, J. A. Molecular model for the transposition and replication of bacteriophage Mu and 
other transposable elements. Proc Natl Acad Sci U S A 76, 1933-1937 (1979). 
150. Seringhaus, M., Kumar, A., Hartigan, J., Snyder, M. & Gerstein, M. Genomic analysis of 
insertion behavior and target specificity of mini-Tn7 and Tn3 transposons in Saccharomyces 
cerevisiae. Nucleic acids research 34, e57 (2006). 
151. Davies, C. J. & Hutchison, C. A., 3rd. Insertion site specificity of the transposon Tn3. Nucleic 
acids research 23, 507-514 (1995). 
152. Garsin, D. A., Urbach, J., Huguet-Tapia, J. C., Peters, J. E. & Ausubel, F. M. Construction of 
an Enterococcus faecalis Tn917-mediated-gene-disruption library offers insight into Tn917 
insertion patterns. Journal of bacteriology 186, 7280-7289 (2004). 
153. Arthur, A., Nimmo, E., Hettle, S. & Sherratt, D. Transposition and Transposition Immunity 
of Transposon Tn3 Derivatives Having Different Ends. Embo Journal 3, 1723-1729 (1984). 
154. Cuzon, G., Naas, T. & Nordmann, P. Functional characterization of Tn4401, a Tn3-based 
transposon involved in blaKPC gene mobilization. Antimicrobial agents and chemotherapy 55, 
5370-5373 (2011). 
155. Arthur, A. & Sherratt, D. Dissection of the transposition process: a transposon-encoded site-
specific recombination system. Mol Gen Genet 175, 267-274 (1979). 
156. DelaFuente, J., Rodriguez-Beltran, J. & San Millan, A. Methods to Study Fitness and 
Compensatory Adaptation in Plasmid-Carrying Bacteria. Methods Mol Biol 2075, 371-382 
(2020). 
157. Lenski, R. E., Rose, M. R., Simpson, S. C. & Tadler, S. C. Long-Term Experimental 
Evolution in Escherichia coli. I. Adaptation and Divergence During 2,000 Generations. The 
American Naturalist 138, 1315-1341 (1991). 
158. Melnyk, A. H., Wong, A. & Kassen, R. The fitness costs of antibiotic resistance mutations. 
Evol Appl 8, 273-283 (2015). 
159. Starikova, I. et al. A Trade-off between the Fitness Cost of Functional Integrases and Long-
term Stability of Integrons. PLoS pathogens 8, e1003043 (2012). 
160. Enne, V. I. et al. Assessment of the fitness impacts on Escherichia coli of acquisition of 
antibiotic resistance genes encoded by different types of genetic element. J Antimicrob 
Chemother 56, 544-551 (2005). 
161. Starikova, I. et al. Fitness costs of various mobile genetic elements in Enterococcus faecium 
and Enterococcus faecalis. J Antimicrob Chemother 68, 2755-2765 (2013). 
162. Nagaev, I., Bjorkman, J., Andersson, D. I. & Hughes, D. Biological cost and compensatory 
evolution in fusidic acid-resistant Staphylococcus aureus. Molecular microbiology 40, 433-
439 (2001). 
163. Bjorkman, J. & Andersson, D. I. The cost of antibiotic resistance from a bacterial perspective. 
Drug Resist Updat 3, 237-245 (2000). 
164. Apjok, G. et al. Limited Evolutionary Conservation of the Phenotypic Effects of Antibiotic 
Resistance Mutations. Mol Biol Evol 36, 1601-1611 (2019). 
165. Vogwill, T., Kojadinovic, M. & MacLean, R. C. Epistasis between antibiotic resistance 
mutations and genetic background shape the fitness effect of resistance across species of 
Pseudomonas. Proc Biol Sci 283 (2016). 
166. San Millan, A. et al. Integrative analysis of fitness and metabolic effects of plasmids in 
Pseudomonas aeruginosa PAO1. ISME J 12, 3014-3024 (2018). 
167. Hubbard, A. T. M., Jafari, N. V., Feasey, N., Rohn, J. L. & Roberts, A. P. Effect of 
Environment on the Evolutionary Trajectories and Growth Characteristics of Antibiotic-
Resistant Escherichia coli Mutants. Frontiers in microbiology 10, 2001 (2019). 
168. Vogwill, T. & MacLean, R. C. The genetic basis of the fitness costs of antimicrobial 
resistance: a meta-analysis approach. Evol Appl 8, 284-295 (2015). 
169. Andersson, D. I. & Levin, B. R. The biological cost of antibiotic resistance. Current opinion 
in microbiology 2, 489-493 (1999). 
 69 
170. Baltrus, D. A. Exploring the costs of horizontal gene transfer. Trends Ecol Evol 28, 489-495 
(2013). 
171. San Millan, A. & MacLean, R. C. Fitness Costs of Plasmids: a Limit to Plasmid Transmission. 
Microbiol Spectr 5 (2017). 
172. Levin, B. R. et al. The population genetics of antibiotic resistance. Clinical Infectious 
Diseases 24 S9-16 (1997). 
173. Sander, P. et al. Fitness cost of chromosomal drug resistance-conferring mutations. 
Antimicrobial agents and chemotherapy 46, 1204-1211 (2002). 
174. Porse, A., Schonning, K., Munck, C. & Sommer, M. O. Survival and Evolution of a Large 
Multidrug Resistance Plasmid in New Clinical Bacterial Hosts. Mol Biol Evol 33, 2860-2873 
(2016). 
175. Ingmer, H., Miller, C. & Cohen, S. N. The RepA protein of plasmid pSC101 controls 
Escherichia coli cell division through the SOS response. Molecular microbiology 42, 519-
526 (2001). 
176. San Millan, A., Toll-Riera, M., Qi, Q. & MacLean, R. C. Interactions between horizontally 
acquired genes create a fitness cost in Pseudomonas aeruginosa. Nat Commun 6, 6845 (2015). 
177. Yano, H. et al. Evolved plasmid-host interactions reduce plasmid interference cost. Molecular 
microbiology 101, 743-756 (2016). 
178. Harrison, E., Guymer, D., Spiers, A. J., Paterson, S. & Brockhurst, M. A. Parallel 
compensatory evolution stabilizes plasmids across the parasitism-mutualism continuum. 
Current Biology 25, 2034-2039 (2015). 
179. Zund, P. & Lebek, G. Generation Time-Prolonging R-Plasmids: Correlation between 
Increases in the Generation Time of Escherichia coli Caused by R-Plasmids and Their 
Molecular-Size. Plasmid 3, 65-69 (1980). 
180. Rajer, F. Multi-Resistance Plasmids : Fitness Costs, Dynamics and Evolution ISBN 978-91-
513-0708-4 thesis, Acta Universitatis Upsaliensis, Uppsala (2019). 
181. Allen, R. C., Angst, D. C. & Hall, A. R. Resistance Gene Carriage Predicts Growth of Natural 
and Clinical Escherichia coli Isolates in the Absence of Antibiotics. Applied and 
environmental microbiology 85 (2019). 
182. Johnsen, P. J., Simonsen, G. S., Olsvik, O., Midtvedt, T. & Sundsfjord, A. Stability, 
persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci 
in the absence of antibiotic selection in vitro and in gnotobiotic mice. Microb Drug Resist 8, 
161-170 (2002). 
183. Stewart, F. M. & Levin, B. R. The Population Biology of Bacterial Plasmids: A PRIORI 
Conditions for the Existence of Conjugationally Transmitted Factors. Genetics 87, 209-228 
(1977). 
184. Bergstrom, C. T., Lipsitch, M. & Levin, B. R. Natural selection, infectious transfer and the 
existence conditions for bacterial plasmids. Genetics 155, 1505-1519 (2000). 
185. Harrison, E. & Brockhurst, M. A. Plasmid-mediated horizontal gene transfer is a 
coevolutionary process. Trends in microbiology 20, 262-267 (2012). 
186. Carroll, A. C. & Wong, A. Plasmid persistence: costs, benefits, and the plasmid paradox. Can 
J Microbiol 64, 293-304 (2018). 
187. Wein, T., Hülter, N. F., Mizrahi, I. & Dagan, T. Emergence of plasmid stability under non-
selective conditions maintains antibiotic resistance. Nature Communications 10, 2595 (2019). 
188. Loftie-Eaton, W. et al. Evolutionary Paths That Expand Plasmid Host-Range: Implications 
for Spread of Antibiotic Resistance. Mol Biol Evol 33, 885-897 (2016). 
189. Stalder, T. et al. Emerging patterns of plasmid-host coevolution that stabilize antibiotic 
resistance. Sci Rep 7, 4853 (2017). 
190. Sota, M. et al. Shifts in the host range of a promiscuous plasmid through parallel evolution of 
its replication initiation protein. ISME J 4, 1568-1580 (2010). 
 70 
191. San Millan, A. et al. Positive selection and compensatory adaptation interact to stabilize non-
transmissible plasmids. Nat Commun 5, 5208 (2014). 
192. Stevenson, C., Hall, J. P. J., Brockhurst, M. A. & Harrison, E. Plasmid stability is enhanced 
by higher-frequency pulses of positive selection. Proc Biol Sci 285 (2018). 
193. Kottara, A., Hall, J. P. J., Harrison, E. & Brockhurst, M. A. Variable plasmid fitness effects 
and mobile genetic element dynamics across Pseudomonas species. FEMS Microbiol Ecol 94 
(2018). 
194. Dionisio, F., Matic, I., Radman, M., Rodrigues, O. R. & Taddei, F. Plasmids spread very fast 
in heterogeneous bacterial communities. Genetics 162, 1525-1532 (2002). 
195. Turner, P. E., Cooper, V. S. & Lenski, R. E. Tradeoff between horizontal and vertical modes 
of transmission in bacterial plasmids. Evolution 52, 315-329 (1998). 
196. Dahlberg, C. & Chao, L. Amelioration of the cost of conjugative plasmid carriage in 
Eschericha coli K12. Genetics 165, 1641-1649 (2003). 
197. Smillie, C., Garcillan-Barcia, M. P., Francia, M. V., Rocha, E. P. & de la Cruz, F. Mobility 
of plasmids. Microbiol Mol Biol Rev 74, 434-452 (2010). 
198. Maisnier-Patin, S. & Andersson, D. I. Adaptation to the deleterious effects of antimicrobial 
drug resistance mutations by compensatory evolution. Research in microbiology 155, 360-
369 (2004). 
199. Schrag, S. J., Perrot, V. & Levin, B. R. Adaptation to the fitness costs of antibiotic resistance 
in Escherichia coli. Proc Biol Sci 264, 1287-1291 (1997). 
200. Reynolds, M. G. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 
156, 1471-1481 (2000). 
201. Bouma, J. E. & Lenski, R. E. Evolution of a Bacteria-Plasmid Association. Nature 335, 351-
352 (1988). 
202. De Gelder, L., Williams, J. J., Ponciano, J. M., Sota, M. & Top, E. M. Adaptive plasmid 
evolution results in host-range expansion of a broad-host-range plasmid. Genetics 178, 2179-
2190 (2008). 
203. Loftie-Eaton, W. et al. Compensatory mutations improve general permissiveness to antibiotic 
resistance plasmids. Nat Ecol Evol 1, 1354-1363 (2017). 
204. Modi, R. I., Wilke, C. M., Rosenzweig, R. F. & Adams, J. Plasmid macro-evolution: selection 
of deletions during adaptation in a nutrient-limited environment. Genetica 84, 195-202 
(1991). 
205. Buckner, M. M. C. et al. Clinically Relevant Plasmid-Host Interactions Indicate that 
Transcriptional and Not Genomic Modifications Ameliorate Fitness Costs of Klebsiella 
pneumoniae Carbapenemase-Carrying Plasmids. mBio 9 (2018). 
206. Schaufler, K. et al. Carriage of Extended-Spectrum Beta-Lactamase-Plasmids Does Not 
Reduce Fitness but Enhances Virulence in Some Strains of Pandemic E. coli Lineages. 
Frontiers in microbiology 7, 336 (2016). 
207. Ma, T. et al. Fitness Cost of blaNDM-5-Carrying p3R-IncX3 Plasmids in Wild-Type NDM-Free 
Enterobacteriaceae. Microorganisms 8 (2020). 
208. Dionisio, F., Conceicao, I. C., Marques, A. C., Fernandes, L. & Gordo, I. The evolution of a 
conjugative plasmid and its ability to increase bacterial fitness. Biol Lett 1, 250-252 (2005). 
209. Lenski, R. E., Simpson, S. C. & Nguyen, T. T. Genetic analysis of a plasmid-encoded, host 
genotype-specific enhancement of bacterial fitness. Journal of bacteriology 176, 3140-3147 
(1994). 
210. European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption in 
the EU/EEA 2019. Annual Epidemiological Report, Stockholm (2020). 
211. Seppala, H. et al. The effect of changes in the consumption of macrolide antibiotics on 
erythromycin resistance in group A streptococci in Finland. Finnish Study Group for 
Antimicrobial Resistance. N Engl J Med 337, 441-446 (1997). 
 71 
212. Sundqvist, M. et al. Little evidence for reversibility of trimethoprim resistance after a drastic 
reduction in trimethoprim use. J Antimicrob Chemother 65, 350-360 (2010). 
213. Enne, V. I., Bennett, P. M., Livermore, D. M. & Hall, L. M. Enhancement of host fitness by 
the sul2-coding plasmid p9123 in the absence of selective pressure. J Antimicrob Chemother 
53, 958-963 (2004). 
214. Andersson, D. I. & Hughes, D. Antibiotic resistance and its cost: is it possible to reverse 
resistance? Nature reviews. Microbiology 8, 260-271 (2010). 
215. Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. Combination therapy for treatment of 
infections with gram-negative bacteria. Clinical microbiology reviews 25, 450-470 (2012). 
216. Baym, M., Stone, L. K. & Kishony, R. Multidrug evolutionary strategies to reverse antibiotic 
resistance. Science 351, aad3292 (2016). 
217. Szybalski, W. & Bryson, V. Genetic studies on microbial cross resistance to toxic agents. I. 
Cross resistance of Escherichia coli to fifteen antibiotics. Journal of bacteriology 64, 489-
499 (1952). 
218. Kim, S., Lieberman, T. D. & Kishony, R. Alternating antibiotic treatments constrain 
evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A 111, 14494-14499 
(2014). 
219. Lazar, V. et al. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol 9, 700 (2013). 
220. Imamovic, L. & Sommer, M. O. Use of collateral sensitivity networks to design drug cycling 
protocols that avoid resistance development. Sci Transl Med 5, 204ra132 (2013). 
221. Munck, C., Gumpert, H. K., Wallin, A. I., Wang, H. H. & Sommer, M. O. Prediction of 
resistance development against drug combinations by collateral responses to component 
drugs. Sci Transl Med 6, 262ra156 (2014). 
222. Gonzales, P. R. et al. Synergistic, collaterally sensitive beta-lactam combinations suppress 
resistance in MRSA. Nat Chem Biol 11, 855-861 (2015). 
223. Rodriguez de Evgrafov, M., Gumpert, H., Munck, C., Thomsen, T. T. & Sommer, M. O. 
Collateral Resistance and Sensitivity Modulate Evolution of High-Level Resistance to Drug 
Combination Treatment in Staphylococcus aureus. Mol Biol Evol 32, 1175-1185 (2015). 
224. Maltas, J. & Wood, K. B. Pervasive and diverse collateral sensitivity profiles inform optimal 
strategies to limit antibiotic resistance. PLoS Biol 17, e3000515 (2019). 
225. Kavanaugh, L. G., Flanagan, J. N. & Steck, T. R. Reciprocal antibiotic collateral sensitivity 
in Burkholderia multivorans. Int J Antimicrob Agents 56, 105994 (2020). 
226. Barbosa, C. et al. Alternative Evolutionary Paths to Bacterial Antibiotic Resistance Cause 
Distinct Collateral Effects. Mol Biol Evol 34, 2229-2244 (2017). 
227. Rodriguez de Evgrafov, M. C., Faza, M., Asimakopoulos, K. & Sommer, M. O. A. Systematic 
Investigation of Resistance Evolution to Common Antibiotics Reveals Conserved Collateral 
Responses across Common Human Pathogens. Antimicrobial agents and chemotherapy 65 
(2020). 
228. Jansen, G. et al. Association between clinical antibiotic resistance and susceptibility of 
Pseudomonas in the cystic fibrosis lung. Evol Med Public Health 2016, 182-194 (2016). 
229. Rosenkilde, C. E. H. et al. Collateral sensitivity constrains resistance evolution of the CTX-
M-15 beta-lactamase. Nat Commun 10, 618 (2019). 
230. Frohlich, C. et al. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with 
Evolutionary Trade-Offs. mSphere 4 (2019). 
231. Herencias, C. et al. Collateral sensitivity associated with antibiotic resistance plasmids. Elife 
10 (2021). 
232. Nichol, D. et al. Antibiotic collateral sensitivity is contingent on the repeatability of evolution. 
Nat Commun 10, 334 (2019). 
233. Barbosa, C., Roemhild, R., Rosenstiel, P. & Schulenburg, H. Evolutionary stability of 
collateral sensitivity to antibiotics in the model pathogen Pseudomonas aeruginosa. Elife 8 
(2019). 
 72 
234. Roemhild, R., Linkevicius, M. & Andersson, D. I. Molecular mechanisms of collateral 
sensitivity to the antibiotic nitrofurantoin. PLoS Biol 18, e3000612 (2020). 
235. Escherich, T. & Bettelheim, K. S. The Intestinal Bacteria of the Neonate and Breast-Fed 
Infant. Reviews of Infectious Diseases 10, 1220-1225 (1988). 
236. Donaldson, G. P., Lee, S. M. & Mazmanian, S. K. Gut biogeography of the bacterial 
microbiota. Nature reviews. Microbiology 14, 20-32 (2016). 
237. Oh, S., Buddenborg, S., Yoder-Himes, D. R., Tiedje, J. M. & Konstantinidis, K. T. Genomic 
diversity of Escherichia isolates from diverse habitats. PloS one 7, e47005 (2012). 
238. Walk, S. T. et al. Cryptic lineages of the genus Escherichia. Applied and environmental 
microbiology 75, 6534-6544 (2009). 
239. Daegelen, P., Studier, F. W., Lenski, R. E., Cure, S. & Kim, J. F. Tracing ancestors and 
relatives of Escherichia coli B, and the derivation of B strains REL606 and BL21(DE3). J 
Mol Biol 394, 634-643 (2009). 
240. Blount, Z. D. The unexhausted potential of E. coli. Elife 4 (2015). 
241. Lederberg, J. & Tatum, E. L. Gene recombination in Escherichia coli. Nature 158, 558 (1946). 
242. Morse, M. L., Lederberg, E. M. & Lederberg, J. Transduction in Escherichia coli K-12. 
Genetics 41, 142-156 (1956). 
243. Hayes, W. Observations on a transmissible agent determining sexual differentiation in 
Bacterium coli. Journal of general microbiology 8, 72-88 (1953). 
244. Lederberg, J. Cell genetics and hereditary symbiosis. Physiol Rev 32, 403-430 (1952). 
245. National Center for Biotechnology Information (NCBI). Available from 
https://www.ncbi.nlm.nih.gov/genome/genomes/167 (accessed 01/2021). 
246. Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 
1453-1462 (1997). 
247. Hayashi, K. et al. Highly accurate genome sequences of Escherichia coli K-12 strains 
MG1655 and W3110. Mol Syst Biol 2, 2006 0007 (2006). 
248. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: 
the Keio collection. Mol Syst Biol 2, 2006 0008 (2006). 
249. Knoppel, A. et al. Genetic Adaptation to Growth Under Laboratory Conditions in Escherichia 
coli and Salmonella enterica. Frontiers in microbiology 9, 756 (2018). 
250. Puentes-Tellez, P. E., Hansen, M. A., Sorensen, S. J. & van Elsas, J. D. Adaptation and 
heterogeneity of Escherichia coli MC1000 growing in complex environments. Applied and 
environmental microbiology 79, 1008-1017 (2013). 
251. Jahn, L. J., Munck, C., Ellabaan, M. M. H. & Sommer, M. O. A. Adaptive Laboratory 
Evolution of Antibiotic Resistance Using Different Selection Regimes Lead to Similar 
Phenotypes and Genotypes. Frontiers in microbiology 8, 816 (2017). 
252. Lenski, R. E., Available from http://myxo.css.msu.edu/index.html (accessed 01/2021). 
253. Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nature reviews. 
Microbiology 2, 123-140 (2004). 
254. Wagenlehner, F. M. E. et al. Epidemiology, definition and treatment of complicated urinary 
tract infections. Nat Rev Urol 17, 586-600 (2020). 
255. Leimbach, A., Hacker, J. & Dobrindt, U. E. coli as an all-rounder: the thin line between 
commensalism and pathogenicity. Curr Top Microbiol Immunol 358, 3-32 (2013). 
256. Manges, A. R. et al. Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages. 
Clinical microbiology reviews 32 (2019). 
257. Crossman, L. C. et al. A commensal gone bad: complete genome sequence of the prototypical 
enterotoxigenic Escherichia coli strain H10407. Journal of bacteriology 192, 5822-5831 
(2010). 
258. Robins-Browne, R. M. et al. Are Escherichia coli Pathotypes Still Relevant in the Era of 
Whole-Genome Sequencing? Front Cell Infect Microbiol 6, 141 (2016). 
 73 
259. Kahlmeter, G. & Eco.Sens. An international survey of the antimicrobial susceptibility of 
pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob 
Chemother 51, 69-76 (2003). 
260. Alteri, C. J. & Mobley, H. L. T. Metabolism and Fitness of Urinary Tract Pathogens. 
Microbiol Spectr 3 (2015). 
261. Bengtsson, S., Naseer, U., Sundsfjord, A., Kahlmeter, G. & Sundqvist, M. Sequence types 
and plasmid carriage of uropathogenic Escherichia coli devoid of phenotypically detectable 
resistance. J Antimicrob Chemother 67, 69-73 (2012). 
262. Calhau, V., Domingues, S., Ribeiro, G., Mendonca, N. & Da Silva, G. J. Interplay between 
pathogenicity island carriage, resistance profile and plasmid acquisition in uropathogenic 
Escherichia coli. J Med Microbiol 64, 828-835 (2015). 
263. Dijkshoorn, L. & Nemec, A. in Acinetobacter Molecular Biology (edited by Ulrike 
Gerischer), Ch. The Diversity of the Genus Acinetobacter, 1 (Caister Academic Press, U.K, 
2008). 
264. List of Prokaryotic names with Standing in Nomenclature (LPSN). Available from 
https://lpsn.dsmz.de/species (accessed 01/2021). 
265. Rossau, R., Van Landschoot, A., Gillis, M. & De Ley, J. Taxonomy of Moraxellaceae fam. 
nov., a New Bacterial Family To Accommodate the Genera Moraxella, Acinetobacter, and 
Psychrobacter and Related Organisms. International Journal of Systematic Bacteriology 41, 
310-319 (1991). 
266. Baumann, P., Doudoroff, M. & Stanier, R. Y. A study of the Moraxella Group. II. Oxidative-
negative Species (Genus Acinetobacter). Journal of bacteriology 95, 1520-1541 (1968). 
267. Baumann, P. Isolation of Acinetobacter from soil and water. Journal of bacteriology 96, 39-
42 (1968). 
268. Carr, E. L., Kampfer, P., Patel, B. K., Gurtler, V. & Seviour, R. J. Seven novel species of 
Acinetobacter isolated from activated sludge. International journal of systematic and 
evolutionary microbiology 53, 953-963 (2003). 
269. Seifert, H. et al. Distribution of Acinetobacter species on human skin: comparison of 
phenotypic and genotypic identification methods. Journal of clinical microbiology 35, 2819–
2825 (1997). 
270. Al Atrouni, A., Joly-Guillou, M. L., Hamze, M. & Kempf, M. Reservoirs of Non-baumannii 
Acinetobacter Species. Frontiers in microbiology 7, 49 (2016). 
271. Towner, K. J. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 73, 355-363 
(2009). 
272. Nemec, A. et al. Genotypic and phenotypic characterization of the Acinetobacter 
calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. 
nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. 
(formerly Acinetobacter genomic species 13TU). Research in microbiology 162, 393-404 
(2011). 
273. Antunes, L. C., Visca, P. & Towner, K. J. Acinetobacter baumannii: evolution of a global 
pathogen. Pathog Dis 71, 292-301 (2014). 
274. Nielsen, K. et al. Natural Transformation and Availability of Transforming DNA to 
Acinetobacter calcoaceticus in Soil Microcosms. Applied and environmental microbiology 
63, 1945-1952 (1997). 
275. Juni, E. & Heym, G. A. Pathways for Biosynthesis of a Bacterial Capsular Polysaccharide. 
Iv. Capsule Resynthesis by Decapsulated Resting-Cell Suspensions. Journal of bacteriology 
87, 461-467 (1964). 
276. Juni, E. & Janik, A. Transformation of Acinetobacter calco-aceticus (Bacterium anitratum). 
Journal of bacteriology 98, 281-288 (1969). 
277. Ramirez, M. S. et al. Naturally competent Acinetobacter baumannii clinical isolate as a 
convenient model for genetic studies. Journal of clinical microbiology 48, 1488-1490 (2010). 
 74 
278. Godeux, A. S. et al. Fluorescence-Based Detection of Natural Transformation in Drug-
Resistant Acinetobacter baumannii. Journal of bacteriology 200 (2018). 
279. Wilharm, G., Piesker, J., Laue, M. & Skiebe, E. DNA uptake by the nosocomial pathogen 
Acinetobacter baumannii occurs during movement along wet surfaces. Journal of 
bacteriology 195, 4146-4153 (2013). 
280. Traglia, G. M. et al. Interspecies DNA acquisition by a naturally competent Acinetobacter 
baumannii strain. Int J Antimicrob Agents 53, 483-490 (2019). 
281. Vallenet, D. et al. Comparative analysis of Acinetobacters: three genomes for three lifestyles. 
PloS one 3, e1805 (2008). 
282. Adams, M. D. et al. Comparative genome sequence analysis of multidrug-resistant 
Acinetobacter baumannii. Journal of bacteriology 190, 8053-8064 (2008). 
283. Chen, T. L. et al. Acinetobacter baylyi as a pathogen for opportunistic infection. Journal of 
clinical microbiology 46, 2938-2944 (2008). 
284. Zhou, Z. et al. Clinical carbapenem-resistant Acinetobacter baylyi strain coharboring blaSIM-
1 and blaOXA-23 from China. Antimicrobial agents and chemotherapy 55, 5347-5349 (2011). 
285. Elliott, K. T. & Neidle, E. L. Acinetobacter baylyi ADP1: transforming the choice of model 
organism. IUBMB life 63, 1075-1080 (2011). 
286. Utnes, A. L. et al. Growth phase-specific evolutionary benefits of natural transformation in 
Acinetobacter baylyi. ISME J 9, 2221-2231 (2015). 
287. Juni, E. Interspecies Transformation of Acinetobacter: genetic evidence for a ubiquitous 
genus. Journal of bacteriology 112, 917-931 (1972). 
288. Harms, K. & Wackernagel, W. The RecBCD and SbcCD DNases suppress homology-
facilitated illegitimate recombination during natural transformation of Acinetobacter baylyi. 
Microbiology 154, 2437-2445 (2008). 
289. Palmen, R., Buijsman, P. & Hellingwerf, K. J. Physiological regulation of competence 
induction for natural transformation in Acinetobacter calcoaceticus. Archives of microbiology 
162, 344-351 (1994). 
290. de Berardinis, V. et al. A complete collection of single-gene deletion mutants of Acinetobacter 
baylyi ADP1. Mol Syst Biol 4, 174 (2008). 
291. Metzgar, D. et al. Acinetobacter sp. ADP1: an ideal model organism for genetic analysis and 
genome engineering. Nucleic acids research 32, 5780-5790 (2004). 
292. CDC. Antibiotic resistance threats in the United States 2019. Atlanta, GA: U.S. Department 
of Health and Human Services, CDC (2019). 
293. Peterson, L. R. Bad Bugs, No Drugs: No ESCAPE Revisited. Clinical Infectious Diseases 49, 
992-993 (2009). 
294. Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: 
no ESKAPE. J Infect Dis 197, 1079-1081 (2008). 
295. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. 
NORM NORM-VET 2018, Tromsø / Oslo (2019). 
296. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance 
surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) Stockholm (2010). 
297. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial 
resistance in Europe 2018. Annual report of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), Stockholm (2019). 
298. Norwegian Directorate of Health. Antibiotic use in Norwegian Primary Healthcare. National 
Guidelines, Version 1.3, Available from www.antibiotikaiallmennpraksis.no (2012). 
299. Gupta, K. et al. International clinical practice guidelines for the treatment of acute 
uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious 
Diseases Society of America and the European Society for Microbiology and Infectious 
Diseases. Clinical Infectious Diseases 52, e103-120 (2011). 
 75 
300. Ray, J. & Nielsen, K. Experimental methods for assaying natural transformation and inferring 
horizontal gene transfer. Methods Enzymol 395, 491-520 (2005). 
301. Harms, K., Schon, V., Kickstein, E. & Wackernagel, W. The RecJ DNase strongly suppresses 
genomic integration of short but not long foreign DNA fragments by homology-facilitated 
illegitimate recombination during transformation of Acinetobacter baylyi. Molecular 
microbiology 64, 691-702 (2007). 
302. Pansegrau, W., Thomas, C. & Stanisich, V. Complete nucleotide sequence of Birmingham 
IncP alpha plasmids. Compilation and comparative analysis. J Mol Biol 239, 623-663 (1994). 
303. San Millan, A. Evolution of Plasmid-Mediated Antibiotic Resistance in the Clinical Context. 
Trends in microbiology 26, 978-985 (2018). 
304. Samuelsen, O. et al. Identification of Enterobacteriaceae isolates with OXA-48 and 
coproduction of OXA-181 and NDM-1 in Norway. J Antimicrob Chemother 68, 1682-1685 
(2013). 
305. McDonald, M. J. Microbial Experimental Evolution - a proving ground for evolutionary 
theory and a tool for discovery. EMBO Rep 20, e46992 (2019). 
306. Lenski, R. E. Phenotypic and Genomic Evolution during a 20,000-Generation Experiment 
with the Bacterium Escherichia coli. Plant Breeding Reviews, 225-265 (2003). 
307. Deatherage, D. E. & Barrick, J. E. Identification of mutations in laboratory-evolved microbes 
from next-generation sequencing data using breseq. Methods Mol Biol 1151, 165-188 (2014). 
308. Levin, B. R., Perrot, V. & Walker, N. Compensatory mutations, antibiotic resistance and the 
population genetics of adaptive evolution in bacteria. Genetics 154, 985-997 (2000). 
309. Varet, H., Brillet-Gueguen, L., Coppee, J. Y. & Dillies, M. A. SARTools: A DESeq2- and 
EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data. PloS 
one 11, e0157022 (2016). 
310. Mi, H., Muruganujan, A., Ebert, D., Huang, X. & Thomas, P. D. PANTHER version 14: more 
genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic 
acids research 47, D419-d426 (2019). 
311. Kahlmeter, G., Ahman, J. & Matuschek, E. Antimicrobial Resistance of Escherichia coli 
Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and 
Comparison with 2000 and 2008. Infect Dis Ther 4, 417-423 (2015). 
312. Liakopoulos, A., Aulin, L. B. S., Buffoni, M., van Hasselt, J. G. C. & Rozen, D. E. Allele-
specific collateral and fitness effects determine the dynamics of fluoroquinolone-resistance 
evolution. bioRxiv 2020.10.19.345058 (2020). 
313. Thulin, E., Thulin, M. & Andersson, D. I. Reversion of High-level Mecillinam Resistance to 
Susceptibility in Escherichia coli During Growth in Urine. EBioMedicine 23, 111-118 (2017). 
314. Ho, P. L. et al. Plasmid-Mediated OqxAB Is an Important Mechanism for Nitrofurantoin 
Resistance in Escherichia coli. Antimicrobial agents and chemotherapy 60, 537-543 (2016). 
315. Giske, C. G. Contemporary resistance trends and mechanisms for the old antibiotics colistin, 
temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 21, 899-905 
(2015). 
316. Dunn, S. J., Carrilero, L., Brockhurst, M. & McNally, A. Limited and strain-specific 
transcriptional and growth responses to acquisition of a multidrug resistance plasmid in 
genetically diverse Escherichia coli lineages. bioRxiv 2020.10.23.351718 (2020). 
317. Phaneuf, P. V., Gosting, D., Palsson, B. O. & Feist, A. M. ALEdb 1.0: a database of mutations 
from adaptive laboratory evolution experimentation. Nucleic acids research 47, D1164-
D1171 (2019). 
318. Chib, S. & Seshasayee, A. S. Modulation of rpoS fitness by loss of cpdA activity during 
stationary-phase in Escherichia coli. bioRxiv 460451 (2018). 
319. San Millan, A., Heilbron, K. & MacLean, R. C. Positive epistasis between co-infecting 
plasmids promotes plasmid survival in bacterial populations. ISME J 8, 601-612 (2014). 
 76 
320. McNally, A. et al. Combined Analysis of Variation in Core, Accessory and Regulatory 
Genome Regions Provides a Super-Resolution View into the Evolution of Bacterial 
Populations. PLoS Genet 12, e1006280 (2016). 
321. Barbe, V., Vallenet, D., Fonknechten, N., Kreimeyer, A. & Oztas, S. Unique features revealed 
by the genome sequence of Acinetobacter sp. ADP1, a versatile and naturally transformation 
competent bacterium. Nucleic acids research 32, 5766-5779 (2004). 
322. Casadaban, M. J., Chou, J. & Cohen, S. N. Overproduction of the Tn3 Transposition Protein 
and Its Role in DNA Transposition. Cell 28, 345-354 (1982). 
323. Saunders, C. W. & Guild, W. R. Monomer plasmid DNA transforms Streptococcus 
pneumoniae. Mol Gen Genet 181, 57-62 (1981). 
324. Berge, M., Mortier-Barriere, I., Martin, B. & Claverys, J. P. Transformation of Streptococcus 
pneumoniae relies on DprA- and RecA-dependent protection of incoming DNA single 
strands. Molecular microbiology 50, 527-536 (2003). 
325. Harms, K. & Wackernagel, W. The RecBCD and SbcCD DNases suppress homology-
facilitated illegitimate recombination during natural transformation of Acinetobacter baylyi. 
Microbiology 154, 2437-2445 (2008). 
326. Kidane, D. et al. Evidence for different pathways during horizontal gene transfer in competent 
Bacillus subtilis cells. PLoS Genet 5, e1000630 (2009). 
327. Dillingham, M. & Kowalczykowski, S. RecBCD Enzyme and the Repair of Double-Stranded 
DNA Breaks. Microbiol. Mol. Biol. 72 (2008). 
328. San Millan, A., Escudero, J. A., Gifford, D. R., Mazel, D. & MacLean, R. C. Multicopy 
plasmids potentiate the evolution of antibiotic resistance in bacteria. Nat Ecol Evol 1, 10 
(2016). 
329. Shi, Q., Huguet-Tapia, J. C. & Peters, J. E. Tn917 targets the region where DNA replication 
terminates in Bacillus subtilis, highlighting a difference in chromosome processing in the 
firmicutes. Journal of bacteriology 191, 7623-7627 (2009). 
330. Evans, D. R. et al. Systematic detection of horizontal gene transfer across genera among 
multidrug-resistant bacteria in a single hospital. Elife 9 (2020). 
331. Twiss, E., Coros, A. M., Tavakoli, N. P. & Derbyshire, K. M. Transposition is modulated by 
a diverse set of host factors in Escherichia coli and is stimulated by nutritional stress. 
Molecular microbiology 57, 1593-1607 (2005). 
332. Guerin, E. et al. The SOS response controls integron recombination. Science 324, 1034 
(2009). 
333. Kretschmer, P. J. & Cohen, S. N. Selected translocation of plasmid genes: frequency and 







Conserved collateral antibiotic susceptibility
networks in diverse clinical strains of Escherichia coli
Nicole L. Podnecky1, Elizabeth G.A. Fredheim1, Julia Kloos1, Vidar Sørum1, Raul Primicerio1, Adam P. Roberts2,3,
Daniel E. Rozen4, Ørjan Samuelsen 1,5 & Pål J. Johnsen1
There is urgent need to develop novel treatment strategies to reduce antimicrobial resistance.
Collateral sensitivity (CS), where resistance to one antimicrobial increases susceptibility to
other drugs, might enable selection against resistance during treatment. However, the suc-
cess of this approach would depend on the conservation of CS networks across genetically
diverse bacterial strains. Here, we examine CS conservation across diverse Escherichia coli
strains isolated from urinary tract infections. We determine collateral susceptibilities of
mutants resistant to relevant antimicrobials against 16 antibiotics. Multivariate statistical
analyses show that resistance mechanisms, in particular efflux-related mutations, as well as
the relative fitness of resistant strains, are principal contributors to collateral responses.
Moreover, collateral responses shift the mutant selection window, suggesting that CS-
informed therapies may affect evolutionary trajectories of antimicrobial resistance. Our data
allow optimism for CS-informed therapy and further suggest that rapid detection of resis-
tance mechanisms is important to accurately predict collateral responses.
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The evolution and increasing prevalence of antimicrobialresistance is driven by the consumption and misuse ofantimicrobials in human medicine, agriculture, and the
environment1–3. Historically, the threat of antimicrobial resis-
tance was overcome by using novel antimicrobials with unique
drug targets. However, the discovery rate of new antimicrobial
agents has dwindled4–6 and severely lags behind the rate of
resistance evolution7. While concerted scientific, corporate, and
political focus is needed to recover antimicrobial pipelines8–10,
there is an urgent need for alternative strategies that prolong the
efficacy of existing antimicrobials and prevent or slow the
emergence, spread, and persistence of antimicrobial resistance.
Current global efforts to improve antimicrobial stewardship lar-
gely focus on reducing overall antimicrobial consumption and
increasing awareness of resistance development9,11–13. While
these efforts will affect the evolution and spread of resistance,
mounting evidence suggests that these changes alone will not lead
to large-scale reductions in the occurrence of antimicrobial
resistance14–18.
Several recent studies have examined novel treatment strategies
using multiple antimicrobials that could reduce the rate of
resistance emergence and even reverse pre-existing resistance.
These approaches, collectively termed selection inversion strate-
gies, refer to cases where resistance becomes costly in the pre-
sence of other antimicrobial agents19. Among the most promising
of these strategies are those based on a phenomenon first reported
in 1952, termed collateral sensitivity (CS), where resistance to one
antimicrobial simultaneously increases the susceptibility to
another20. CS and its inverse, cross-resistance (CR), have been
demonstrated for several bacterial species and across different
classes of antimicrobials21–27. These results have formed the basis
of proposed CS-informed antimicrobial strategies that combine
drug pairs22,28 or alter temporal administration, e.g. drug
cycling21,29. CS-informed strategies would force bacteria to evolve
resistance along a predictable trajectory, resulting in CS; this
predictability could be exploited to ultimately reverse resistance
and prevent the fixation of resistance and multi-drug resistance
development at the population level of bacterial communities.
Initial in vitro experiments support using CS-based strategies
to re-sensitize resistant strains21 and reduce rates of resistance
development29; however, the broader application of this prin-
ciple depends on predictable bacterial responses during anti-
microbial therapy. This predictability must be general for a
given drug class and should not vary across strains of the same
species. To date, most studies of CS and CR have focused on
describing collateral networks21–23 using resistant mutants
derived from single laboratory-adapted strains and limited
numbers of clinical isolates. Two studies on Pseudomonas
aeruginosa have investigated CS in collections of clinical
isolates30,31. However, these studies lack either baseline con-
trols30 or sufficient genetic diversity among tested strains31. As
valuable as earlier work has been, the responses of single strains
(laboratory or clinical) may not be representative of CS and CR
responses in other strains.
To address this limitation, here we focus on understanding
collateral networks in clinical urinary tract isolates of Escherichia
coli with selected resistance to drugs widely used for the treatment
of urinary tract infections: ciprofloxacin, trimethoprim, nitro-
furantoin, and mecillinam. We investigate collateral networks to
16 antimicrobials from diverse drug classes in 10 genetically
diverse clinical strains (corresponding to 49 laboratory-generated
mutants) to assess the factors contributing to collateral responses
(both CS and CR). This approach allows us to identify variation
in the sign and magnitude of collateral responses and identify
mechanisms of CS and CR that are preserved in various genetic
backgrounds. Using multivariate statistical modeling, we show
that resistance mutations, particularly those affecting efflux
pumps, and the relative fitness of resistant isolates are more
important determinants of collateral networks than genetic
background. Our results support the idea that collateral responses
may be predictable.
Results
Collateral responses vary between and across resistance groups.
We examined collateral responses to antimicrobial resistance in
a panel of 10 genetically diverse (Supplementary Fig. 1a–b)
E. coli strains isolated from urinary tract infections. For each of
these pan-susceptible strains (Supplementary Fig. 1c)32, a single
resistant mutant was generated to each of four individual
antimicrobials used to treat urinary tract infections: cipro-
floxacin, trimethoprim, nitrofurantoin, and mecillinam. Here
we define resistance group as the collection of mutants from the
10 different genetic backgrounds that were selected for resis-
tance to the same antimicrobial. Mutants resistant to mecilli-
nam required only a single selection step, while multiple
selection steps were required to select for resistance above
clinical breakpoints for the remaining antimicrobials. In total,
40 resistant mutants were generated with resistance levels above
clinical breakpoints, as determined by antimicrobial suscept-
ibility testing using both gradient strip diffusion (Supplemen-
tary Table 1) and inhibitory concentration 90% (IC90)21 testing
(Table 1). The two methods are correlated, but IC90 measure-
ments allow for more robust detection of small relative differ-
ences in susceptibility33,34. Changes in the IC90 of resistant
mutants from each respective wild-type strain (Supplementary
Fig. 2) were compared for 16 antimicrobials (Table 2). Overall,
collateral responses were observed in 39% (233/590) of possible
instances (Supplementary Table 2); of these 49% (115/233)
were associated with only a 1.5-fold change in IC90. Such small
changes would not be observed by typical two-fold anti-
microbial susceptibility testing methods frequently used in
clinical laboratories.
Overall CR was more frequent than CS, 141 versus 92 instances
(Supplementary Table 2), and collateral networks varied con-
siderably between resistance groups. We observed 19 cases of
conserved collateral responses (Fig. 1a), where CR or CS to a
specific antimicrobial was found in ≥50% of the mutants within a
resistance group, defined as CR50 or CS50, respectively. For each
CR50 and CS50 observation, IC90 results were further assessed by
generating dose–response curves of representative strain:drug
combinations (Supplementary Fig. 3). Inhibition of growth was
shown to vary across antimicrobial concentrations between
resistant mutants and respective wild-type strains, confirming
the changes in antimicrobial susceptibility determined by the IC90
assays.
During the selection of resistant mutants, we often observed
colonies of varying size for all resistance groups, suggesting
changes to bacterial fitness. To test this, we measured the growth
rates of mutants relative to the respective wild-type strains
(Supplementary Fig. 4). In general, mutants resistant to
ciprofloxacin and mecillinam displayed severely reduced growth
rates, suggesting high costs of resistance. Relative growth rates
varied between 0.34–0.75 with a mean of 0.53 for ciprofloxacin-
resistant mutants and between 0.49–0.79 with a mean of 0.64 for
mecillinam-resistant mutants. Mutants resistant to nitrofurantoin
and trimethoprim displayed lower fitness effects, and several
resistant mutants harbored apparent cost-free resistance muta-
tions (Supplementary Fig. 4). Only two of ten nitrofurantoin-
resistant mutants and four of ten trimethoprim-resistant mutants
displayed an apparent cost of resistance. Relative growth rates
varied between 0.93–1.05 and 0.68–1.07 with averages of
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0.99–0.94 for nitrofurantoin- resistant and trimethoprim-
resistant mutants, respectively.
Ciprofloxacin resistance linked to conserved collateral
responses. Nearly half (108/233, 46%) of the observed collateral
responses were in ciprofloxacin-resistant mutants, while the
remaining 125 were distributed between the other three resistance
groups (Supplementary Table 2). Within the ciprofloxacin-
resistant group, the majority of collateral responses were CR
(70/108, 65%). Additionally, CS responses in ciprofloxacin-
resistant mutants were the most conserved in our dataset, with
CS to gentamicin occurring in 8 of 10 strains and CS to fosfo-
mycin in 7 of 10 strains (Fig. 1a). Gentamicin and other ami-
noglycosides are important for the treatment of a wide range of
infections35, while fosfomycin is primarily used for treatment of
uncomplicated urinary tract infections36,37. The ciprofloxacin-
resistant mutants were also unique in the magnitude of observed
changes, with cases of CR close to 30-fold and CS as high as six-
fold changes in IC90 (Supplementary Fig. 2).
Characterization of antimicrobial-resistant mutants. We
hypothesized that CS and CR variation in and between resistance
groups could be attributed to different mutations causing resis-
tance in each strain. Using whole genome sequencing, we iden-
tified a total of 149 mutations in the resistant mutants
(Supplementary Data 1–4). Of these, 88 mutations affect pre-
viously described or putative antimicrobial resistance-associated
genes, gene-regions, or pathways (Supplementary Data 1–4). The
remaining mutations were found in other cellular processes not
known to affect antimicrobial susceptibility (e.g. metabolic
pathways and virulence factors), such as mutation to the FimE
regulator of FimA that was frequently observed in mecillinam-
resistant mutants (Supplementary Data 2). Aside from FimE, we
did not observe mutations in regions unrelated to resistance
Table 1 Description of Escherichia coli strains used in the study and average IC90 changes following antimicrobial selection
Strain STa Origin CIPb MECb NITb TMPb
WTc cCIPR WTc cMECR WTc cNITR WTc cTMPR
K56-2 73 Greece 0.014 16 0.146 >30 8 >64 0.225 >28
K56-12 104 Portugal 0.016 1.67 0.273 28 7.33 >64 0.563 >32
K56-16d 127 Portugal 0.009 3 0.167 18.7 4 >64 0.25 >30
K56-41 73 Greece 0.016 2.33 0.104 13.3 6 >64 0.25 6.67
K56-44d 12 Greece 0.013 1.67 0.141 16 6.67 >64 0.375 6
K56-50 100 Greece 0.012 3 0.141 10.7 12 >64 0.172 18
K56-68 95 Sweden 0.014 4 0.141 30 6.67 >64 0.208 18.7
K56-70 537 Sweden 0.007 2.67 0.083 >32 4.67 >64 0.25 14.7
K56-75e 69 UK 0.008 1.17 0.063 13 6 >64 0.167 5.33
K56-78 1235 UK 0.015 6 0.141 16 8 >64 0.5 7.33
aMulti-locus sequence type (ST)
bThe average IC90 values (µgmL−1) of three or more biological replicates for wild type (WT) and resistant (R) mutants to ciprofloxacin (CIP), mecillinam (MEC), nitrofurantoin (NIT), and trimethoprim
(TMP). Individual results above detection limits (MEC= 32 µgmL−1, NIT= 64 µgmL−1, TMP= 32 µgmL−1) were analyzed as those values, yielding final results with uncertainty (>average). EUCAST
Clinical Breakpoints v 7.1 for Enterobacteriaceae63 were: >0.5 µg mL−1 CIP, >8 µgmL−1 MEC, >64 µgmL−1 NIT, and >4 µg mL−1 TMP
cThe strain number names the WT, and designations CIPR, MECR, NITR, and TMPR describe which drug the isolates were selected with, and resistance achieved
d, eStrains containing the Col156 or Col(MP18) replicon, respectively
Table 2 List of antimicrobials used in this study
Antimicrobiala Abbreviation Drug class Drug target(s) Solvent
Amoxicillin AMX β-lactam (Penicillin) Cell wall synthesis Phosphate bufferb
Azithromycin AZT Macrolide Protein synthesis (50S) ≥95% Ethanol
Ceftazidime CAZ β-lactam (Cephalosporin) Cell wall synthesis Water+ 10% (ww-1) Na2CO3
Chloramphenicol CHL Amphenicol Protein synthesis (50S) ≥95% Ethanol
Ciprofloxacin CIP Fluoroquinolone DNA replication, cell division 0.1 N HCl
Colistin COL Polymyxin Cell wall & cell membrane Water
Ertapenem ETP β-lactam (Carbapenem) Cell wall synthesis Water
Fosfomycin FOS Phosphonic Cell wall synthesis (MurA) Water
Gentamicin GEN Aminoglycoside Protein synthesis (30S) Water
Mecillinam MEC β-lactam (Penicillin) Cell wall synthesis (PBP2) Water
Nitrofurantoin NIT Nitrofuran Multiplec Dimethyl sulfoxide
Trimethoprim TMP Antifolate Folate synthesis (FolA) Dimethyl sulfoxide
Sulfamethoxazole SMX Antifolate Folate synthesis (FolP) Dimethyl sulfoxide
TMP+ SMX (1:19) SXT Antifolate Folate synthesis (FolA+ FolP) Dimethyl sulfoxide
Temocillin TEM β-lactam (Penicillin) Cell wall synthesis Water
Tetracycline TET Tetracycline Protein synthesis (30S) Water
Tigecycline TGC Tetracycline Protein synthesis (30S) Water
aWhen available, final antimicrobial concentration was determined using manufacturer-provided or calculated drug potencies, otherwise potency was assumed to be 100%. Aliquots were stored at −20
or −80 °C in single-use vials. All antimicrobials and chemical solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) with the exception of ciprofloxacin (Biochemika, now Sigma-Aldrich) and
temocillin (Negaban®)
b0.1 mol L−1, pH 6.0 phosphate buffer supplemented with 6.5% (v v−1) 1 M NaOH (sodium hydroxide)
cNitrofurantoin is thought to target macromolecules including DNA and ribosomal proteins, affecting multiple cellular processes, including protein, DNA, RNA, and cell wall synthesis
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across mutants of the same resistance group (parallel evolution),
suggesting that such mutations had limited, if any, effect on
collateral responses in this study.
For each of the 40 resistant mutants at least one putative
resistance mechanism was identified, including mutations to
previously described antimicrobial drug targets and promoters of
drug targets, drug-modifying (activating) enzymes, regulators of
efflux pumps, RNA polymerases and mutations to other
metabolic and biochemical processes that may contribute to
resistance (Table 3). Briefly, all but one ciprofloxacin-resistant
mutant contained mutations in both gyrA and efflux regulatory
genes and/or gene-regions likely affecting efflux expression
(acrAB and/or mdtK), while one strain had only drug target
mutations and displayed the well-described GyrA (S83L) and
ParC (G78D) mutation combination (Supplementary Data 1).
Both efflux and drug target mutations are frequently found in
surveys of clinical isolates38–41. Nitrofurantoin-resistant mutants
had mutations in one or both nitro-reductases (nfsA, nfsB) and
the majority of strains had additional mutations in mprA, which
encodes an efflux regulator of EmrAB-TolC pump expression
(Supplementary Data 3). Mutants resistant to trimethoprim
contained mutations either in folA and/or its promoter or genetic
amplification of a large region containing folA (Supplementary
Data 4). The mecillinam-resistant mutants are unique in that they
evolved as single step mutants, where a single mutation could
confer clinical resistance to mecillinam. Resistance development
for the remaining three drugs required several steps, as multiple
mutations were required for resistance above clinical breakpoints.





















































Fig. 1 Conserved collateral responses in antimicrobial resistant mutants. a Relative change in antimicrobial susceptibility was determined by comparing
average IC90 values of resistant mutants to the respective wild-type strain. Collateral responses that were found in ≥50% of the strains are displayed,
excluding CR observed in all trimethoprim-resistant mutants to trimethoprim-sulfamethoxazole (see Supplementary Fig. 2). Antimicrobials are ordered by
most frequent CR (red; left) to most frequent CS (blue; right) for each group. *The slow growing K56-12 CIPR was incubated an additional 24 h for IC90
determination. b The average IC90 (open circles) and average mutation prevention concentration (MPC; filled circles) were determined and compared
between resistant mutants (colored) with collateral responses, either CS (blue) or CR (red), and their respective wild-type strain (black) in strain:drug
combinations representing conserved collateral responses, excluding temocillin. The mutant selection window (vertical lines) was defined as the range
between IC90 (lower bound) and MPC (upper bound). K56-16 NITR had equivalent IC90 and MPC values for azithromycin, thus no mutation selection
window was reported. Generally, changes in MPC values reflected observed IC90 changes, shifting the mutation selection window upwards or downwards
accordingly. In 8/10 tested combinations an increase in IC90 value (CR) from wild-type to resistant mutant correlated with at least a small increased MPC,
with the remaining combinations showing no change in MPC value. Similarly, decreased IC90 values (CS) correlated with decreased MPCs (5/7)
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In total, 12 different mutations in genes and/or cellular processes
previously linked to mecillinam resistance were identified in this
resistance group (Supplementary Data 2)42.
The ciprofloxacin-resistant group displayed a clear trend where
conserved CR responses were strongly linked to mutations in
efflux regulatory regions suggesting that gyrA drug target
mutations had a limited effect on CS and CR. Trimethoprim-
resistant mutants also had few collateral responses, likely due to
the specific mechanism of resistance affecting a single unique
drug target (i.e. overexpression/alteration of FolA). To further
investigate the effects of drug target mutations, we assessed the
collateral responses of mutants generated following a single
selection-step with ciprofloxacin. These first-step mutants con-
tained single, non-synonymous mutations to gyrA and no other
mutations (e.g. in efflux pumps) linked to ciprofloxacin resistance
(Supplementary Data 1). The IC90 of these strains was uniformly
lower than in ciprofloxacin-resistant strains containing multiple
resistance mutations. Few collateral responses were observed in
these first-step mutants (Fig. 2), and none were conserved across
different strain backgrounds. These results suggest that most
collateral responses observed in the ciprofloxacin-resistant
mutants are due to the observed efflux mutations.
Efflux and fitness are main contributors to collateral responses.
Multivariate statistical approaches were used to investigate the
extent to which genetic (strain) background, resistance group, the
putative mechanism of resistance (in particular efflux-related
mutations), growth rate, and the fitness cost of resistance explain
the variation in collateral responses. All factors were investigated
individually (Supplementary Fig. 5a–e). Throughout the
remaining analyses we focus mainly on efflux-related mutations,
rather than resistance group, to explicitly address putative
mechanisms of resistance, and relative fitness rather than growth
rate.
We estimated several models with individual, or a combination
of, factors to assess their effect size and significance given some
level of collinearity between fitness and efflux-type (Fig. 3,
Supplementary Fig. 5a–r). A model including strain background,
relative fitness, and efflux-related mutations as factors explained
62.5% of the total variation in IC90 values (Fig. 3a, b,
Supplementary Table 3). In this three-factor model there was
clear separation of the mutants by resistance group (Fig. 3a). The
ciprofloxacin-resistant mutants showed strong CR towards
temocillin, chloramphenicol, ceftazidime, and amoxicillin, separ-
ating this resistance group from the others along the first
ordination axis (Fig. 3a, b). Along the second ordination axis,
mecillinam-resistant isolates were distinct, had CR to temocillin,
and were more likely to have CS towards drugs, such as
azithromycin and chloramphenicol (Fig. 3a, b). Both efflux-type
and relative fitness were significant predictors when tested alone
and in combination (Supplementary Table 3). The model (Fig. 3a,
b) also revealed that strain background had a non-significant
(p= 0.993) contribution (Supplementary Table 3). Even when
modeled alone (Supplementary Fig. 5a), strain background only
accounted for 6.5% of the variation and was non-significant
(Supplementary Table 3).
We initially hypothesized that genetic background would
significantly affect collateral responses. Our initial analysis
suggests that it does not. Arguably, the inclusion of IC90 data
from the drugs to which primary resistance was selected could
confound the analysis, despite our efforts to minimize these
effects using log-transformed data. We used the same approaches
to assess a subset of collateral responses, excluding data for all of
the 40 resistant mutants to five antimicrobials containing the
drugs used for selection (ciprofloxacin, mecillinam, nitrofuran-
toin, trimethoprim) and trimethoprim-sulfamethoxazole. Within
the subset model, patterns consistent with the full model were
observed, but with a lower degree of clustering by resistance
group (Fig. 3c). For example, K56-2 CIPR is now co-localized
with the mecillinam-resistant isolates, indicating that this isolate
is distinct from other ciprofloxacin-resistant mutants (Fig. 3c),
which still showed strong tendencies of CR to temocillin,
chloramphenicol, ceftazidime, and amoxicillin (Fig. 3c, d).
Despite these changes, efflux-type and fitness were still significant
predictors of collateral networks, and strain background
remained non-significant (Supplementary Table 3) when mod-
eled alone (Supplementary Fig. 5f) and in two-factor combina-
tions (Supplementary Fig. 5n–o), but had a limited, significant
contribution (p= 0.040), determined by permutation tests, in the
three-factor model (Fig. 3c, d, Supplementary Table 3). However,
mutations in efflux-related genes and gene regulators were the
strongest predictor of collateral responses tested, explaining over
33% of the variation in the subset. Fitness alone also had
significant predictive value, but to a lesser extent (17% variation
explained). It is important to note that we observed a correlation
between efflux mutations and relative fitness that is likely
explained by reduced fitness resulting from the cost of over-
expression of efflux pump(s)39.
To investigate the influence of resistance mechanism on IC90
variation at a higher resolution, we modeled each resistance
group separately relating the putative resistance mechanism
(beyond efflux-type) and fitness separately and in combination
(Supplementary Fig. 6a–o). However, potentially due to a lower
number of samples within each resistance group that were
separated into more detailed classifications of resistance mechan-
ism, these factors had varying degrees of contribution. For
mutants resistant to ciprofloxacin (Supplementary Fig. 6a) and
trimethoprim (Supplementary Fig. 6j), resistance mechanism was
non-significant, but it was a significant factor for those resistant
to mecillinam (Supplementary Fig. 6d) and nitrofurantoin
(Supplementary Fig. 6g). Fitness was a significant factor only
for the mecillinam resistance group (Supplementary Fig. 6e) and
similarly, models containing both resistance mechanism and
fitness were non-significant for all resistance groups, with the
exception of the mecillinam-resistant mutants (Supplementary
Fig. 6f).
In the first-step (GyrA) ciprofloxacin mutants, strain back-
ground was a significant factor for collateral responses
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aAll mutants resistant to ciprofloxacin contained one mutation in the gyrA gene, except the K56-
2 CIPR mutant that contained two mutations in gyrA and a mutation in parC
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Fig. 2 Collateral effects in gyrA mutants with decreased susceptibility to ciprofloxacin. Relative changes in antimicrobial susceptibilities, CS (blue) and CR
(red), were determined by comparing average IC90 values of nine first-step mutants to their respective wild-type strain. Antimicrobials are ordered by
antimicrobial class, as in Supplementary Fig. 2
















































































































Fig. 3 Results of multivariate statistical modeling. Graphical representations of two redundancy analyses (RDA, triplot) results relating various parameters
to the observed changes in IC90 between resistant mutants and respective wild-type strains for (a, b) 16 antimicrobials tested and (c, d) a subset of these
antimicrobials, excluding ciprofloxacin, mecillinam, nitrofurantoin, trimethoprim, and trimethoprim-sulfamethoxazole. Each RDA is broken down into two
plots; (a, c) where weighted averages of resistant mutants are plotted as colored symbols (color indicates resistance group, shape the assigned efflux
group, and symbol size proportional to relative fitness, see Supplementary Fig. 4). In (b, d) antimicrobial drug names indicate the tip of vectors that pass
through the origin in the direction of increasing IC90 fold change or CR (direction of steepest ascent). Vectors can be used to interpret the change in IC90
for the antimicrobials shown. For both statistical models, the first and second RDA axes shown display the majority of explained variation in IC90 changes.
Large gray symbols show centroids (average effect) for all resistant mutants within a given efflux group (shape). The vector tip of relative fitness (brown)
is also shown. a The majority of explained variation is driven by primary resistances, where ciprofloxacin (pink)-resistant and mecillinam (green)-resistant
mutants cluster distinctly from the other resistance groups, which showed higher relative fitness. b Resistant mutants possessing MdtK mutations alone
(diamond) or together with AcrAB-TolC mutations (circle) are likely to show CR to chloramphenicol, ceftazidime, temocillin, and azithromycin, but
sensitivity to gentamicin, fosfomycin, and trimethoprim. Whereas those without efflux mutations (triangle) are more likely to display low-level CS or no
change to most antimicrobials tested. The analysis of the subset RDA (c, d) shows patterns consistent with the full model, but with less clustering of
mutants by resistance group (c). The combination of AcrAB-TolC and MdtK efflux mutations displayed the greatest fitness costs, while mutants lacking
efflux-related mutations were the most fit (d). RDA significance was assessed by permutation tests (1000 permutations), where p≤ 0.05 was considered
significant. For more comprehensive multivariate models see Supplementary Fig. 5–6
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(Supplementary Fig. 6m). However, this was not the case when
the original ciprofloxacin-resistant mutants from the same strain
backgrounds were added to the analysis (Supplementary Fig. 6n),
suggesting again that other factors are more important than strain
background. Overall, in comparison to the ciprofloxacin-resistant
mutants, collateral responses of first-step mutants were far less
frequent and more closely resembled those of the GyrA/ParC
mutation-containing K56-2 CIPR mutant. A final redundancy
analysis was performed on all ciprofloxacin-resistant and first-
step mutants (Supplementary Fig. 6o), and showed a significant
effect of resistance mechanism, supporting that mechanism,
efflux in particular, is a major driver of collateral responses.
Collateral responses shift the mutation selection window. The
mutant selection window can be defined as the concentration
space between the lowest antimicrobial concentration that selects
for and enriches resistant mutants43 and the concentration that
prevents the emergence of first-step resistant mutants, the
mutation prevention concentration (MPC)44,45. In theory, if drug
concentrations remain above the MPC during treatment, anti-
microbial resistance is less likely to evolve44,45. It was recently
demonstrated in E. coli MG1655 that changes in MPC correlated
with collateral responses in resistant mutants21. We determined
the MPC for 17 strain:drug combinations that exemplified con-
served collateral responses (Fig. 1b). The MPC for each resistant
mutant and its respective wild-type were compared. In 12/17
(70.6%) the change in MPC was consistent with the sign of col-
lateral responses as determined by IC90. This demonstrates that
even small CS/CR changes can affect the mutant selection win-
dow, correspondingly shifting it down or up. In 4/17 (23.5%) the
MPC displayed no change between the wild-type and mutant.
This was observed when testing the MPC for mecillinam, tri-
methoprim, and azithromycin, though we speculate that
increasing the precision of the MPC assay (as was done with IC90
testing) might negate these discrepancies. Changes in MPC
results with azithromycin were inconsistent with the change in
IC90 for a ciprofloxacin-resistant mutant and the mutants resis-
tant to mecillinam and nitrofurantoin, which displayed a
decreased MPC instead of an expected increase or no change,
respectively.
Discussion
Here, we identify conserved collateral responses in antimicrobial
susceptibility across genetically diverse clinical E. coli strains
following antimicrobial resistance development. Our findings are
relevant beyond urinary-tract infections because uropathogenic
E. coli are shown to also stably colonize the bladder and gut46 and
to cause bloodstream infections47. Our data show that CS and CR
are pervasive in clinical E. coli strains, consistent with earlier
results based on laboratory-adapted strains of various species21–
23,25,30,48 and a limited number of clinical isolates21,30. Resistance
to ciprofloxacin resulted in a greater number of collateral
responses than resistance to mecillinam, nitrofurantoin, or tri-
methoprim. This is likely due to mutations to known regulators of
the AcrAB-TolC and MdtK efflux pumps. Both have broad
substrate specificities to diverse antimicrobials including fluor-
oquinolones, β-lactams, tetracycline, chloramphenicol, trimetho-
prim-sulfamethoxazole, and some macrolides for the AcrAB-
TolC efflux pump49,50, and fluoroquinolones, chloramphenicol,
trimethoprim, and some β-lactams for the MdtK pump39,51.
Interestingly, both overexpression of MdtK51 and RpoB39 muta-
tions (that were linked to MdtK expression) have been shown to
reduce susceptibility to fosfomycin, as was observed in the
ciprofloxacin-resistant mutants in this study (Fig. 1a). Overall, CR
was much more prevalent than CS, and the magnitude of
collateral responses were most often small, consistent with other
reports21–23. We observed that collateral responses varied sub-
stantially by resistance group, but variation was also observed
within resistance groups.
Using CS50 and CR50 thresholds to identify conserved
responses, we found that conserved CR was more than twice as
common as conserved CS. Whereas many of the conserved col-
lateral responses identified in this study support the findings in
previous work using single laboratory-adapted strains, we
observed several clinically relevant differences. For example, our
finding of conserved CS in ciprofloxacin-resistant mutants to
gentamicin was previously reported in E. coli K1222 but not in E.
coli MG165521. In mutants resistant to ciprofloxacin we also
observed conserved CR towards chloramphenicol, as reported in
ref. 21, but not in ref. 23. We identified conserved CR of
nitrofurantoin-resistant mutants to amoxicillin, and this was not
reported in MG165521. These observations underscore the
importance of exploring collateral networks in multiple mutants
of different clinical strain backgrounds and with different resis-
tance mechanisms to assess their potential clinical application.
Visual inspection of the data revealed a few clinically relevant
examples of CS phenotypes that appeared independent of puta-
tive mechanism of resistance. We show that E. coli strains resis-
tant to ciprofloxacin display CS towards gentamicin, fosfomycin,
ertapenem, and colistin, and these phenotypes were conserved
across multiple mechanisms of resistance. These results parallel
those of a recent study on P. aeruginosa clinical isolates from
cystic fibrosis patients, where resistance to ciprofloxacin was
associated with CS to gentamicin, fosfomycin, and colistin31.
Taken together these data support the presence of general, con-
served collateral networks that may both affect the population
dynamics of antimicrobial resistance during treatment and
counter-select for resistance, as recently indicated31.
We assumed a priori that genetic background, resistance
group, resistance mechanism, and the fitness cost of resistance
could potentially affect the generality, sign, and magnitude of
collateral networks in clinical E. coli strains. Despite the fact
that some collateral responses are conserved across different
strains and mechanisms of resistance, our multivariate statis-
tical approaches show overall that mechanism of resistance is
the key predictor of CS and CR variability. This is primarily the
case for efflux-related mutations. However, mechanism of
resistance also significantly contributed to the observed CS and
CR variation in the mecillinam mutants where no efflux
mutations were found. The presented data are consistent with
earlier reports based on multiple resistant mutants derived from
single strains with different resistance mechanisms towards
specific antimicrobials22,23,52. Our finding that genetic back-
ground did not significantly contribute to collateral responses is
an important addition to these earlier studies. Finally, we found
that the fitness cost of resistance also contributed significantly
to the observed variation in CS and CR, despite some colli-
nearity between efflux-related mutations and reduced fitness.
Taken together, our data and previous reports indicate that
applied use of collateral networks in future treatment strategies
may be dependent on rapid identification of specific resistance
mechanisms. Moreover, clinical application of CS as a selection
inversion strategy warrants further investigations to ideally
explore CS in isogenic backgrounds, representing several
diverse strains, with permutations of all known antimicrobial
resistance-associated traits. Such extensive studies would likely
provide valuable information on the mechanisms of CS. Other
confounding factors such as mobile genetic elements with
heterogeneous resistance determinants should also be investi-
gated as they would likely influence and reduce the predict-
ability of collateral networks.
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Selection inversion, as described by ref. 21, depends on the
cycling of drug pairs that display reciprocal CS. We did not
observe reciprocal CS between any of the four drugs studied here
that are widely used for treatment of urinary tract infections.
However, we asked if modest reductions and increases in anti-
microbial susceptibilities would affect the mutant selection win-
dow44 for the most prevalent CS and CR phenotypes. We
subjected conserved CS and CR phenotypes to MPC assays and
revealed that even a small 1.5-fold change in IC90 could equally
alter the MPC, resulting in a shift of the mutant selection win-
dow (Fig. 1b). These results suggest that antimicrobial treatment
strategies informed by collateral networks could affect the evo-
lutionary trajectories of antimicrobial resistance. Sequential
treatment using drug pairs that display CR would, following
resistance development, shift the mutant selection window
towards higher antimicrobial concentrations, as was previously
observed53, and increase the likelihood for resistance develop-
ment to subsequent treatment options (Fig. 4a). Conversely,
sequential treatment based on drug pairs that display CS can shift
the mutant selection window down and reduce the window of
opportunity for high-level resistance development (Fig. 4b). This
result suggests that the initial choice of antimicrobial may set the
stage for later resistance development.
Based on our in vitro findings, trimethoprim and nitrofur-
antoin are attractive from a clinical perspective, as resistance to
these resulted in few collateral responses, preserving the innate
sensitivity to available secondary antimicrobials (Fig. 4c, d).
However, mecillinam could be even more attractive, as CS
largely dominates the observed collateral responses in resistant
mutants. Additionally, isolates resistant to mecillinam,
especially those evolved in vivo, are associated with high fitness
costs42. In contrast, exposure to ciprofloxacin was more likely
to cause dramatic collateral responses that depend on the
mechanism of resistance and could potentially negatively
impact future therapeutic options (Fig. 4c). These observations
align with antimicrobial treatment recommendations in Nor-
way, where mecillinam, nitrofurantoin, and trimethoprim are
recommended for first-line therapy of uncomplicated urinary-
tract infections, and ciprofloxacin is reserved for otherwise
complicated infections54. Similarly, in the United States nitro-
furantoin, trimethoprim-sulfamethoxazole, and mecillinam are
recommended before fluoroquinolones, such as ciprofloxacin,
ofloxacin, and levofloxacin55.
Our conclusions are not without limitations. First, we
acknowledge that including more clinical isolates from different
infection foci, more diverse genetic backgrounds including dif-
ferent bacterial species, as well as other selective agents, could
change the outcome of our statistical analyses. This would allow
increased sensitivity for the assessment of the different factors
controlling collateral responses. A more targeted approach to
assess the impact of specific resistance mechanisms on CS and CR
across genetically diverse clinical strains is lacking in the field.
Our analyses suggest that the fitness cost of resistance explains
some variability in the collateral networks reported here. We used
relative growth rates as a proxy for relative fitness, and our data
are consistent with reports demonstrating that growth rates affect
susceptibilities to several antimicrobials56,57. It is unclear if col-
lateral networks will be perturbed by compensatory evolution,
which eliminates the fitness costs of primary resistance58–60.






























































Fig. 4 Presentations of the potential effects and implications of CS and CR. a Sequential drug administration informed by CS (blue) could potentially narrow
or shift the mutant selection window (MSW) downwards in concentration space whereas (b) CR (red) results in a widened or shifted upwards mutant
selection window for secondary antimicrobials. This would affect the probability of acquiring second-step mutations leading to high-level resistance.
Consequently, CS-informed secondary therapies could reduce selection and thus propagation of first-step mutants resulting in a reduced opportunity for
second-step mutations to occur. Dots represent bacteria resistant to a primary antibiotic (gray), spontaneous mutants with reduced susceptibility to a
secondary drug (pink), or those with high-level resistance to the secondary drug (dark red). Note that these are hypothetical schematics and in many cases
the maximum concentration achieved (Cmax) may be below the MPC. c Arrows indicate conserved collateral responses, where CS (blue) and CR (red) are
depicted. The collateral responses in this study are mainly predicted by efflux-related mutations in the ciprofloxacin-resistant mutants. These data suggest
potential secondary treatment options that may reduce the rate of resistance evolution (a, b) following initial treatment failure. d Green arrows indicate
putative temporal administration of four antimicrobials used for the treatment of urinary-tract infections, as informed by the collateral networks in (c)
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resistance development to a single drug, and there is a complete
lack of data on how multidrug resistance, including resistance
genes on mobile genetic elements, will affect collateral networks.
We are currently investigating these and other questions that will
aid in our understanding of collateral networks and their
potential therapeutic application.
Methods
Bacterial strains. We used 10 clinical, urinary-tract infection isolates of E. coli
from the ECO-SENS collections61,62 originating from countries across Europe
between 2000 and 2008 (Table 1). The isolates were chosen to represent pan-
susceptible strains with diverse genetic backgrounds and were reported plasmid-
free32. Subsequent analysis based on whole-genome sequencing discovered two
changes to previously reported sequence types and the presence of plasmid repli-
cons in three strains (Supplementary Table 4). E. coli ATCC 25922 was used for
reference and quality control purposes. For general growth, bacterial strains were
grown in either Miller Difco Luria–Bertani (LB) broth (Becton, Dickinson and Co.,
Sparks, MD, USA) or on LB agar; LB broth with select agar (Sigma-Aldrich) at 15 g
L−1 and incubated at 37 °C.
Selection of antimicrobial-resistant mutants. Single antimicrobial-resistant
mutants were selected at drug concentrations above the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints63 for cipro-
floxacin, nitrofurantoin, trimethoprim, and mecillinam (Supplementary Table 1).
Briefly, 100 µL of 10× concentrated overnight culture was spread on Mueller
Hinton II agar (MHA-SA; Sigma-Aldrich) plates containing ciprofloxacin (Bio-
chemika), nitrofurantoin (Sigma-Aldrich), or trimethoprim (Sigma-Aldrich) with
two-fold increasing concentrations of the antimicrobial. After 24–48 h, a mixture of
growth from the highest concentration plate with multiple colonies was used to
start a new overnight culture at the same antimicrobial concentration. This was
repeated until there was growth above the clinical breakpoint63. Mecillinam-
resistant mutants and first-step ciprofloxacin mutants (gyrA mutation-containing)
were selected as single-step mutants on LB or MHA-SA agar, respectively. Mutants
were confirmed as E. coli using matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) analysis with MALDI BioTyper software (Bruker, MA, USA).
Antimicrobial susceptibility testing. Mutants were initially screened for resis-
tance above EUCAST breakpoints63 with gradient diffusion strips following
manufacturers guidelines (Liofilchem, Italy), on Mueller Hinton II agar (MHA-BD;
Becton, Dickinson and Company). Plates with insufficient growth were incubated
for an additional 24 h.
To maximize the precision of our susceptibility estimates and in accord with
related studies on CS, collateral changes were determined by IC90 testing21 with
some modifications. IC90 values were determined following 18 h incubation at 700
rpm (3 mm stroke) in Mueller Hinton Broth (MHB, Becton, Dickinson and Co.).
Slow-growing strains where positive growth controls did not reach OD600 nm of 0.3
after 18 h (i.e. K56-12 CIPR) were interpreted after 42 h incubation. Standard two-
fold concentrations and the median values between them were used as a 1.5-fold
testing scale. IC90 values were the lowest concentration tested that resulted in ≥90%
inhibition of growth. Percent inhibition was calculated compared to the positive
control (untreated sample) with background removed21. IC90 results were
determined in at least three biological replicates on separate days. The final result
reflects the average of a minimum of three replicates that met quality control
standards, including the result of ATCC 25922 on each plate, positive growth
control OD600 nm > 0.3, negative growth control OD600 nm < 0.05, and accepting no
more than one skip (defined as a break in the inhibition pattern). When one skip
was observed, the IC90 value was consistently interpreted as the lowest
concentration tested that resulted in ≥90% inhibition of growth. Fold change in
IC90 was calculated as the ratio between the resistant mutant and its respective
wild-type. The IC90 testing varied for two antimicrobials (according to EUCAST
recommendations), where fosfomycin was tested in MHB supplemented with
25 µg mL−1 glucose-6-phosphate (Sigma-Aldrich) and tigecycline was tested in
fresh MHB media that was prepared daily.
Dose–response curves were generated with average OD600 values (background
subtracted) for concentrations tested during IC90 testing. Averages were plotted for
mutants and respective wild-type strains.
MPC testing. We determined the MPC for 17 of 20 conserved collateral responses.
Temocillin was excluded due to lack of supply and trimethoprim-sulfamethoxazole
was excluded for trimethoprim-resistant isolates due to fundamental CR between
trimethoprim and trimethoprim-sulfamethoxazole. MPC determination was based
on previous work by Marcusson et al.64. Briefly, 10 mL overnight culture was
centrifuged and the pellet re-suspended in 1 mL MHB, estimated to contain ≥1010
CFU (actual values were 1.4 × 1010–7 × 1010 CFU). The inoculum was split and
spread onto four large (14 cm diameter) MHA-SA agar plates for each anti-
microbial concentration tested in a two-fold dilution series. The MPC was the
lowest concentration with no visible growth after 48 h. Where growth/no growth
was difficult to interpret, suspected growth was re-streaked on plates at the same
antimicrobial concentration. Azithromycin and ertapenem were regularly incon-
sistent, making re-streaking essential. Resistant mutants and wild-types were tested
in parallel, and results represent the average of at least two biological replicates.
Growth rate measurements. To obtain growth curves of wild-types and resistant
mutants, single colonies were used to inoculate at least three biological replicates of
MHB starter cultures (2 mL) that were incubated at 37 °C for 24 h shaking at 500
rpm. Each culture was diluted 1:100 in MHB (resulting in ~2 × 107 cell mL−1) and
250 µL was added in triplicate to a 96-well microtiter plate. The plate was incubated
overnight at 37 °C in a Versamax plate reader (Molecular Devices Corporation,
California, USA) with shaking for 9.2 min between reads. OD600 measurements
were taken every 10 min and growth rates were estimated using the GrowthRates
v.2.1 software65. To a varying extent, the ciprofloxacin-resistant mutants of K56-12,
K56-16, K56-44, and K56-68, as well as, K56-44 MECR, K56-68 MECR, and K56-70
TMPR displayed noise in the growth curves due to clumping or non-homogeneous
growth, and GrowthRates was unable to fit a line with R-value above the 0.98 cut-
off value. Additional experiments and visual inspection of the log-transformed
OD600 values were used to solve this issue. If GrowthRates failed to analyze the
curves, a line was fitted within the log phase through at least five consecutive points
that displayed log-linear growth. Growth rate (r) was calculated based on the
slope65. Relative growth rates were calculated as r(resistant mutant) r(wild-type)−1.
Whole genome sequencing. Genomic DNA was isolated using the GenElute
Bacterial Genomic DNA kit (Sigma-Aldrich) following guidelines for Gram-
positive DNA extraction. Purity and quantification was determined with Nanodrop
(Thermo Scientific) and Qubit High Sensitivity DNA assay (Life Technologies),
respectively. For library preparation of wild-types and resistant mutants, 1 µg of
DNA was sheared on a Covaris S2 to ≈400 bp using the recommended settings
(intensity: 4, duty cycle: 10%, cycles per burst: 200, treatment time: 55 s). Libraries
were then prepared and indexed using the DNA Ultra II Library Preparation Kit
(New England Biolabs, E7645). For library preparation of DNA from first-step
ciprofloxacin mutants, 1 ng of DNA was used with the Nextera XT DNA prep kit
(Illumina, San Diego), according to the producer’s instructions. All libraries were
quantified by Qubit High Sensitivity DNA assay and distributions and quality
assessed by Bioanalyser DNA 1000 Chip (Agilent, 5067-1504) before normalizing
and pooling. Illumina sequencing, NextSeq 550, and MiSeq, was used for the first-
step ciprofloxacin mutants and the wild-types and resistant mutants, respectively,
using paired-end reads. For NextSeq 550 a mid-output flowcell with 300 cycles was
used. V2 chemistry was used for the MiSeq sequencing.
Wild-type genomes were assembled, as follows. Illumina adapters on wild-type
reads were removed with Trimmomatic version 0.3666 using standard settings, then
assembled with SPAdes67. Contigs less than 500 bp in length or less than 2.0
coverage were removed. Wild-type genome assemblies were inspected and
compared to the E. coli MG1655 genome (GenBank U00096.2) using QUAST68.
Final assembled genomes of wild-type strains were annotated using the automated
Prokaryotic Genome Annotation Pipeline (https://www.ncbi.nlm.nih.gov/genome/
annotation_prok/).
Wild-type and mutant sequences were compared to identify putative resistance
mechanisms. First, wild-type genomes were annotated with Rapid Annotation
using Subsystem Technology server (RAST, version 2.0) for E. coli69. SeqMan
NGen (DNASTAR, Madison, WI) was used to align raw mutant reads to the
corresponding, annotated wild-type genomes, using standard settings. Reported
SNPs had ≥10× coverage depth and ≥90% variant base calls. SNPs present in the
wild-type assembly or in at least two mutants resistant to different antimicrobials
from the same strain background were excluded. Reported SNPs, indels, and
rearrangements were manually inspected and gene annotations confirmed using
Gene Construction Kit (Textco Biosoftware Inc., Raleigh, NC) and NCBI BLAST
searches, respectively.
Multilocus sequence typing (MLST), as well as, plasmid replicon and acquired
antimicrobial resistance gene content were determined for the wild-type genomes
using MLST version 1.8, PlasmidFinder version 1.3, and ResFinder version 3.070,
respectively (http://genomicepidemiology.org/). The MLST of each wild-type strain
was confirmed compared to the original reported sequence type32 for all but two
strains, K56-41 and K56-70. These strains were originally described as ST420 and
ST550, but were ST73 and ST537 in our analysis, respectively (Supplementary
Table 4). The wild-type strains were previously described as plasmid free, but we
identified two small plasmid replicons, Col156 in K56-16 and K56-44 and Col
(MP18) in K56-75 (Supplementary Table 4). Using ResFinder, we detected only
one acquired genetic element, sul2 (linked to sulfonamide resistance) in K56-44,
and two point mutations, PmrB V161G in K56-50 and K56-70 and ParE D475E in
K56-78, that are linked to colistin and quinolone (ciprofloxacin) resistance,
respectively (Supplementary Table 4). Though all of the wild-type strains were
phenotypically pan-susceptible (Supplementary Fig. 1c), these resistance
determinants could affect antimicrobial susceptibilities differentially in the
presence of other mutations71,72.
To assess genetic diversity, a phylogenic tree was generated based on the
genome sequences of wild-type strains. Assembled wild-type genomes were
annotated with PROKKA73, the core gene-encoding regions were extracted and
compared using ROARY74, and a maximum-likelihood tree with 100 bootstraps
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was generated using RAxML75. Genetic distances were calculated in R76 using
previously described methods77.
Multivariate statistical analyses. The fold changes of mean IC90 values relative
to the parental wild-type strain (collateral responses) were log transformed.
Statistical analyses were performed on the complete data set, as well as a subset
of the data excluding five antimicrobials (ciprofloxacin, mecillinam, nitrofur-
antoin, trimethoprim, and trimethoprim-sulfamethoxazole). To estimate and
test the effects of strain background, resistance group, resistance mechanism,
growth rate, and relative fitness we relied on multivariate modeling (redundancy
analysis) to address the co-variation in IC90 across antimicrobials. A redundancy
analysis is a constrained version of a principle component analysis that addi-
tionally allows for hypothesis testing. Linear constraint scores were plotted for
each mutant. Response variables were overlaid with independent scaling to
illustrate the direction of steepest ascent (increasing CR) from the origin for each
antimicrobial. Data were inspected to check whether the assumptions underlying
redundancy analysis were met. Significance testing of multivariate models and
their factors (Supplementary Table 3) was done via permutation tests (1000
permutations), an approach robust to deviations from multivariate normality
and variance homogeneity; p < 0.05 was considered significant. Analyses were
done in R76 using the Vegan work package78.
Data availability
Whole-genome sequencing data are available at NCBI (BioProject PRJNA419689). All
other relevant data are available within this article, the Supplementary Information, or
from the corresponding author upon request.
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Abstract
Transposons are genetic elements that change their intracellular genomic position by transposition and are spread horizontally 
between bacteria when located on plasmids. It was recently discovered that transposition from fully heterologous DNA also 
occurs in the course of natural transformation. Here, we characterize the molecular details and constraints of this process 
using the replicative transposon Tn1 and the naturally competent bacterium Acinetobacter baylyi. We find that chromosomal 
insertion of Tn1 by transposition occurs at low but detectable frequencies and preferably around the A. baylyi terminus of rep-
lication. We show that Tn1 transposition is facilitated by transient expression of the transposase and resolvase encoded by the 
donor DNA. RecA protein is essential for the formation of a circular, double- stranded cytoplasmic intermediate from incom-
ing donor DNA, and RecO is beneficial but not essential in this process. Absence of the recipient RecBCD nuclease stabilizes 
the double- stranded intermediate. Based on these results, we suggest a mechanistic model for transposition during natural 
transformation.
INTRODUCTION
Horizontal gene transfer drives bacterial evolution through 
the acquisition of novel genetic material and accelerates the 
spread of adaptive traits such as antimicrobial resistance 
(AMR) between bacteria [1]. AMR in bacterial pathogens 
represents a growing public health concern [2] and there is 
an urgent need to increase our understanding of the basic 
mechanisms of AMR spread.
Conjugation, transduction and natural transformation are 
believed to be the main routes of intercellular gene transfer 
[3]. During conjugation, conjugative plasmids or conjuga-
tive transposons move into a recipient bacterium through 
cell- to- cell contact. Transduction includes the transfer of 
host DNA, mispackaged into bacteriophage particles during 
late infection, to a recipient cell. Natural transformation is 
the active uptake of free DNA from the environment and 
subsequent genomic integration [4]. Only bacteria that are 
competent for natural transformation can actively take up free 
DNA. Competence to undergo natural transformation was 
experimentally demonstrated in at least 80 bacterial species, 
both Gram- positive and Gram- negative [5]. The majority of 
the 12 global priority pathogens are naturally transformable, 
including those categorized as critically antibiotic- resistant: 
Acinetobacter baumannii, Pseudomonas aeruginosa and some 
Enterobacteriaceae [6, 7]. Natural transformation as a pathway 
for recruiting genetic variation, including AMR genes, was 
recently demonstrated between different species of the genus 
Acinetobacter [8] and different genera, for example from 
carbapenem- resistant Klebsiella pneumoniae to A. baumannii 
[9].
AMR determinants are frequently captured on mobile genetic 
platforms such as plasmids and transposons, and in associated 
mobilizable elements such as integrons, which all represent 
multidrug resistance- conferring units [10–12]. Transposons 
are widespread genetic elements in bacteria [13] and in 
other domains of life. They move intra- and intermolecularly 
between different genomic positions within a cell in a process 
called transposition [14]. Through transposition, transposons 
can be inserted into conjugative plasmids or into bacte-
riophages, which facilitates the mobility of non- conjugative 
transposons between cells [12]. Thus, transposon- embedded 
AMR determinants can be mobilized at multiple hierarchical 
genetic levels, and intermolecular movement of transpo-
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chromosomal locations also occurs within clinical pathogens 
[15–18]. Therefore, the investigation of transposon mobility 
across different bacterial hosts could aid the understanding 
of AMR spread.
Stable integration of horizontally acquired mobile genetic 
elements into the bacterial recipient genome is crucial for 
long- term inheritance and is facilitated by plasmid establish-
ment or rearrangement events between donor and recipient 
DNA such as homology- based recombination, site- specific 
recombination, or transposition [12]. A recent study demon-
strated the transposition of a Tn21- like transposon (Tn3- 
family) of Salmonella enterica serovar Typhimurium 490 into 
the chromosome of Acinetobacter baylyi ADP1 in the course 
of natural transformation [19]. Tn21 insertion occurred 
independently at different loci in several transformants, and 
target site duplications (TSDs) at the insertion sites strongly 
suggested DNA recombination by transposition [19]. Since 
ADP1 harbours no transposons of the Tn3- family [20], these 
results indicated that the transposase was expressed from 
the incoming donor DNA. The authors concluded that a 
cytoplasmic, linear DNA double- strand formed after uptake, 
allowing gene expression and movement of the structural 
transposon [19].
In the present study, we used the Tn3- like replicative trans-
posons Tn1 [21] and Tn4401 [22] as donor DNA to quantify 
and characterize transposition during natural transformation 
in molecular detail. As a recipient, we employed the naturally 
competent soil bacterium A. baylyi strain ADP1 also used 
by Domingues et al. [19]. ADP1 is transformable at high 
frequency by DNA from any source, including PCR products, 
which allows the detection and quantification of rare DNA 
recombination events [23, 24].
METHODS
Bacterial strains and growth conditions
A. baylyi ADP1 strain BD413 Rpr (wild- type) [25] and the 
derivative mutants ΔrecA::tetA (JV37) [26], ΔdprA::aacC1 
(NH29) [27], ΔrecO (KOM82) [27] and ΔrecBCD ΔsbcCD 
(KOM45) [28] were employed as recipient strains in natural 
transformation assays and have been described previously. 
The ΔxerC::nptII sacB mutant was constructed as reported 
previously for A. baylyi deletion strains [29, 30]. Briefly, DNA 
sequences of about 1000 bp each upstream and downstream 
of xerC (ACIAD2657) in ADP1 (GenBank CR543861) were 
PCR- amplified using primers xerC- up- f/xerC- up- r (upstream 
segment) and xerC- down- f/xerC- down- r (downstream 
segment; all primer sequences are listed in Table S1 available 
in the online version of this article). The PCR products were 
inserted sequentially into the plasmid vector pGT41 upstream 
and downstream of a nptII sacB selectable marker gene pair. 
The resulting plasmid contained a ΔxerC::nptII sacB allele 
embedded into its natural flanking regions and was used to 
naturally transform ADP1. The resulting XerCD- deficient 
transformant (kanamycin- resistant) was confirmed pheno-
typically and by PCR (primers xerC- up- f/xerC- down- r and 
xerC- ctrl/xerC- down- r; Table S1). PCR assays were carried 
out with high- fidelity Phusion DNA polymerase (Thermo 
Scientific) and standard parameters except using an additional 
10 % dimethylsulfoxide, or with DreamTaq DNA polymerase 
(Thermo Scientific).
Escherichia coli strains EC100 (Epicentre), DH5α [31] or SF8 
recA [32] were employed as host strains for strain construc-
tions and donor DNA preparations. Strains were grown 
in Luria–Bertani (LB) medium at either 30 °C (A. baylyi) 
or 37 °C (E. coli). For transformant selection, media were 
supplemented with antibiotics at the following concentra-
tions: ampicillin, 100 mg l−1 (Tn1 in pJK2, pJKH1, pJK7 and 
pTn4401); streptomycin, 40 mg l−1 (RSF1010); kanamycin, 10 
mg l−1 (pKH80- PCR).
Donor DNA preparations for natural transformation 
experiments
Plasmid pJK2 (6896 bp; Fig. 1) was constructed as follows: 
transposon Tn1 on plasmid RP4 (4951 bp; GenBank 
BN000925) was PCR- amplified from the left to the right 
border without TSDs using DNA from E. coli K12 J53 RP4 
[German Collection of Microorganisms and Cell Cultures 
(DSMZ), DSM 3876] as template and primer Tn1- f+r (Table 
S1) as forward and reverse primer. The resulting PCR product 
was 5′-phosphorylated with polynucleotide kinase (Thermo 
Scientific) and ligated to a 1945 bp PCR product containing 
the p15A origin of replication and the chloramphenicol 
resistance gene cat of plasmid pACYC184 [33] (GenBank 
Fig. 1. Map of plasmid pJK2. The plasmid backbone contains the p15A 
origin of replication (green) and the cat gene (yellow; chloramphenicol 
resistance) of the E. coli cloning vector pACYC184. Transposon Tn1 (4.9 
kb) was cloned from plasmid RP4. In Tn1, tnpA and tnpR (blue) encode 
the transposase and resolvase, respectively. Ampicillin resistance is 
conferred by blaTEM-2 (magenta). The transposon contains a res site for 
cointegrate resolution and is flanked by two terminal 38 bp inverted 
repeats (dashed). Neither Tn1 nor pACYC184 display significant 
sequence identity with the A. baylyi genome.
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X06403; primers cat- r and p15A- r1; Table S1) using T4 
DNA ligase (Fermentas). pJKH1 (carrying Tn1ΔtnpA; 4289 
bp) was derived from pJK2 by digestion with EcoRV and 
circularization of the large fragment (T4 DNA ligase). The 
partial deletion of tnpA (869 internal of 1002 codons) was 
confirmed by restriction analysis. To construct plasmid pJK7 
(Tn1ΔtnpR; 6399 bp), we PCR- amplified pJK2 excluding tnpR 
with primers pJK2- tnpR- del- f and pJK2- tnpR- del- r (Table 
S1). The PCR- product was 5′-phosphorylated (polynucleotide 
kinase) and circularized (T4 DNA ligase), and the deletion 
of tnpR was confirmed by Sanger sequencing. The plasmids 
RSF1010, pKH80 and pTn4401 have been described previ-
ously [28, 34–36]. Plasmid donor DNA was isolated using the 
Qiagen Plasmid Extraction kit (Qiagen) and genomic donor 
DNA was purified with the GenElute Bacterial Genomic DNA 
kit (Sigma- Aldrich).
When PCR products were employed as donor DNA, PCR 
reactions were performed using high- fidelity Phusion DNA 
polymerase. Linear donor DNA substrate pJK2- PCR (6908 
bp) was obtained by inverse PCR amplification of pJK2 with 
primers cat- f and p15A- ori- f- c (Table S1). This PCR product 
carried a 12 bp overlap at the ends. Donor DNA substrate 
pKH80- PCR (4760 bp) was PCR- amplified with primers 
sbcD- up- f and sbcC- down- r (Table S1) from plasmid pKH80. 
This substrate carried two approximately neighbouring 1.0 
kbp DNA stretches from the A. baylyi chromosome covering 
parts of ACIAD0915 and ACIAD0918, interrupted in the 
centre by a 2.7 kbp nptII sacB marker gene cassette conferring 
kanamycin resistance. The PCR products were purified using 
the Qiaquick PCR purification kit (Qiagen). When indicated, 
pJK2- PCR was purified by agarose gel electrophoresis (Sea 
Plaque, LONZA) and subsequent recovery using the Qiaquick 
Gel Extraction kit (Qiagen).
Natural transformation assays in liquid medium
Preparation of naturally competent cells of A. baylyi as well 
as natural transformation assays were conducted as described 
previously [29]. In brief, competent cell stocks were prepared 
by dilution of an overnight culture 1:100 into liquid LB and 
growth of that culture under aeration until logarithmic growth 
(1×109 cells ml−1 determined with a haemocytometer) was 
reached. The cells were chilled, centrifuged for 10 min at 5000 
g and 4 °C, and concentrated 1:10 in LB media containing 
20 % glycerol (v/v). Finally, the cells were aliquoted and stored 
at −80 °C until further use.
For transformation assays, aliquoted competent cells were 
thawed on ice, diluted 1:40 in liquid LB to 2.5×108 cells ml−1, 
and DNA was added at 100 ng ml−1 unless indicated other-
wise. The assays were incubated under aeration for 90 min 
before the cells were chilled on ice, washed and resuspended 
in phosphate- buffered saline. Appropriate dilutions were 
plated on LB (recipient titre) and media containing selective 
antibiotics (transformant titre). LB plates were incubated for 
24 h while transformant plates were incubated 48 to 72 h. 
Colonies were counted and transformation frequencies were 
calculated as transformants per recipient. If no transformant 
colonies were obtained, the limit of detection was calculated 
instead. In control experiments, recipient cells were incubated 
without donor DNA to identify resistant mutants arising and 
unselective and selective plating were performed according 
to the respective assay with donor DNA.
Verification of transposition events
To identify transposition events, ampicillin- resistant trans-
formant colonies were picked and restreaked three times on 
selective medium. In some cases, an intermittent cultivation 
step on non- selective medium was carried out. Typically, 
isolates were investigated after the final restreak by PCR 
for the presence of Tn1 (primer Tn1- f+r) and pJK2 vector 
backbone DNA (primers cat- r/p15A- r1), or for the presence 
of Tn4401 (primers KPC- A/KPC- B) and pTn4401 vector 
backbone DNA (primers cat- r/p15A- r1), respectively (Table 
S1). Occasionally, ampicillin- resistant mutants arose during 
these cultivation steps, presumably through mutations. These 
isolates typically displayed an aberrant colony phenotype 
and were distinguished by the absence of transposon and 
pJK2 vector DNA in PCR analyses. These procedures clearly 
separated so- termed transposants from transient (unstable) 
transformants and mutants. Divergent transformant types 
were found in experiments using wild- type ADP1 with pJK7 
donor DNA, or strain ΔrecBCD ΔsbcCD with pJK2 donor 
DNA (see the Results and Discussion section for details).
To verify transposants, genomic DNA was isolated from 
stable ampicillin- resistant isolates that were PCR- positive for 
Tn1 and PCR- negative for pJK2 vector backbone, using the 
GenElute Bacterial Genomic DNA kit (Sigma- Aldrich). Puri-
fied DNA was used as template for Sanger DNA sequencing 
(BigDye 3.1 technology; Applied Biosystems) as follows: 1 µg 
genomic DNA was mixed with 4 µl BigDye, 2 µl BigDye buffer 
and 10 µM of primer (either bla- ins- f or Tn1- tnpA- ins- f; Table 
S1) in a volume of 20 µl. Assays were denatured for 5 min at 
95 °C, followed by 99 cycles of 30 s at 95 °C, 10 s at 55 °C and 
4 min at 60 °C, and subsequently analysed on an Applied 
Biosystems 3130xl Genetic Analyzer (in- house sequencing 
facility). blast was used to identify both recombinant joints of 
Tn1 with the chromosome of ADP1 (GenBank CR543861.1) 
and to verify the TSDs (Tables S2 and S3). The transposition 
frequency was calculated as transposants per transformant 
isolates multiplied by the transformation frequency.
Characterization of target site sequences
A consensus DNA sequence logo was generated by multiple 
sequence alignment and visualized using WebLogo software 
[37] (Figs 2 and Fig. S1) The aligned regions covered the 5 
bp TSD plus 45 nucleotides upstream and downstream of the 
duplication (Table S4). The total number and positions of this 
TSD consensus sequence (TTWTA) were determined for the 
chromosome of ADP1 using Gene Construction kit v 4.0.3 
(Textco BioSoftware, Inc.). Linear regression analysis of the 
TSD consensus sequence distribution over the chromosome 
of ADP1 was performed using GraphPad v 8.4.2 (GraphPad 
Software; P *** <0.001, ** <0.01, * <0.05).
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Susceptibility testing
The minimal inhibitory concentrations (MICs) were deter-
mined using gradient diffusion strips (Liofilchem) following 
the manufacturer’s instructions. Briefly, 0.5 McFarland 
solutions in 0.9 % saline (w/v) were prepared from freshly 
grown colonies on LB and spread evenly onto Müller–Hinton 
agar plates with a sterile cotton swab. A gradient strip for 
ampicillin was applied and plates were incubated at 30 °C 
for 18 h. Results were read at 100 % growth inhibition (n=1 
per strain).
Electroporation assays
Electrocompetent cells of A. baylyi were prepared as published 
for E. coli [38] with modifications. Briefly, a logarithmic 
culture of A. baylyi was grown at 30 °C in LB to 2.5×108 
cells ml−1. The cells were chilled, washed twice with ice- cold 
distilled water, and concentrated 500 times in 10 % ice- cold 
glycerol solution (v/v). A 40 µl aliquot was mixed with DNA 
(400 ng pJK2 or 200 ng RSF1010 DNA), transferred into a 
2 mm gap electroporation cuvette and pulsed with 12.5 kV 
cm−1 (25 µF, 200 Ω) using a BioRad electroporator. Next, the 
cells were suspended in 1 ml prewarmed SOC (2 % tryptone, 
0.5 % yeast, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 20 mM glucose) and aerated for 1 h at 30 °C. 
Appropriate dilutions were plated on LB (recipient titre) and 
LB containing antibiotics (transformants) and the plates were 
incubated at 30 °C for 16 to 20 h or 36 to 48 h, respectively.
RESULTS AND DISCUSSION
Natural transformation by transposon-containing 
DNA
We inserted the replicative transposon Tn1 into the narrow- 
host- range plasmid vector pACYC184 that replicates in 
Enterobacteriaceae but not in A. baylyi. The resulting circular 
plasmid pJK2 (Fig. 1) was used as donor DNA to naturally 
transform A. baylyi ADP1 wild- type cells. Ampicillin- 
resistant transformant colonies were obtained at a frequency 
of (6.4±8.4)×10−8 per recipient cell (Fig. 3).
Analyses of resistant colonies revealed two distinguishable 
groups of transformants. In the first group, ampicillin resist-
ance was stably maintained after repeated restreaking on 
selective medium and also after intermittent non- selective 
cultivation. PCR analyses showed the presence of Tn1 but 
the absence of pJK2 vector backbone DNA. This result indi-
cates that Tn1 was chromosomally acquired by DNA uptake 
and transposition. In contrast, the ampicillin resistance was 
unstable in transformants of the second group, resulting in 
heterogeneous colony size and shape when restreaked. The 
resistance was generally lost after repeated purification on 
selective medium or after intermittent non- selective cultiva-
tion, and both Tn1 and pJK2 backbone DNA could be PCR- 
amplified from cell material of the first, and with decreasing 
frequency of subsequent recultivations. This result suggests 
that transformants of group 2 received the pJK2 plasmid and 
became resistant through transient expression of blaTEM-2, but 
lost the plasmid and resistance with further cultivation due to 
the inability of pJK2 to propagate stably in A. baylyi.
To confirm that transformants of the first group occurred 
by transposition of Tn1 into the recipient chromosome, we 
determined the DNA sequences upstream and downstream of 
Tn1 by Sanger sequencing of genomic DNA. We analysed 20 
group 1 isolates with circular pJK2 DNA and an additional 8 
Fig. 3. Frequencies of transformation (black bars) and transposition 
(white bars) in A. baylyi wild- type using different transposon- containing 
donor DNA substrates: pJK2 (Tn1; n=3), pJKH1 (Tn1∆tnpA; n=4), pJK7 
(Tn1∆tnpR; n=3), pJK2- PCR (agarose gel- purified; n=3) and pTn4401 
(Tn4401; n=9). Bars represent the mean with standard deviation. 
Striped bars indicate the detection limit (dl) when no transformation or 
transposition events were observed.
Fig. 2. Consensus DNA sequence logo for Tn1- insertions into the 
chromosome of ADP1. Blue background colour indicates the target site 
duplication (TSD) consensus sequence at positions −4 to 0. Additional 
conserved positions around the TSD are shown. The TSD sequence 
motif (TTWTA; W: T or A) and preference for T at position −7 are typical 
for this transposon family. The logo was generated using WebLogo [37].
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isolates obtained with linear pJK2- derivatives (Supplemental 
Information: Supplemental Results). Altogether, we identified 
29 transposition events of Tn1 into the chromosome of ADP1, 
including one isolate with two transposons (Table S2). In all 
transposition transformants (‘transposants’), Tn1 was found 
as a chromosomal insert with a 5 bp TSD at the recombi-
nant joints, which is a hallmark of transposase activity. The 
consensus sequence of the TSD is in agreement with previous 
reports on Tn3- family transposons (Fig. 2) [39, 40]. We did 
not identify fragments of pACYC184 vector DNA or indica-
tions of non- transposition recombination events. The MIC of 
ADP1 for ampicillin (2 μg ml−1) was increased to >256 μg ml−1 
in eight randomly chosen transposants (Table S2). Together, 
these results confirm that the transposants have acquired Tn1 
during natural transformation through transposition.
The frequency of transposants using pJK2 donor DNA 
was (7.9±7.1)×10−9 (Fig. 3). To compare this transposition 
frequency to extra- chromosomal plasmid establishment or 
to homologous recombination during natural transforma-
tion, we used circular plasmid DNA (RSF1010) or linear 
homologous DNA (pKH80- PCR) in transformation assays 
with A. baylyi and obtained frequencies of (5.4±1.1)×10−6 
and (1.3±0.5)×10−4, respectively. These data indicate that Tn1 
transposition in the course of natural transformation is about 
680 times lower than plasmid aquisition and about 16 000 
times lower than homologous recombination during natural 
transformation. Nonetheless, the transposant frequency was 
higher than illegitimate recombination frequencies with fully 
heterologous donor DNA in A. baylyi [24, 41]. We conclude 
that transposon spread through natural transformation can 
occur at biologically relevant frequencies, although reports 
showing this process in situ are currently lacking. The impor-
tance of transposant formation in the environment or for 
AMR spread in the hospital is unknown but probably low 
compared with conjugation.
Chromosomal distribution of transposition events
All but one of the Tn1 insertions occurred in nonessential 
genes [42] or in intergenic regions of the ADP1 chromosome 
(Tables S2 and S3). However, the distribution of insertions 
was nonrandom, and 24 of 29 transpositions clustered within 
a 170 kbp sector around the assumed terminus of replication 
(Fig. 4a) [20]. This distribution was supported by 14 additional 
unique Tn1 insertions recovered from an A. baylyi ΔrecBCD 
Fig. 4. Characterization of Tn1 insertion sites. (a) Chromosome map of ADP1 with a magnified section of ∼170 kbp (box) around the 
approximate terminus of replication (ter; G- C/G+C skew inversion site). This region contains 174 open reading frames, of which 12 are 
essential [42]. The two major prophage regions of ADP1 and the dif site for chromosome partitioning by XerCD are indicated by grey 
open boxes and grey arrows, respectively [20, 47]. Tn1 insertions are marked as triangles (red, wild- type; blue, ∆recBCD ∆sbcCD). The 
orientation of Tn1 is indicated by the colour intensity (light, transcriptional orientation of tnpA in sense; dark, tnpA in antisense). A dashed 
triangle edge specifies insertion sites in a double transposant. Thirty- four out of 43 insertions occurred around the terminus (24 in wild- 
type and 10 in the ∆recBCD ∆sbcCD strain). (b) Number and distribution of TSD consensus sequences across the chromosome of ADP1, 
which was bi- directionally grouped into 2×18 100 kb segments from origin (ori) to ter. The number of TSD consensus sequence hits per 
group is plotted along the ori–ter axis (black and orange, first and second replichore, respectively). For both directions, linear regression 
showed a significant increase in the number of hits (first replichore: P=0.0076, R2=0.5544; second replichore: P=0.0004, R2=0.3683; 95 % 
confidence intervals are indicated); lowest hit number: 798 (group 2, second replichore), highest hit number: 1153 (group 9, second 
replichore). (c) Number of experimentally observed transposition events per region.
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ΔsbcCD strain (Supplemental Information: Supplemental 
Results and Fig. 4a). To further characterize the distribution 
bias, we determined the total number of TSD consensus 
sequence sites and their positions across the A. baylyi chro-
mosome. The TSD consensus sequence positions (n=34 863) 
followed a normal distribution, indicated by a small difference 
between the median and mean (0.16 %) relative to genome 
size. Although the incidence of TSD consensus sequence 
hits increases significantly along the origin–terminus axis of 
replication (Fig. 4b), even the highest increase in hit counts 
(30 %) does not explain why we observed more than 80 % of 
the verified Tn1 insertions in a region representing only 5 % 
of the ADP1 chromosome (Fig. 4c).
A comparable transposon insertion bias has been observed 
previously, although not in the context of natural transforma-
tion. Tn917  is a Tn3- like transposon in Gram- positive bacteria 
and preferentially inserts at the terminus in B. subtilis [43] and 
Entercoccus faecalis [44], but not in staphylococci [45, 46]. The 
bias is less strong in B. subtilis cells lacking functions involved 
in postreplicational chromosome segregation (RipX, SpoIIIE) 
or lacking the replication termination protein RTP [43]. In 
B. subtilis, codV and ripX encode the dif- directed chromosome 
partitioning recombinase often termed XerCD in Gram- 
negative bacteria [47]. We hypothesized that the absence 
of XerCD would alter the observed insertion bias of Tn1 in 
A. baylyi. We naturally transformed an ADP1 ΔxerC mutant 
by pJK2 donor DNA but did not obtain any transformants 
(detection limit: 2.2×10−10; n=3). The reason for this result 
is unclear. Further experimental investigation was impeded 
by the genetic limitations of the employed recipient strain: 
A. baylyi carries no gene homologous to rtp (tus in E. coli) [24], 
and the orthologue of spoIIIE (ftsK) is essential in A. baylyi 
[42]. Using RSF1010 as donor DNA for the A. baylyiΔxerC 
strain, the transformation frequency was (1.4±0.7)×10−6 
(n=3), which was only four times decreased compared to the 
wild- type.
Finally, we hypothesized that the distribution of Tn1 
insertions would be different using artificial transforma-
tion (electroporation). During electroporation, circular 
double- stranded DNA is directly delivered to the cytoplasm. 
However, no ampicillin- resistant isolates were obtained after 
electroporation of A. baylyi by circular pJK2 DNA (detection 
limit: 3.6×10−10; n=3). In contrast, electroporation by RSF1010 
(n=1) resulted in streptomycin- resistant transformants at a 
frequency of 5.6×10−5, which was 10 times higher than the 
frequency observed with natural transformation of A. baylyi. 
The reason for the distribution bias of transposition events 
remains unknown.
Requirement of transposon genes for transposition
Tn1 carries two genes involved in transposition: tnpA is the 
transposase gene, and tnpR encodes the resolvase for coin-
tegrate intermediates created by TnpA. TnpR also acts as a 
repressor for both tnpA and tnpR [48] (Fig. 1). We hypoth-
esized that transposition and cointegrate resolution during 
natural transformation were conferred by the tnpA and tnpR 
gene products encoded by the donor DNA and that dele-
tion of these genes would decrease transposant frequency. 
We removed the tnpA gene from Tn1 of pJK2, and natural 
transformation of A. baylyi by the resulting plasmid pJKH1 
yielded no ampicillin- resistant transformants (detection 
limit: 5.2×10−11; Fig. 3), confirming that tnpA of Tn1 but no 
recipient functions act as transposase for Tn1.
We also used plasmid pJK7 (carrying Tn1ΔtnpR) as donor 
DNA for the transformation of A. baylyi and the transfor-
mation frequency was similar to that obtained with pJK2 
[(3.5±3.5)×10−8; Fig. 3]. We PCR- screened 150 transformant 
isolates that were stably resistant after three consecutive 
streakouts and found that Tn1 and pJK2 vector backbone 
was detectable in all isolates. This transformant type was 
not detected with pJK2 but is consistent with unresolved 
cointegrate intermediates. We conclude that in the absence 
of TnpR, the derepressed TnpA efficiently recombined Tn1 
with the recipient and formed cointegrates that remained 
unresolved. Recipient functions such as RecA may contribute 
to their eventual resolution, but, taken together, these findings 
indicate that the main resolvase is the TnpR encoded by the 
donor DNA.
Formation of double-stranded cytoplasmic 
intermediates
Taken together, the presented results demonstrate that tnpA 
and tnpR genes as well as blaTEM-2- in the transient transfor-
mants of group 2 described above are expressed after uptake 
of DNA into the cytoplasm. Moreover, our data suggest 
that a circular intermediate is involved in the first (coin-
tegration) step of transposition. However, the donor DNA 
is transported as linear single- strands into the cytoplasm 
Fig. 5. Transformation frequencies of A. baylyi mutant strains (∆recO, 
∆recA or ∆dprA) by circular donor DNA substrates (RSF1010 or pJK2). 
Bars represent the mean with standard deviation from three to five 
experiments. Striped bars indicate the detection limit (dl) when no 
transformation or transposition events were observed.
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during natural transformation [49, 50]. We hypothesized 
that the uptake of two complementary DNA single- strands 
is required for double- strand formation by hybridization. 
The resulting linear DNA double- strands, however, would 
be susceptible to degradation by exonucleases such as 
RecBCD [51, 52-]. Subsequent circularization by annealing 
at overlapping ends, followed by fill- in DNA synthesis or gap 
repair, would protect these double- strands from exonucleo-
lytic degradation [53].
In B. subtilis, recO is required for efficient plasmid transfor-
mation [54], which can be explained by the activity of RecO 
to hybridize complementary DNA single- strands [55]. To 
investigate the role of RecO in double- strand formation in 
A. baylyi, we transformed a ΔrecO strain by circular pJK2 
DNA. The resulting frequency of ampicillin- resistant trans-
formants was eight times lower than in wild- type A. baylyi 
[(7.7±2.4)×10−9; Fig. 5]. With RSF1010 as donor DNA, the 
frequency was (2.4±0.4)×10−6, which was two times lower 
than in wild- type A. baylyi (Fig. 5).
Unlike recO, the recA gene is not required for plasmid trans-
formation of B. subtilis [54], suggesting that RecO is suffi-
cient to restore circular plasmids from two complementary 
single- strands in this organism. We tested whether this was 
also the case in A. baylyi. In a ΔrecA mutant transformed by 
circular RSF1010 DNA, plasmid transformants occurred at 
a frequency of (3.4±1.3)×10−7 (Fig. 5), which was ~16 times 
lower than in wild- type A. baylyi. With pJK2 as donor DNA, 
no transformants were obtained (detection limit: 1.8×10−10; 
Fig. 5). This result suggests an unexpected role of RecA in 
plasmid circularization in A. baylyi.
The DprA (DNA processing A) protein is thought to load 
incoming DNA single- strands with RecA protein [56]. In 
many naturally competent bacteria, deletion of dprA abol-
ishes or severely reduces natural transformation [27, 57–60]. 
We investigated whether natural transformation by circular 
extrachromosomal DNA was affected in an A. baylyi ΔdprA 
mutant. Using pJK2 as donor DNA, the transformation 
frequencies of the ΔdprA strain dropped below detection 
limit (7.8×10−11) (Fig. 5). With RSF1010, the transformation 
frequency was (1.4±0.2)×10−7 and thus approximately 50 times 
lower than that of the wild- type (Fig. 5). These frequencies 
are comparable with those using the ΔrecA strain as recipient. 
The results support the assumption that DprA acts upstream 
of the RecA recombination pathway. They also demonstrate 
that plasmid transformation (RSF1010) is not abolished in 
the absence of DprA.
Our findings show that deficiencies of RecA, DprA and, to a 
lesser degree, RecO reduce transformation of circular extra-
chromosomal DNA in A. baylyi, suggesting a role of these 
functions in plasmid circularization. In our experiments, the 
non- replicative plasmid pJK2 generally yielded poorer trans-
formation frequencies than the replicative plasmid RSF1010. 
We cannot exclude the possibility that some or all of the 
investigated genes also modulate the transposition efficiency 
in addition to double- strand conversion and circularization.
Next we tested whether circularization is a requirement for 
transposons to jump during natural transformation. We used 
an inverse PCR product of pJK2 as donor DNA with Tn1 
approximately in the centre (pJK2- PCR). The substrate was 
agarose gel- purified to eliminate all traces of contaminating 
template DNA (confirmed by PCR; Supplemental Informa-
tion: Supplemental Results). Using this linear DNA substrate 
for transformation of wild- type A. baylyi, no ampicillin- 
resistant transformants were obtained (detection limit: 
1.6×10−10, Fig. 3), suggesting that pJK2- PCR is insufficient 
to produce both transient transformants and transposants, 
presumably due to the cytoplasmic instability of linear 
double- stranded intermediates.
Antagonistic activity of RecBCD
Cytoplasmic linear double- stranded DNA is target for degra-
dation by the RecBCD exonuclease in many bacteria [52] and 
the absence of the nuclease may protect linear intermediates 
and enhance plasmid circularization. In A. baylyi, RecBCD 
is thought to destroy donor DNA following uptake into the 
Fig. 6. Transformation frequencies of the ∆recBCD ∆sbcCD strain using 
plasmid DNA substrates (RSF1010 or pJK2; n=5). Bars represent the 
mean with standard deviation.
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Fig. 7. Model of Tn1 transposition during natural transformation of A. baylyi. Proteins with beneficial or necessary functions are 
represented in green, and proteins with antagonistic functions are red; exemplary sequence segments providing homology are indicated 
by a shaded background. (a) Circular monomeric as well as sporadic dimeric forms of plasmid DNA are available for uptake into 
the periplasm. (b) DNA single- strands are taken up into the cytoplasm and protected from degradation by DprA (orange). DprA also 
loads RecA (yellow) onto single- stranded DNA. (c) RecO (purple) is involved in the annealing of DNA single- strands [55], in initiating or 
improving gap repair as part of RecFOR or RecOR [63, 64], or both. The linear double- stranded molecule is susceptible to degradation 
by RecBCD exonuclease (red). (d) The RecA- loaded DNA 3’-single- strand end invades the double- stranded fragment at its terminal 
homology, and circularization of the donor plasmid is completed by DNA repair and gap synthesis. (e) From the established circularized 
plasmid, the genes necessary for transposition (tnpA, tnpR) are expressed, and TnpA together with a recipient DNA polymerase form 
a transposon–target DNA cointegrate and generate the TSD. (f) TnpR resolves the cointegrate, and the recipient chromosome contains 
now a copy of Tn1.
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cytoplasm after the creation of double- stranded ends during 
homologous recombination [30]. However, in the context 
of plasmid transformation, in B. subtilis strains lacking 
AddAB, the functional equivalent of RecBCD, transforma-
tion frequencies are somewhat reduced [61]. To investigate 
the effect of RecBCD deficiency on plasmid transformation 
in A. baylyi, we transformed a ΔrecBCD ΔsbcCD strain by 
RSF1010 and obtained a 70 times increased transformation 
frequency [(3.9±0.4)×10−5] compared with the wild- type 
(Fig. 6). We also transformed the ΔrecBCD ΔsbcCD strain 
by Tn1- containing donor substrates. Using a gel- purified 
linear pJK2- PCR substrate, no transformants were obtained 
(detection limit: 4.9×10−10; n=3), strongly suggesting that a 
circular intermediate is required for transposition and trans-
formation. With circular pJK2 donor DNA the frequency 
of ampicillin- resistant transformants was (6.8×±5.6)×10−4 
(Fig. 6), which was four orders of magnitude higher than that 
of the wild- type. Analysis of 40 ampicillin- resistant isolates 
revealed stable resistance even after repeated recultivation. 
PCR analyses verified the presence of Tn1 and pJK2 vector 
backbone DNA in all isolates and circular pJK2 plasmid DNA 
could be isolated from cell material of restreaks, indicating 
extrachromosomal DNA rather than cointegrates. No trans-
posants were identified during our standard screening, but 
a transformational screening approach revealed 14 unique 
chromosomal insertions (Supplemental Information: Supple-
mental Results and Table S3). These results were unexpected, 
and we concluded that established pJK2 replicated relatively 
stably in A. baylyi in the absence of RecBCD. The parental 
plasmid of pJK2, pACYC184 [33], propagates as a theta 
replicon in E. coli and in other Enterobacteriaceae [62]. It is 
possible that absence of RecBCD allows rolling circle replica-
tion of pACYC184 in A. baylyi, as in E. coli RecBCD- deficient 
mutants [62]. In wild- type E. coli, the exonucleolytic activity 
of RecBCD is thought to degrade the nascent multimers of 
the rolling circle, forcing the plasmid into theta replication. In 
contrast, loss of RecBCD allows rolling circle replication [62].
A model for natural transformation by transposons
In this study we experimentally verify that bacteria can 
acquire transposons horizontally through transposition in 
the course of natural transformation, as observed previ-
ously for a Tn21 transposon [19]. In control experiments, 
we investigated the circularization of a replicative plasmid in 
A. baylyi during transformation, which has been studied 
before in B. subtilis [54]. Our results indicate differences in 
plasmid transformation between the two species. In contrast 
to our results, absence of RecA in B. subtilis did not affect 
plasmid establishment; instead RecO protein was required 
for that process [54].
Based on our findings, we propose a model for plasmid 
transformation and transposition in A. baylyi (Fig. 7). We 
suggest that sporadic dimeric forms of plasmid DNA with 
redundant ends are the main substrate for cytoplasmic 
donor DNA circularization. To initiate circularization, a 
small single- strand fragment is annealed with a large dimeric 
complementary strand with 5′- and 3′-overhangs. DNA fill- in 
synthesis converts the 5′-overhang into a double- strand 
(using the 3′-recessed end as primer), while the 3′-overhang 
is charged with RecA protein. It is consistent with our findings 
that DprA has a RecA- loading function [56]. The resulting 
nucleoprotein filament can undergo homology search. When 
it finds the homology of the redundant double- stranded end, 
the result is a circular intermediate with a displaced strand, 
and textbook DNA repair and gap synthesis generate a 
circular double- strand. This model is supported by lack of 
transformants with linear pJK2- PCR as donor DNA, since 
this substrate did not contain dimeric DNA molecules. The 
resulting circular double- stranded intermediate is temporally 
protected from DNA degradation (Fig. 7). Finally, the tnpA 
and tnpR genes are expressed and can lead to transposition 
of Tn1.
Is circular double- stranded DNA in general a necessary 
requirement for transposition in the course of natural trans-
formation? Probably not. Domingues et al. obtained trans-
posants using chromosomal DNA for natural transformation 
of A. baylyi [19]. Hypothetically, such DNA can form circular 
intermediates at direct repeats, and transposons surrounded 
by direct repeats may be stabilized through DNA circulariza-
tion. It is also conceivable that Chi sequences surrounding the 
transposon protect the double- stranded intermediate from 
exonucleolytic degradation [51].
To put the results of this study into broader perspective, we 
employed a published transposon- containing plasmid as 
donor DNA for transformation of ADP1. The pACYC184 
derivative pTn4401 (15.6 kbp) [35] carries the replicative 
transposon Tn4401 (~10 kbp) of the Tn3- family that contains 
the carbapenemase gene blaKPC-2 [22]. Ampicillin- resistant 
transformants formed at a frequency of (1.5±1.2)×10−9 
(Fig. 3), which was 40 times lower than the frequency observed 
with pJK2 DNA. Among 60 investigated transformants, no 
transposants were found (detection limit: 9.8×10−11). Several 
explanations for the lack of transposition of Tn4401 are 
conceivable: the MIC conferred by KPC-2 may be too low 
to detect transposants in this organism. The plasmid size 
possibly reduces the dimer/monomer ratio. Alternatively, 
the repression of tnpA may be tighter in Tn4401 than in Tn1. 
Taken together, this result shows that additional constraints 
exist for transposition during natural transformation, and 
further investigations are needed.
In conclusion, we showed that transposition of Tn1 in the 
course of natural transformation occurs at biologically 
relevant frequencies. Our results open up the possibility 
that transposable elements can even spread from dead 
cells, where fully heterologous, transposon- containing free 
DNA can transform naturally competent bacteria, albeit at 
low frequencies. Transposons play an important role in the 
dissemination of multi- drug resistance, and the identifica-
tion of both the transferred resistance genes and the genetic 
context that was transferred is crucial to understand AMR 
spread.
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Abstract 
The persistence of plasmids in bacterial populations represents a puzzling evolutionary problem with 
serious clinical implications due to their role in the ongoing antibiotic resistance crisis. Recently, 
major advancements have been made towards resolving this “plasmid paradox” but mainly in a non-
clinical context. Here we propose an additional explanation for the maintenance of multidrug 
resistance (MDR) plasmids in clinical Escherichia coli strains. After co-evolving two MDR plasmids 
encoding last resort carbapenem resistance with an extraintestinal pathogenic E. coli strain, we 
observed that chromosomal media adaptive mutations in the global regulatory systems CCR (Carbon 
Catabolite Repression) and ArcAB (Aerobic Respiration Control) pleiotropically improved the 
maintenance of both plasmids. Mechanistically, a net downregulation of plasmid gene expression 
reduced the fitness cost. Our results suggest that global chromosomal transcriptional re-wiring during 
bacterial niche-adaptation may facilitate plasmid maintenance. 
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Introduction 
Plasmids are self-replicating extrachromosomal elements that often decrease bacterial fitness 
due to the requirement of host functions for their own replication and spread (reviewed in [Baltrus 
2013; San Millan and MacLean 2017]), although beneficial (or non-costly) plasmids have been 
reported (Enne et al. 2004; Monarrez et al. 2019). These genetic elements play a key role in the 
evolution and spread of antibiotic resistance determinants in bacterial populations world-wide 
(Carattoli 2013; Partridge et al. 2018). This is particularly true for nosocomial pathogens in the family 
Enterobacteriaceae including Escherichia coli and Klebsiella pneumoniae where resistance 
determinants of high clinical relevance such as carbapenemases and extended-spectrum β-lactamases 
are frequently encoded on plasmids (Mathers et al. 2015; Rozwandowicz et al. 2018). 
From an evolutionary perspective, persistence of plasmids in bacterial populations has for a 
long time been a conundrum often referred to as the “plasmid paradox” (Stewart and Levin 1977; 
Harrison and Brockhurst 2012). This paradox can be resolved in at least five different ways. First, 
maintenance can be ensured by positive selection for plasmid encoded traits (Gullberg et al. 2014; San 
Millan et al. 2014; Stevenson et al. 2018). But, if too beneficial, positively selected traits may be 
captured by the chromosome rendering the plasmid obsolete and consequently lost, as demonstrated 
theoretically (Bergstrom et al. 2000) and experimentally (Kottara et al. 2018). Second, mathematical 
models predict that high rates of horizontal plasmid transfer can counteract segregational plasmid loss 
and the competitive disadvantage of plasmid-carriers (Stewart and Levin 1977). In vitro studies report 
that conditions exist where conjugation frequencies are indeed extremely high (Dionisio et al. 2002; 
Lopatkin et al. 2017). It is however generally accepted that conjugation is a costly process (San 
Millan and MacLean 2017) and evolution towards increased conjugation rates does not constitute a 
general solution of the paradox (Turner et al. 1998; Dahlberg and Chao 2003; Porse et al. 2016). 
Third, transmissible plasmids under purifying selection may “escape” their host and enter less hostile 
environments. This has been termed cross-ecotype transfer (Bergstrom et al. 2000). Fourth, plasmid 
stability can evolve through improved replication control (Wein et al. 2019) and the acquisition of 
addiction mechanisms (Loftie-Eaton et al. 2016). Fifth, and perhaps most prominent, negative effects 
on host fitness can be mitigated through compensatory evolution (San Millan and MacLean 2017), 
and plasmids may even become beneficial (Bouma and Lenski 1988; Dionisio et al. 2005; Starikova 
et al. 2013; Loftie-Eaton et al. 2017). Fitness compensating mutations have been demonstrated to 
occur both in the presence and absence of selective agents and identified on bacterial chromosomes 
(San Millan et al. 2014; Harrison et al. 2015; Loftie-Eaton et al. 2017), on plasmids (De Gelder et al. 
2008; Sota et al. 2010; Porse et al. 2016), or both (Dahlberg and Chao 2003; Starikova et al. 2013; 
Bottery et al. 2017). 
The last ten years have brought significant advancements in the understanding of plasmid-host 
evolutionary dynamics. However, it is not clear how the different solutions to the plasmid paradox as 
listed above are relevant for clinical strains and plasmids since the majority of published work has 
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focused on emblematic laboratory strains and/or environmental bacteria. In this report we asked if and 
how two clinical plasmids encoding the VIM-1 and NDM-1 carbapenemases affected fitness of an E. 
coli strain isolated from a patient, before and after experimental evolution. We observed striking 
parallel evolution of the CCR (Carbon Catabolite Repression) and ArcAB (Aerobic Respiration 
Control) regulatory systems in the chromosomes of both plasmid-containing and plasmid-free 
populations resulting in adaptation to the experimental conditions. No apparent plasmid-specific 
compensatory mutations were identified across evolved populations and the plasmid sequences were 
largely unchanged. Yet, the initial plasmid costs were ameliorated in the co-evolved cultures. We 
demonstrate that fitness amelioration resulted from “piggybacking” on the clinical strains’ adaptation 
to a new niche, suggesting a novel solution to the “plasmid paradox”. 
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Results 
Plasmid acquisition moderately reduces fitness in a clinical E. coli host strain. To mimic the 
acquisition of plasmid-mediated resistance to a last resort antibiotic, we transferred each of the two 
carbapenemase-producing clinical plasmids pG06-VIM-1 from K. pneumoniae (blaVIM-1 [Samuelsen 
et al. 2011]) and pK71-77-1-NDM from E. coli (blaNDM-1 [Samuelsen et al. 2011]) into an 
Extraintestinal Pathogenic E. coli sequence type (ST) 537 (strain ExPEC [Bengtsson et al. 2012]; 
Supplementary Table 1). pG06-VIM-1 is non-conjugative (Di Luca et al. 2017) while pK71-77-1-
NDM is conjugative (Gama et al. 2020). Plasmid transfer resulted in strains ExPEC+VIM and 
ExPEC+NDM, both otherwise isogenic to strain ExPEC (Figure 1a and Supplementary Table 1). 
We measured the cost of the newly introduced clinical plasmids in head-to-head competition 
experiments lasting ∼40 generations. Acquisition of either pG06-VIM-1 or pK71-77-1-NDM affected 
host fitness similarly, resulting in moderate but significant costs of 5.3% and 5.5%, respectively (one-
sample t-test, two-sided: ExPEC+VIM: w = 0.947 ± 0.002, P < 0.001; ExPEC+NDM: w = 0.945 ± 
0.012, P = 0.017; Figure 1b and Supplementary Table 6). 
 
Strong parallel evolution in global E. coli regulators occurs independently of plasmid-carriage. 
Four replicate lineages of the plasmid-containing strains ExPEC+VIM and ExPEC+NDM as well as 
the plasmid-free strain ExPEC were serially transferred for ∼300 generations (over which the 
plasmids are stably maintained [Di Luca et al. 2017; Gama et al. 2020]). This resulted in 12 evolved 
populations (Pop 1-4VIM, Pop 5-8NDM and Pop 9-12; Figure 1c and Supplementary Table 1), that we 
deep sequenced to identify putative mutations mitigating the fitness costs of plasmid carriage.  
At the population level, no changes were identified in the evolved plasmid sequences except 
in Pop 5NDM harboring a deletion in the evolved pK71-77-1-NDM (Supplementary information 
section IIIa, Supplementary Table 3 and Supplementary Figure 1). However, all 12 evolved lineages 
revealed patterns of extensive parallel evolution in chromosomal genes that are directly or indirectly 
linked to the CCR and the ArcAB regulatory systems of E. coli (Figure 2a). In total, 68 different 
mutations were identified in genes cpdA (3',5'-cyclic adenosine monophosphate (cAMP) 
phosphodiesterase), crp (cAMP receptor protein; DNA-binding transcriptional regulator), arcA 
(aerobic respiration control protein; DNA-binding transcriptional regulator) and arcB (aerobic 
respiration control sensor protein; histidine kinase). Evolved lineages had on average acquired eight 
variations in these genes ranging from three (Pop 5NDM) to 18 (Pop 6NDM) different mutations for 
individual populations (Supplementary Figure 2). Our data revealed 25, 12, 23 and eight unique 
mutations in arcA (717 bp), arcB (2337 bp), cpdA (828 bp) and crp (633 bp), respectively 
(Supplementary Figure 2). Among these unique mutations in the respective target genes, 12, one, 
three and three were found repeatedly across more than one evolved population. The majority of 
mutations in these genes were non-synonymous single nucleotide exchanges leading to amino acid 
substitutions (88%). Furthermore, Pop 2VIM acquired mutations upstream and in the open reading 
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frame of cyaA (adenylate cyclase; cAMP synthesis). For a detailed list of mutations identified across 
evolved populations, including small indels, as well as mutations found in single populations, see 
Supplementary Table 4. Whereas cpdA and arcA were mutation targets in all 12 populations, crp and 
arcB were identified in ten and four populations, respectively (Figure 2a and Supplementary Figure 
2). Surprisingly, the mutation profiles were not different in populations that co-evolved with any of 
the plasmids compared to the plasmid-free control populations, strongly suggesting that the observed 
mutational changes were not plasmid-specific. Genes of the CCR and ArcAB systems are indeed 
frequently reported as mutational targets for adaptive responses to the experimental growth conditions 
occurring during laboratory evolution experiments (Knoppel et al. 2018; Phaneuf et al. 2019). 
 
Mutations in CCR and ArcAB regulatory systems pleiotropically mitigate the cost of pG06-
VIM-1 and pK71-77-1-NDM carriage. Immediate acquisitions of pG06-VIM-1 and pK71-77-1-
NDM reduced host fitness significantly (Figure 1b). We have previously demonstrated complete 
retention of the same plasmids following experimental evolution under the same antibiotic-free 
conditions (Di Luca et al. 2017; Gama et al. 2020). Since one of the plasmids was non-conjugative, 
we assumed that fitness amelioration by compensatory adaptation was the most likely route for the 
plasmids to persist in evolved populations. However, the sequencing data presented above revealed no 
apparent plasmid-specific compensatory mutations. Therefore, we hypothesized that adaptation to the 
growth conditions could have pleiotropic effects on the costs of plasmid carriage. 
To test this hypothesis, we isolated a single clone from each evolved plasmid-carrying 
population (Pop 1-4VIM and Pop 5-8NDM) with mutations in both regulatory systems, CCR and ArcAB, 
since population sequencing data suggested that both systems were affected simultaneously (Figures 
2a and 2b). In the selected Clones 1-4VIM and Clones 5-8NDM, Sanger and Illumina sequencing 
confirmed the presence of mutations as expected from population sequencing results and no further 
chromosomal or plasmid-located point mutations (Figure 1c and 2c; Supplementary information 
section I and IIIb, and Supplementary Table 1).  
Here, we also identified large deletions in the evolved pK71-77-1-NDM for Clone 5NDM and 
Clone 7NDM (∼8.8 kb and ∼58.9 kb, respectively; Supplementary information section IIIb, 
Supplementary Table 3, Supplementary Figure 1), and susceptibility testing by disc diffusion 
phenotypically confirmed the deletions involving antibiotic resistance genes (Supplementary 
information section VI, Supplementary Table 8). The plasmid copy-number for pG06-VIM-1 and 
pK71-77-1-NDM before and after experimental evolution was unchanged (0.9-1.5 copies in all 
sequenced plasmid-carrying clones based on read coverage; Supplementary information section IIIb; 
Supplementary Table 5). Next, we attempted to isolate a set of spontaneous plasmid-free segregants 
of Clones 1-4VIM and Clones 5-8NDM, to use in competition experiments, by screening for ampicillin-
susceptible colonies. We obtained segregants for pG06-VIM-1 resulting in Clones 1-4, but not for 
pK71-77-1-NDM, which we confirmed by Sanger sequencing to have the niche-adaptive 
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mutations (Figure 1c). Illumina sequencing of Clones 2 and 3 verified that no chromosomal 
mutations were acquired during the curing procedure. 
The costs of pG06-VIM-1-carriage in co-evolved Clones 1-4VIM were assessed in head-to-
head competitions with the respective plasmid-free isogenic strains (Clones 1-4) over ∼40 
generations. Our data show that the initial costs were significantly ameliorated to ≤ 1% in all four 
evolved backgrounds irrespective of the combination of chromosomal mutations in these clones (one-
sample t-test, two-sided: Clone 1VIM: 0.7% or w = 0.993 ± 0.002, P = 0.017; Clone 2VIM: 0.4% or w = 
0.996 ± 0.001, P = 0.016; Clone 3VIM: 0.9% or w = 0.991 ±  0.0003, P = 0.001 and Clone 4VIM: 0.6% 
or w = 0.994 ± 0.002, P = 0.056; one-way ANOVA assuming equal variances, df = 4, P < 0.001, 
followed by Dunnett’s test: P < 0.001; Figure 3a and Supplementary Table 6). Illumina sequencing 
confirmed that the plasmid sequences in Clones 1-4VIM were unchanged after evolution suggesting that 
the chromosomal mutations were responsible for the fitness mitigation. To further test this we 
introduced the ancestral pG06-VIM-1 into Clone 2 and Clone 3 carrying mutations in arcA/cpdA and 
arcA/crp, respectively, resulting in Clone 2+VIM and Clone 3+VIM (Figure 3b). Competition 
experiments with the isogenic, plasmid-free genetic backgrounds revealed a significant fitness 
increase compared to the original plasmid-host combination and an amelioration of the initial cost of 
harboring pG06-VIM-1 to 1.3% and 1%, respectively (one-sample t-test, two-sided: Clone 2+VIM: w 
= 0.987 ± 0.004, P = 0.026; Clone 3+VIM: w = 0.990 ± 0.001, P = 0.002; one-way ANOVA 
assuming equal variances, df = 2, P < 0.001, followed by Dunnett’s test: P < 0.001; Figure 3b and 
Supplementary Table 6). To exclude that plasmid-specific adaptation in these pG06-VIM-1-co-
evolved clones was responsible for the observed fitness amelioration, we introduced the ancestral 
pG06-VIM-1 into an isolated clone of Pop 12 (Clone 12+VIM; Figure 3d) and determined fitness as 
described above. In this background, which had evolved without a plasmid and acquired mutations in 
arcA/cpdA, the cost of pG06-VIM-1-carriage was also significantly reduced to ≤ 1% (one-sample t-
test, two-sided: Clone 12+VIM: 0.9% or w = 0.991 ± 0.002, P = 0.009, Figure 3d). While this was 
significantly different from the initial plasmid cost, it did not differ from the cost of ancestral pG06-
VIM-1 in co-evolved Clones 2+VIM and 3+VIM (one-way ANOVA assuming equal variances, df = 
3, P < 0.001, followed by Tukey’s test; Supplementary Table 6). 
Similarly, the initial fitness cost of 5.5% imposed by the ancestral pK71-77-1-NDM in strain 
ExPEC+NDM was significantly decreased in pG06-VIM-1-free segregants carrying this plasmid 
(one-sample t-test, two-sided: Clone 2+NDM: 2.4% or w = 0.976 ± 0.007; P = 0.025; Clone 3+NDM: 
2.7% or w = 0.973 ± 0.002; P = 0.002; one-way ANOVA assuming equal variances, df = 2, P = 
0.006, followed by Dunnett’s test: P = 0.006 and P = 0.010, respectively; Figure 3c and 
Supplementary Table 6). Note that we did not obtain a plasmid-free background of Clones 5-8NDM to 
test the fitness of pK71-77-1-NDM-co-evolved strains. The results from competition experiments 
with Clone 2+NDM and Clone 3+NDM carrying the ancestral pK71-77-1-NDM strongly suggest that 
the chromosomal mutations are responsible for partial fitness amelioration. We acknowledge that the 
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deletions in evolved plasmids of Clone 5NDM and Clone 7NDM, removing conjugation and resistance 
genes, could result in further fitness improvements as demonstrated previously (Turner et al. 2014; 
Porse et al. 2016). 
We transformed the evolved pG06-VIM-1 from Clone 2VIM into the ancestral ExPEC strain 
(Figure 3d) to test for adaptive changes occurring in plasmid sequences that could be undetected using 
short-read sequencing. The evolved pG06-VIM-1 affected the ancestral host significantly (one-sample 
t-test, two-sided: ExPEC+evVIM: 3.2% or w = 0.968 ± 0.005, P = 0.01) being less costly than the 
ancestral pG06-VIM-1, but more costly in the ancestral than in an adapted background (one-way 
ANOVA assuming equal variances, df = 3, P < 0.001, followed by Tukey’s test; Figure 3d and 
Supplementary Table 6). Some undetected plasmid mutations may reduce the cost of the evolved 
plasmid, however to a lesser extent than the mutations in CCR and ArcAB systems as demonstrated 
with Clone 12+VIM above. 
Taken together, our data indicate clearly that the different mutations identified in the CCR 
and ArcAB regulatory systems are sufficient to improve plasmid maintenance. The usage of isogenic 
strains, distinguishable only by plasmid-encoded markers is however a limitation that could skew the 
accuracy of the fitness measurements because of plasmid loss or conjugation. Plasmid loss could lead 
to an over-estimation of the fitness cost, but during the ∼40 generations of fitness measurement 
(Methods and Supplementary information section IV) all tested plasmids were stable (Supplementary 
Table 7) such that the effect of this parameter can be neglected. This is further corroborated by our 
inability to select any spontaneous pK71-77-1-NDM-free segregant. We also measured the 
conjugation efficiencies for pK71-77-1-NDM (12 hours) in additional experiments (Methods and 
Supplementary information section V), revealing small but significantly increased plasmid transfer 
frequencies in the adapted backgrounds (Supplementary Figure 3). This effect could lead to under-
estimation of the fitness cost of pK71-77-1-NDM in evolved hosts. Nevertheless, we conclude that the 
mutations in the regulatory systems improve the maintenance of this plasmid, either directly reducing 
the fitness cost or through increased conjugative transfer.  
 
Plasmid cost mitigation is linked specifically to the CCR system. To investigate the individual 
roles of the CCR and ArcAB systems on plasmid cost mitigation we measured plasmid costs in 
deletion mutants for arcA, cpdA and crp – the targeted loci for adaptation in our co-evolved clones. 
Unfortunately, genetic modifications using clinical strains are notoriously difficult and for these 
experiments we used deletion mutants of E. coli (K-12 derivatives) from the Keio collection (Baba et 
al. 2006). We introduced the ancestral pG06-VIM-1 into the individual deletion strains as well as the 
Keio parent strain (Datsenko and Wanner 2000) by electroporation, resulting in strains 
BW25113+VIM, BWΔcpdA+VIM, BWΔarcA+VIM and BWΔcrp+VIM (Supplementary information 
section I and Supplementary Table 1). We measured fitness of plasmid-carrying strains relative to 
their plasmid-free counterparts in head-to-head competitions as described above. As a general 
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observation, pG06-VIM-1 was less costly in BW25113 than in the clinical isolate (one-sample t-test, 
two-sided: 2.3% or w = 0.977 ± 0.005, P = 0.016; Figure 4a and Supplementary Table 6). While 
deletion of arcA and crp had no significant effect on the fitness burden imposed by pG06-VIM-1 
compared to BW25113+VIM, we measured a significant fitness improvement of the pG06-VIM-1-
carrying DcpdA mutant (one-way ANOVA not assuming equal variances, df = 3, P = 0.004 followed 
by Dunnett’s test: BWDarcA+VIM, P = 0.993; BWDcrp+VIM, P = 0.051; BWDcpdA+VIM, P = 
0.001; Figure 4a and Supplementary Table 6) and a reduction of plasmid cost to 0.4% (one-sample t-
test, two-sided: BWDarcA+VIM: 2.2% or w = 0.978 ± 0.007, P = 0.007; BWDcrp+VIM: no cost or w 
= 1.006 ± 0.020, P = 0.534; BWDcpdA+VIM: w = 0.996 ± 0.002, P = 0.034; Figure 4a and 
Supplementary Table 6). These data strongly suggest that beyond the known effect on adaptation to 
growth conditions, cpdA mutations identified in our study pleiotropically mitigated plasmid costs. We 
could however not obtain the same level of consistency across biological replicates in competitions 
using the Dcrp mutant even though CpdA and CRP are tightly linked in the CCR regulatory system 
(Imamura et al. 1996; Matange 2015). Based on the observation that pG06-VIM-1 no longer imposes 
a cost in the Dcrp mutant, as confirmed by the one-sample t-test, we argue that crp is also involved in 
fitness mitigation despite the relatively high variance that renders the Dunnett’s test (borderline) not 
significant. 
In E. coli, the phosphodiesterase CpdA affects intracellular levels of cAMP by specifically 
hydrolyzing this signaling molecule (Imamura et al. 1996). To investigate the effect of the most 
frequently observed mutation in cpdA (cpdA.D3.bp488-490; Supplementary Table 4) on protein 
function, we measured intracellular cAMP concentrations in ancestral and evolved strains with and 
without pG06-VIM-1. The levels of intracellular cAMP increased significantly by 49% between 
ancestral and evolved strains (ExPEC and ExPEC+VIM: 2.6 to 4.3 pmol mL-1, mean = 3.7 ± 0.72 
pmol mL-1; Clone 2 and Clone 2VIM: 5.7 to 11.6 pmol mL-1, mean = 7.2 ± 2.2 pmol mL-1; two-way 
ANOVA with interactions: df = 3, P = 0.005 [assuming equal variances] and P = 0.001 [adjusted for 
unequal variances]; Figure 4b), but were unaffected by plasmid presence (two-way ANOVA with 
interactions: df = 3, P = 0.53 [assuming equal variances] and P = 0.40 [adjusted for unequal 
variances]). These data are consistent with the previously observed CpdA deficiency of an identical E. 
coli mutant resulting in an approximate doubling of intracellular cAMP (Chib and Seshasayee 2018). 
Similarly, protein function analysis of evolved population data indicates that the majority of mutations 
in cpdA lead to the loss of CpdA function (Supplementary information section VII and Supplementary 
Table 9). 
 
Mutations in CCR and ArcAB regulatory systems lead to general adaptation to the growth 
conditions. The gene products of cyaA, cpdA, crp, arcA, arcB can be associated with transcription in 
E. coli involving the global regulators CRP and ArcA (Martínez-Antonio and Collado-Vides 2003). 
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cAMP is an important second messenger that binds to CRP (Frendorf et al. 2019) and the complex 
activates cAMP-dependent regulation of carbon source utilization via the CCR system (Imamura et al. 
1996; Matange 2015). Intracellular levels of cAMP in E. coli are controlled by CyA (synthesis) and 
CpdA (degradation) (Imamura et al. 1996). Proteins ArcA and ArcB compose the ArcAB two-
component regulatory system involved in respiratory and energy metabolism of E. coli (Iuchi and Lin 
1988; Iuchi et al. 1989). Mutations in CCR- and ArcAB-associated proteins may lead to growth 
optimization in varying environments due to adaptation in downstream transcriptional regulatory 
networks (Saxer et al. 2014; Frendorf et al. 2019; Phaneuf et al. 2019). 
To verify that the mutations identified in the two regulatory systems increase fitness in the 
given in vitro environment, we assessed the fitness of pG06-VIM-1-containing and -free, evolved and 
ancestral strains by measuring exponential growth rates. Plasmid pG06-VIM-1 in Clones 1-4VIM 
displayed no mutations after experimental evolution and this approach allowed us to directly measure 
the effects of the chromosomal mutations on general fitness. Growth rates of evolved strains were 
increased by 7-17% across all comparisons independent of presence or absence of the plasmid (one-
sample t-test, one-sided: Clone 1: w = 1.11 ± 0.02; P = 0.022; Clone 2: w = 1.17 ± 0.03; P = 0.019; 
Clone 3: w = 1.13 ± 0.02; P = 0.009; Clone 4: w = 1.14 ± 0.02; P = 0.007; Clone 1VIM: w = 1.07 ± 
0.02; P = 0.023; Clone 2VIM: w = 1.13 ± 0.06; P = 0.072; Clone 3VIM: w = 1.17 ± 0.05; P = 0.040; 
Clone 4VIM: w = 1.16 ± 0.04; P = 0.026; Figure 5a and b). Despite lower resolution than competition 
experiments, these data show that the identified mutations increase fitness under the given growth 
conditions and independent of plasmid carriage. They provide further support for the plasmid cost 
mitigating role of the observed chromosomal mutations. 
 
Transcriptional alterations contribute to reduced plasmid costs. CRP and ArcA represent two of 
seven global transcription factors in E. coli and directly or indirectly control the expression of several 
hundred genes (Liu and De Wulf 2004; Shimada et al. 2011). Changes in gene expression may lead to 
a reduced burden of plasmid carriage as demonstrated previously (Harrison et al. 2015; San Millan et 
al. 2015; Kawano et al. 2020). We sought to elucidate both the origin of the initial pG06-VIM-1 cost 
and its amelioration due to mutations in CCR and ArcAB associated genes and performed RNA-Seq. 
Six replicate samples of plasmid-free strains ExPEC, Clone 2 and Clone 3, and plasmid-carrying 
strains ExPEC+VIM, Clone 2+VIM, Clone 3+VIM were sequenced resulting in on average 25 million 
paired-end reads per sample (Supplementary Table 10). Comparing the two ancestral strains ExPEC 
and ExPEC+VIM revealed differential expression of seven chromosomal genes immediately upon 
plasmid acquisition, of which only the one encoding a putative selenium delivery protein displayed a 
fold-change (2.36) beyond a 2-fold threshold (Figure 6a and Supplementary Table 11). Similarly, 
plasmid pCAR1 also significantly changes the expression of only a limited set of chromosomal genes 
in Pseudomonas putida, but with a stronger effect (>40 fold) on only one gene designated parI 
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(Miyakoshi et al. 2007). The lack of substantial evidence for altered chromosomal gene expression 
in our work suggests that the costly plasmid acquisition may not severely disrupt transcriptional 
regulation (Buckner et al. 2018) or specific cellular pathways e.g. SOS response (San Millan et al. 
2015). Instead, the cost can derive from the usage of building blocks or molecular machinery for 
plasmid replication (e.g. nucleotides), but most likely those required for expression and post-
translational events, such as amino acids, ribosomes, chaperones and acetyl/succinyl modification 
(San Millan et al. 2018; Vasileva et al. 2018 and reviewed in Baltrus 2013). 
Given that the CCR and ArcAB systems are involved in global gene regulation it is not 
surprising that mutations in evolved Clone 2 and 3 lead to considerable changes in chromosomal gene 
expression when compared to the ancestral ExPEC strain. Indeed, hundreds of genes are differently 
up and downregulated independently of pG06-VIM-1 presence (Figure 6c; Supplementary Table 11). 
Despite some differences among the four evolved clones, enrichment (Supplementary Table 12) and 
over-representation (Supplementary Table 13) analyses of protein-encoding genes show common 
trends; cell motility via cilia/flagella (and other processes that require cell component organization, 
such as the expression of adhesion factors) tends to be downregulated (Supplementary Figure 5), 
while there is upregulation of diverse metabolic processes that target macromolecule biosynthesis 
(e.g. amino acids) and ribosome assembly which are, directly or indirectly, connected to translation 
and gene expression (Supplementary Figure 4).  
After evolution, only 16 chromosomal genes of Clone 3 were affected by pG06-VIM-1 
acquisition, of which one gene encoding a phage tail protein, exhibited overexpression > 2-fold 
(Figure 6a; Supplementary Table 11). In Clone 2 we found upregulation of four chromosomal genes 
while 116 were downregulated (Figure 6a; Supplementary Table 11). Analyzing the 115 
downregulated protein-encoding genes revealed an over-representation of biological processes 
involved in tRNA metabolism and nucleotide biosynthesis (Supplementary Table 13; Supplementary 
Figure 6), while the remaining gene encodes a tRNA. Furthermore, the comparison Clone 2+VIM vs 
ExPEC+VIM revealed that 52 (or 65%) of the strain’s tRNA-encoding genes are downregulated 
(Figure 6c; Supplementary Table 11) which is indicative of altered translation processes. Therefore, at 
least in Clone 2 the low cost of pG06-VIM-1 can be attributable to interference in translation, which 
is in agreement with other reports showing that low plasmid costs are associated with gene expression 
(McNally et al. 2016; Buckner et al. 2018).  
Interestingly, overall expression of pG06-VIM-1 genes decreased in evolved hosts, such that 
in Clone 2+VIM 12 plasmid genes are downregulated and four upregulated, while in Clone 3+VIM 
seven plasmid genes are downregulated but only one is upregulated (Figure 6b; Supplementary Table 
11). Although transcriptional changes in these genes never exceed a 2-fold threshold, the net fold-
change is negative (-13.08 for Clone 2+VIM and -9.01 for Clone 3+VIM; Supplementary Table 17). 
Plasmid RNA represents 2.33 ± 0.11% of the total transcripts for ExPEC+VIM, but a significantly 
lower proportion for evolved strains (one-way ANOVA assuming equal variances, df = 2, P = 0.001, 
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followed by Dunnett’s test: P < 0.001 and P = 0.03), respectively 2.08 ± 0.08% for Clone 2+VIM and 
2.18 ± 0.11% Clone 2+VIM (Supplementary Figure 7). Taken together, these data suggest that net 
downregulation of plasmid genes after evolution offer a plausible explanation for the reduced fitness 
costs, while in other works such reduction is explained by down-regulation of highly specific plasmid 
genes (San Millan et al. 2015). Although the differences in the proportions of plasmid transcripts 
among hosts are small, they can lead to significant fitness effects if the synthesized proteins require 
chaperones (Ma et al. 2018) and post-translational modification (Vasileva et al. 2018). Thus, 
reshaping gene expression at a global level through the identified mutations in the CCR and ArcAB 
systems affects plasmid transcription levels. This represents a novel solution to the plasmid paradox 
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Discussion 
In this report we asked if and how plasmid-host coevolution would mitigate the fitness costs 
of two clinically highly relevant MDR plasmids newly acquired by a plasmid-free ExPEC isolate. Our 
data show that the moderate initial costs of both carbapenemase-encoding plasmids were significantly 
alleviated during laboratory evolution. Curiously, the main causes for amelioration were not plasmid-
specific compensatory mutations as reported in several recent studies (San Millan et al. 2014; 
Harrison et al. 2015; Loftie-Eaton et al. 2016; Loftie-Eaton et al. 2017), although deletions of costly 
plasmid regions (Turner et al. 2014; Porse et al. 2016) and undetected plasmid mutations could also 
have played a role. Instead, after ∼300 generations we identified strong parallel evolution in 
chromosomal genes only, independent of plasmid carriage. The mutational target genes represented 
two global regulatory systems involved in E. coli carbon catabolite repression (CCR) and aerobic 
respiration (ArcAB). Moreover, the mutations in these transcriptional regulators improved the 
maintenance of two unrelated plasmids strongly suggesting that the ExPEC host became generally 
more permissive towards plasmid acquisition, and in the future it would be interesting to test the 
effect on additional plasmid types. The pleiotropic effects on plasmid cost amelioration appears to be 
mainly due to mutations affecting the CCR regulatory system, as demonstrated by fitness results using 
cpdA and crp deletion mutants. Mechanistically, RNA-seq analyses revealed a net transcriptional 
relief on plasmid genes as a collateral cost-mitigating effect of environmental adaptation by global 
regulatory changes. 
Other studies have also reported that mutations in regulatory systems improved plasmid-host 
relationships. In a seminal study, mutations in the gacA/gacS two-component regulatory system 
reduced the cost of the mega plasmid pQBR103 by decreasing plasmid transcriptional demand in 
Pseudomonas fluorescens (Harrison et al. 2015). These mutations were specifically ameliorating the 
cost of the plasmid since they did not appear in the plasmid-free evolved lineages (true compensatory 
mutations) (Harrison et al. 2015). This is categorically different from our findings since we observed 
that adaptation in the CCR and ArcAB regulatory systems was not specific to plasmid-carrying 
populations. Two other reports frequently identified mutations in regulatory systems across multiple 
plasmid-carrying evolving populations that improved plasmid maintenance (Loftie-Eaton et al. 2016; 
Stalder et al. 2017). However, the absence of evolved plasmid-free lineages in these studies preclude 
direct comparisons with the results presented here. 
On a broader perspective, our results warrant further research on plasmid-evolutionary 
dynamics in different E. coli lineages and sub-lineages to better understand why some of them appear 
to be more prone to acquire and maintain MDR plasmids (Mathers et al. 2015; McNally et al. 2016). 
Available data support that plasmids of clinical origins rarely reduce fitness of clinical host strains 
(Sandegren et al. 2012; Schaufler et al. 2016; Di Luca et al. 2017; Buckner et al. 2018; Gama et al. 
2020; Ma et al. 2020) to the extent often seen in the pioneering studies of plasmid-host compensatory 
evolution (Lenski et al. 1994; Sota et al. 2010; San Millan et al. 2014; Harrison et al. 2015). It is also 
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clear that this alone cannot explain how successful clone-plasmid associations emerge. From 
population genomic analyses McNally and co-workers demonstrated an association between 
mutations in regulatory regions of the high-risk E. coli ST131 subclade C and the accessory genome, 
including MDR plasmids. In their interpretation, this finding represented evidence of compensatory 
evolution towards MDR plasmid acquisition. However, taken together with a recent report showing 
that ExPEC ST131 has adapted to separate ecological niches at the sub-clade level, our results provide 
an alternative explanation (McNally et al. 2019).  
Based on data presented here, it can be hypothesized that regulatory changes could also in 
part represent niche-adaptations that coincidentally facilitate MDR plasmid acquisition and 
maintenance. Moreover, chromosomal antibiotic-resistance mutations, which can be viewed as a form 
of niche-adaptation, display epistatic interactions affecting plasmid fitness cost (Silva et al 2011) as 
well as stability (Sota and Top 2008). Therefore, different types of mutations causing environmental 
adaptation can collaterally increase the permissiveness to plasmids. However, we acknowledge that 
the pleiotropic effects on plasmid costs reported here may be specific to a single environment, as 
others have reported that both fitness costs (Knoppel et al. 2018; San Millan et al. 2018; Hubbard et 
al. 2019) and compensatory evolution (Hall et al. 2020) are highly media-dependent. Consequently, 
the specific mutations reported here may be media-dependent, but the processes targeted (i.e. global 
gene regulation) are widely reported across different media, strains, and plasmids supporting the 
generality of our findings.  
Our study is not without limitations. We specifically dissected the causes of plasmid fitness 
cost amelioration for the non-conjugative pG06-VIM-1, but not in detail for pK71-77-1-NDM. 
Maintenance of the latter improved due to mutations in CCR/ArcAB regulons, but the contribution of 
each system remains unclear. Due to our experimental approaches, we could not precisely identify 
whether the chromosomal mutations affected fitness directly, or indirectly due to observations that 
conjugative transfer increased in the evolved clones. To that end, ArcA has been shown to impact 
conjugative transfer of other plasmid types (Strohmaier et al. 1998; Serna et al. 2010). However, we 
cannot exclude the possibility that the small increase in pK71-77-1-NDM conjugation is an artifact 
resulting from different growth rates, since adapted donors display faster growth than unevolved 
donor and recipient strains. The effects of CCR/ArcAB mutations on the different parameters for 
pK71-77-1-NDM maintenance (fitness costs, stability and conjugation) need further exploration. 
Also, the role of large plasmid deletions represents a subject for future research. 
 In this report, we propose “piggybacking” on niche-adaptation as a novel, not mutually 
exclusive, solution for the “plasmid paradox”. Our approaches also underscore the importance of 
using clinically relevant strains and plasmids to investigate the evolutionary dynamics of plasmid-
mediated antibiotic resistance. This knowledge can be used jointly with data from molecular 
epidemiology to better predict future emergence of successful combinations of clones, sub-lineages 
and antibiotic resistance determinants. 
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Methods 
Bacterial hosts, plasmids and culture conditions. Strains, plasmids and primers used in this study 
are listed in Supplementary Tables 1 and 2. The ancestral plasmid-free strain ExPEC was chosen as it 
represents a clinically relevant E. coli isolate (originating from urinary tract infection) while being 
plasmid-naïve. It belongs to sequence type 537, as tested by multi-locus sequence typing, and 
phenotypically susceptible to 24 antibiotics tested by disc diffusion (Bengtsson et al. 2012; Kahlmeter 
and Poulsen 2012) (Supplementary Table 1). The lack of detected replicons and antibiotic resistance 
genes make this strain an ideal clinical model to study the behavior MDR plasmids. Plasmids pG06-
VIM-1 and pK71-77-1-NDM originated from a K. pneumoniae wound infection isolate (Samuelsen et 
al. 2011) and an uropathogenic E. coli (Samuelsen et al. 2011) and were introduced into ExPEC by 
electroporation or conjugation, respectively. Strains were grown at 37°C under aeration in Miller 
Difco Luria-Bertani liquid broth (LB; Becton, Dickinson and Co.) or on LB agar (LBA) containing 
additional Select agar (15 g L-1, Sigma-Aldrich). For selection of plasmid-carrying strains, media 
were supplemented with ampicillin (100 mg L-1; Sigma-Aldrich). See Supplementary information 
section I for more details on strains constructed in this study. 
 
Experimental evolution. Single colonies of strains ExPEC, ExPEC+VIM and ExPEC+NDM were 
used to initiate four independent lineages each. The 12 lineages were evolved in 1 mL of antibiotic-
free LB medium using 2 mL-deep-96-well plates in checkered pattern (VWR International) and 
incubated at 37°C with 700 rpm constant shaking (Microplate Shaker TiMix 5, Edmund Bühler). In 
total, 48 transfers with estimated 6.6 generations between two transfers (∼300 generations) were 
performed involving a 1:100 dilution of stationary-phase cultures into fresh LB every 12 hours (∼107 
cells transferred). Endpoint populations (Pop 1-4VIM, Pop 5-8NDM and Pop 9-12) and one 
representative clone per plasmid-carrying evolved population (Clones 1-4VIM and Clones 5-8NDM) 
were stored at -80°C (Supplementary information section I and Supplementary Table I). 
 
Whole-genome sequencing. See Supplementary information section II for details on long-read 
sequencing and assembly of a closed reference genome of strain ExPEC (GenBank accession 
CP053079). For Illumina whole-genome sequencing, genomic DNA of ancestral strains ExPEC, 
ExPEC+VIM, ExPEC+NDM, eight evolved clones (Clones 1-4VIM, Clones 5-8NDM) and 12 evolved 
mixed populations (Pop 1-4VIM, Pop 5-8NDM, Pop 9-12) (Figure 1) was isolated using the GenElute 
Bacterial Genomic DNA Kit (Sigma-Aldrich). DNA-purity and -quantity was assessed using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Short-read sequencing library 
preparation and sequencing was performed following manufacturers’ instructions at the Genomic 
Support Centre Tromsø, UiT The Arctic University of Norway. The Nextera XT DNA Library 
preparation kit (Illumina) was used with an input of 1 ng genomic DNA and dual indexes. Samples 
were sequenced on a NextSeq 550 instrument (Illumina) with 300 cycles (2 × 150 bp paired-end 
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reads), and a NextSeq 500/550 mid-output flow cell was used for clonal samples. One entire high-
output flow cell was explicitly used for the population samples aiming at deep coverage. We ran Trim 
Galore v0.5.0 with default settings to remove adapter sequences (CTGTCTCTTATA) and low-quality 
bases, and SPAdes v3.13.0 with read error correction (Bankevich et al. 2012; Krueger 2012). 
Trimmed and error corrected short-reads were controlled for adapters and quality score using FastQC 
v0.11.4 (Andrews 2010). The raw sequence reads (long and short) of 24 libraries are available from 
the NCBI Sequence Read Archive (SRA, BioProject accession PRJNA630076). 
 
Short-read sequence analysis. We used the breseq computational pipeline v0.33.0 and v0.35.0 for 
prediction of mutations from clonal and population short-read sequencing data (Deatherage and 
Barrick 2014). Preprocessed reads (see above) of all evolved populations were mapped against the 
reference genome of strain ExPEC (GenBank accession CP053079), and against plasmid sequences of 
pG06-VIM-1 (Pop 1-4VIM; GenBank accession KU665641 [Di Luca et al. 2017]) or pK71-77-1-NDM 
(Pop 5-8 NDM; GenBank accession CP040884 [Gama et al. 2020]) when appropriate. Breseq was run 
with default settings except for specifications when analyzing clonal sequencing data (‘consensus-
mode’; ‘frequency-cutoff 0.9’; ‘minimum-variant-coverage 10’; ‘consensus-minimum-total-coverage 
10’) or population sequencing data (‘polymorphism-mode’; ‘frequency-cutoff 0.01’; ‘minimum-
variant-coverage 10’; ‘minimum-total-coverage 100’; ‘base quality score 20’). We focused on the 
identification of de novo single nucleotide substitutions, deletions, insertions and small indels by 
manually evaluating the predicted mutations from the breseq outputs (Supplementary information 
section IIIb). The use of short-read sequencing data bears an inherent limitation regarding the 
interpretation of chromosomal inversions, rearrangements and mutations in repeat regions due to 
misaligned reads, and these mutations were thus omitted from further analysis. Repeats were 
confirmed using ‘tandem repeat finder’ v4.09 (Benson 1999) or by manually searching the reference 
genome for multiple alignment options. For population sequencing analysis, we report genetic 
changes as low as 1% mutation frequency considering that the mutated locus reached ≥ 10% mutation 
frequency at least in one of the evolved populations. Artemis v16.0.0 (http://sanger-
pathogens.github.io/Artemis/), Gene Construction Kit v4.0.3 (Textco Biosoftware Inc.) and the 
Integrative Genomics Viewer v2.6.0 (http://software.broadinstitute.org/software/igv/) were used to 
support manual inspection of sequencing data.  
 
Competitive fitness and plasmid stability. The relative competitive fitness (w) of plasmid-carrying 
clones was determined in pairwise serial competition experiments (∼40 generations) with the isogenic 
plasmid-free strain, as described before (Starikova et al. 2013), with minor modifications. Briefly, 
pre-adapted cultures of each competitor were adjusted to the same OD600, mixed in a 1:1 ratio, and 
used to initiate 1 mL batch cultures at a density of ∼107	CFU	(= T0), in antibiotic-free LB and 2 mL-
deep-96-well plates in checkered pattern (VWR International). Plates were incubated at 37°C with 
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700 rpm shaking (Microplate Shaker TiMix 5, Edmund Bühler), and the cultures were diluted 1:100 
into fresh LB every 12 hours (= T12-72). To determine the CFU of each competitor, cultures were 
diluted in 0.9% saline (m/v) and plated selectively on LBA-ampicillin (CFUplasmid-carrying) and non-
selectively on LBA (CFUtotal) at T0 and every following timepoint. The selection coefficient was 
calculated as s = 0.5 × )/ln(1/*) with b (= slope) obtained from regressing the natural logarithm of the 
ratio (CFUplasmid-carrying/CFUplasmid-free) over timepoints, and d as the dilution factor at each transfer (here 
1:100) (Levin et al. 2000). It was multiplied by 0.5 to account for two transfers per day (to obtain s 
per day). Relative fitness was calculated as w = 1+s, where the fitness of the plasmid-free strain 
equals 1 (Supplementary Table 6). To determine spontaneous plasmid loss during competition 
experiments we proceeded similarly with pre-adapted cultures of plasmid-carrying strains as 
described above. Briefly, the density at T0 was ∼5 × 106 CFU mL-1 and cultures were transferred, 
diluted and plated selectively and non-selectively, as described above. The slope obtained by 
regressing the frequency of the plasmid-carrying population (CFUplasmid-carrying/CFUtotal) over timepoints 
was calculated (Supplementary Table 7). For determination of relative competitive fitness and 
spontaneous plasmid loss, results were obtained from at least three biological replicates, initiated on 
separate days, with three technical replicates each.  
 
Exponential growth rates. As a proxy for fitness changes due to acquired mutations in evolved 
clones with and without the plasmid, the exponential growth rates of separately growing strains were 
determined. Briefly, overnight cultures in 1 mL LB were started from a single colony grown on LBA, 
diluted 1:100 in LB, and 250 μl were aliquoted into a 96-well-microtiter plate (Thermo Scientific). 
Absorbance at OD600 nm was measured in a BioTek EPOCH2 microtiter spectrophotometer (BioTek 
Instruments), every 10 minutes, and with linear shaking. Growth rates (r) were determined using 
GrowthRates v3.0 (Hall et al. 2014). Fitness of the evolved strain was calculated as relative growth 
rate = revolved strain/rancestral strain. Results were obtained from three biological replicates including five 
technical replicates all displaying a correlation coefficient R ≥ 0.97. 
 
Intracellular cyclic adenosine monophosphate (cAMP) concentration. Intracellular cAMP was 
quantified using the Cyclic AMP Select ELISA Kit (Cayman Chemical) following manufacturers’ 
instructions. For this purpose, overnight cultures were started from single colonies into 2 mL LB, 
diluted 1:100 into fresh LB and incubated until mid-exponential growth phase (between 5.3-6.7 × 108 
CFU mL-1). Five mL of each culture were spun down at 4°C, 4000 rpm for 10 min (Eppendorf 
Centrifuge 5810), supernatant was removed, and the pellet was subsequently washed three times in 
ice-cold 0.9% saline (m/v). Cells were resuspended in 250 μl of 0.1 M HCl to stop endogenous 
phosphodiesterase activity and the suspensions were boiled for 5 minutes. After centrifugation at 4°C, 
4000 rpm for 10 min (Eppendorf Centrifuge 5810) an aliquot of the supernatant was diluted 1:2 
(ExPEC, ExPEC+VIM) or 1:8 (Clone 2VIM, Clone 2) in ELISA buffer followed by a subsequent 1:2 
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dilution step for all samples. The cAMP standard was reconstituted in 0.1 M HCl but thereafter 
diluted into ELISA buffer. Samples were applied in two dilutions, each in three biological and three 
technical replicates on the same ELISA plate. The standard was applied once and in two technical 
replicates on the same plate. The plate was incubated in the dark for 18 hours at 4°C and thereafter 
developed under slow orbital shaking and dark conditions. Absorbance was measured at 410 nm 
periodically in a BioTek EPOCH2 microtiter spectrophotometer (BioTek Instruments). Final reads 
were taken at B0-average = 0.7 and data was analyzed using the spreadsheet available at 
https://www.caymanchem.com/analysisTools/elisa (R2 standard curve = 0.96). 
 
Total RNA isolation. For transcriptome analysis, overnight cultures were initiated from single 
colonies into 2 mL LB, diluted 1:100 into fresh LB, and incubated until mid-exponential growth 
phase (OD600 0.5-0.6; average 2.2±0.9 ´ 108 CFU mL-1). Total RNA was isolated in six biological 
replicates per strain from 0.5 mL of culture using the RNeasy Protect Bacteria Mini kit (Qiagen) on 
six consecutive days. RNA-quality and -quantity were assessed with Nanodrop ND-1000 
spectrophotometer (Thermo Scientific). Contaminating genomic DNA (gDNA) was digested 
following rigorous DNAse I treatment of the Ambion DNA-free DNase kit (Thermo Scientific). 
Briefly, 50 μl assays of maximum 10 μg RNA were treated in two consecutive incubation steps at 
37°C for 30 minutes and addition of 5 μl DNase I enzyme before each step. RNA-quality and -
quantity were again assessed as described above and the absence of gDNA was tested by PCR 
amplification (40 cycles) of the adk housekeeping gene (Supplementary Table 2). The RNA integrity 
numbers (RIN) were obtained via the Agilent RNA 6000 Nano kit and the Agilent 2100 Bioanalyzer 
system (Agilent Technologies 2100), and all samples reached RIN > 9 (Supplementary Table 10). 
Depletion of ribosomal RNA from 1 μg total RNA per sample with the QIAseq FastSelect RNA 
Removal kit and library preparation using the Truseq Stranded mRNA library kit were performed at 
Qiagen (Genomic Service Hilden, Germany). The Norwegian Sequencing Centre (NSC) 
(http://www.sequencing.uio.no) performed sequencing of the library on 1/2´SP Novaseq flow cell 
with 300 cycles (2 × 150 bp paired-end reads). The raw sequence reads of 36 libraries are available 
from NCBI SRA (BioProject accession PRJNA630076). 
 
RNA-Seq analysis. NSC performed initial filtering of raw reads including adapter trimming and 
removal of low-quality reads using BBMap v34.56 (therein BBDuk) (Bushnell 2014). NSC mapped 
clean and adapter removed reads against the merged version of the ExPEC chromosome and the 
pG06-VIM-1 sequence using Hisat2 v2.1.0 (Kim et al. 2019) and generated count tables using 
FeatureCounts v1.4.6-p1 (Liao et al. 2014), resulting in an average sample alignment of 65% 
(Supplementary Table 10). Count tables were used as input for the Differential Expression analysis 
(data normalization and statistical tests) performed in R version 4.0.2 (R Core Team 2018) using the 
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default script for SARTools version 1.7.3 (Varet et al. 2016) with default settings and strain ExPEC as 
reference. 
PANTHER Generic Mappings of chromosomal genes were generated using the PANTHER 
HMM Scoring tool with the PANTHER HMM library Version 15.0 (Ashburner et al. 2000; Huaiyu 
Mi et al. 2019; H. Mi et al. 2019; The Gene Ontology Consortium 2019; Supplementary Table 16) 
and functional classification of the PANTHER accessions was retrieved from the website 
(Supplementary Table 15). Tabular lists containing the gene ID, PANTHER accession and fold 
change for all differentially expressed chromosomal genes were uploaded as PANTHER Generic 
Mappings to http://pantherdb.org/ and ran for enrichment of PANTHER GO-Slim Biological 
Processes with FDR (false discovery rate) correction. Enrichment analysis (Supplementary Table 12) 
was performed for each of the comparisons in Supplementary Table 11, except ExPEC+VIM vs 
ExPEC. For the over-representation analyses, subsets of the same lists (up and downregulated genes 
only) were uploaded separately to http://pantherdb.org/. Over-representation analyses (Supplementary 
Table 13) was performed against the PANTHER Generic Mapping of all chromosomal protein-
encoding genes (Supplementary Table 14), with Fisher exact test and FDR correction. All GO terms 
displaying significant enrichment or over-representation were compiled in three subsets (up and 
downregulated processes independent of plasmid presence, and downregulated processes due to 
plasmid presence) and used to generate Supplementary Figures 4-6, respectively, in Visualize (Day-
Richter et al. 2007) available at http://amigo.geneontology.org/visualize?mode = client_amigo. 
 
Statistical analyses. Statistical analyses were performed in R version 4.0.2 (R Core Team   2018). 
Samples were verified for normality with Shapiro-Wilk test and/or graphical visualization. 
Homogeneity of variances was tested with Levene’s test (from package car [Fox and Weisberg 2019]) 
and/or graphical visualization. One-sample or two-sample comparisons were performed with Student 
t-tests. Packages sandwich (Zeileis 2004), car (Fox and Weisberg 2019) and multcomp (Hothorn et al. 
2008) were required for ANOVA and multiple comparisons, respectively. Graphs in Figures 1, 3, 4, 5 
and 6 were produced with packages ggplot2 (Kassambara 2020), patchwork (Pedersen 2020), 
ggthemes (Arnold 2019), and RColorBrewer (Neuwirth 2014). Significance levels are indicated as: P-
value * < 0.05; ** < 0.01; *** < 0.001. Packages openxlsx (Schauberger and Walker 2019) and 
writexl (Ooms 2020) were used to read/write xlsx files. Packages data.table (Dowle and Srinivasan 
2019) and jsonlite (Ooms 2014) were required to generate Supplementary Tables 11-16. 
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Fig. 1 Fitness effect of plasmid acquisition and experimental procedures. a An ExPEC strain (black) 
acquired each of the two MDR plasmids pG06-VIM-1 (green; 53 kB; IncR [Di Luca et al. 2017]) and 
pK71-77-1-NDM (purple; 145 kB; IncC [Gama et al. 2020]) of clinical origin encoding the 
carbapenemases VIM-1 and NDM-1, respectively. b Initial fitness costs of newly transferred plasmids 
in strains ExPEC+VIM and ExPEC+NDM (n = 4 and 3, respectively). Significant plasmid costs are 
indicated by asterisks (P = * < 0.05, ** < 0.01, *** < 0.001; one-sample t-test, two-sided). Error bars 
indicate ± s.e.m. c Experimental evolution in absence of selective pressure (∼300 generations) resulted 
in plasmid-carrying (Pop 1-4VIM and Pop 5-8NDM) and plasmid-free (Pop 9-12) populations which were 
subjected to whole-genome sequencing (WGS). Representative clones per plasmid-carrying evolved 
population (Clones 1-4VIM and Clones 5-8NDM) were sequenced and segregants without evolved pG06-
VIM-1 (filled green circle) were generated for subsequent competition experiments (Clones 1-4). 




Fig. 2 Identified mutations in the ArcAB (Aerobic Respiration Control) and CCR (Carbon 
Catabolite Repression) regulatory systems. a Chromosomal mutations after ∼300 generations of 
experimental evolution. Plasmid-carrying (Pop 1-4VIM = green; Pop 5-8NDM = purple) and plasmid-
free (Pop 9-12 = grey) populations had acquired chromosomal mutations in genes associated to the 
ArcAB (yellow) and CCR (orange) regulatory system. Black indicates otherwise mutated genes in 
single evolved populations. No point mutations were identified in plasmid sequences. See also 
Supplementary information section IIIa and Supplementary Table 4. b Total frequency of all mutations 
targeting the same gene within single evolved populations for genes linked to ArcAB and CCR 
regulatory systems (entire bar length = 100%). c Chromosomal mutations identified in co-evolved, 
plasmid-carrying, whole-genome sequenced Clones 1-4VIM and Clones 5-8NDM; ‘D3 bp’ in cpdA = 
cpdA.D3.bp488‑490.  
  





























Fig. 3 Fitness costs of evolved and ancestral plasmids in adapted backgrounds. a Relative fitness 
of co-evolved pG06-VIM-1-carrying clones (n = 3). Fitness of the ancestral strain ExPEC+VIM is 
indicated by a dotted green line. b Fitness cost of ancestral pG06-VIM-1 re-introduced into co-evolved 
Clone 2 and Clone 3. Fitness of ancestral strain ExPEC+VIM is indicated by a dotted green line. c 
Fitness cost of ancestral pK71-77-1-NDM introduced into co-evolved Clone 2 and Clone 3 (n = 3). 
Fitness of the ancestral strain ExPEC+NDM is indicated by a dotted purple line. d Fitness cost of 
ancestral pG06-VIM-1 introduced into evolved Clone 12, and of evolved pG06-VIM-1 isolated from 
co-evolved Clone2VIM introduced into ancestral strain ExPEC (n = 3-4). Significant plasmid costs are 
indicated by asterisks (P = * < 0.05, ** < 0.01, *** < 0.001; one-sample t-test, two-sided). Error bars 
indicate ± s.e.m. 





























Fig. 4 Effect of CCR and ArcAB systems mutations on plasmid cost and intracellular cAMP 
concentration. a Relative fitness of pG06-VIM-1 in parent strain BW25133 and deletion strains (n = 
3-5). Significant plasmid costs are indicated by asterisks (P = * < 0.05, ** < 0.01, *** < 0.001; one-
sample t-test, two-sided). Error bars indicate ± s.e.m. b Intracellular cAMP concentrations of ancestral 
strains (ExPEC and ExPEC+VIM; n = 6; left) and evolved strains (Clone 2 and Clone 2VIM carrying 
mutation cpdA.D3.bp488-490; n = 6; right) (two-way ANOVA; P = ** < 0.01; df = 3). 
  






























Fig. 5 Fitness-improved adapted backgrounds. Exponential growth rates of a co-evolved pG06-
VIM-1-carrying strains relatively to strain ExPEC+VIM and (each comparison n = 3) b co-evolved 
pG06-VIM-1 segregants relatively to ancestral strain ExPEC (each comparison n = 3). Significant 
fitness changes are indicated by asterisks (P = * < 0.05, ** < 0.01, *** < 0.001; one-sample t-test, one-
sided). Error bars indicate ± s.e.m. 
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Fig. 6 Differential expression analysis. Number of up and downregulated genes (Log2-fold change) 
on a chromosomes of ancestral strain ExPEC+VIM, evolved Clone 2+VIM and Clone 3+VIM upon 
acquisition of native pG06-VIM-1 (compared to respective plasmid-free strain) b evolved pG06-VIM-
1 of Clone 2+VIM and 3+VIM due to adaptive chromosomal mutations (compared to ancestral 
ExPEC+VIM) c chromosomes of evolved pG06-VIM-1-free/-carrying Clone 2 and Clone 3 due to 
adaptive chromosomal mutations (compared to ExPEC and ExPEC+VIM, respectively). Circles: up 
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